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Abstract
Feline leukaemia virus is one of the most common causes of viral disease 
in the domestic cat. Virus infection causes a number of diseases, including 
lymphoma, immunodeficiency, reproductive problems and a form of anaemia 
known as pure red cell aplasia (PRCA). There are three known subgroups of the 
virus (FeLV-A, FeLV-B and FeLV-C), as determined previously by interference 
assays and each subgroup displays a distinct in vitro cell tropism. FeLV-A is 
present in all natural isolates, whereas FeLV-B and FeLV-C are more seldom 
isolated (FeLV-B is present in approximately 40% of all natural isolates, while 
FeLV-C is present in only 1% of all natural isolates). The subgroups are 
determined by the amino acid sequence of the envelope glycoprotein with each 
subgroup of virus utilising a distinct cellular receptor. It is the specificity of the 
FeLV-C receptor interaction that is thought to underlie the development of PRCA 
with the selective destruction of erythroid progenitors by this subgroup of virus.
Subgroup C envs were cloned from a panel of primary isolates (the 
subgroup of these isolates had been established previously by superinfection 
interference). The envs were then characterised in order to determine the amino 
acids responsible for the characteristic in vitro tropism of subgroup C viruses. 
These analyses revealed that the subgroup C-component was more abundant in 
some primary isolates than in others. Furthermore, in some of the primary isolates 
more than one C-component was identified, suggesting that each isolate may 
consist of multiple viral variants. In agreement with previous studies, the env 
sequences were found to be relatively conserved with the majority of changes 
located within discrete variable regions, and in particular, the first variable region, 
the "VRA" region. However, a small number of characteristic mutations (unique to 
the isolate) were distributed throughout the entire envelope glycoprotein.
Although these mutations may simple reflect drift in the Env sequence due to the 
low fidelity of the viral reverse transcriptase, an alternative explanation is that they 
compensate for mutations within the VRA and ensure that the protein adopts a 
viable conformation enabling receptor recognition.
The env clones that displayed an in vitro tropism similar to the prototypic strain 
FeLV-C/Sarma shared two common motifs in the VRA region; the loss of a six 
amino acid stretch (®TNVKHG®®) and a valine to tryptophan substitution on 
position 63 (VeaW) (tryptophan residues have been implicated in the formation of a 
hydrophobic pocket that is thought to be critical for interaction between the virus 
and its receptor).
In contrast with previous findings, the ability to infect porcine cells was 
found not to be a unique property of subgroup B viruses, both subgroup A and 
subgroup C Env clones were isolated that were capable of mediating infection of 
the porcine cell line ST Iowa (for example, an A-component of primary isolate 
FA27 and a C-component of primary isolate FY981). The presence of an aspartic 
acid to asparagine mutation on position 51 (D5 1 N) in the A-component of the 
isolate appeared to correlate with the expanded cell tropism. However, the C- 
components of primary isolate FA27, which also displayed the DsiN mutation, 
were incapable of infecting ST Iowa cells. This may be due to additional mutations 
in the env resulting in an altered conformational structure of the C-component Env 
compared with the A-component that was capable of infecting this cell line. These 
findings suggest that a single mutation may not be sufficient to alter the in vitro 
tropism of a clone; additional mutations may ensure the correct folding of the 
protein and thus the accessibility of the receptor binding site. Although previous 
studies suggested that the amino acid sequence of the envelope glycoprotein of 
FeLV-A is highly conserved between isolates, it was found that minor differences 
in sequence were distributed throughout the entire env. These variations in the 
envelope glycoprotein may account for the differences in in vitro tropism displayed 
by the novel FeLV-A isolates.
To understand fully the extent of expression of the feline FeLV-C receptor 
(feFLVCR) and its possible role in the onset of PRCA, a panel of both 
haematopoietic and non-haematopoietic tissues was screened for feFLVCR 
mRNA. In contrast with the human FeLV-C receptor (thought to be expressed 
preferentially in haematopoietic tissues), the feFLVCR is expressed in both 
haematopoietic and non-haematopoietic tissues and there was no single tissue 
where the receptor was consistently expressed to higher or lower levels. Next, the 
extent of receptor expression in cells that are involved in the erythroid maturation 
was examined. Bone marrow samples were collected and subsequently enriched 
for or depleted of cells that are involved in erythroid maturation using a monoclonal 
antibody directed against cells of this lineage. Although only a small number of 
bone marrow samples were tested, the feFLVCR appeared to be expressed at 
high levels in the bone marrow populations that were enriched for cells of the 
erythroid lineage. These findings support the hypothesis that the normal function 
of this gene is disrupted upon infection and subsequently leads to the onset of 
PRCA.
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CHAPTER ONE
INTRODUCTION
1.1 General introduction
Feline leukaemia virus (FeLV) is a naturally occurring retrovirus and a 
widespread pathogen of the domestic cat. Infection may result in the development of 
a number of diseases, including immunodeficiency, haematopoietic tumours and 
anaemia. FeLV is a member of the retroviridae and can be classified into four main 
subgroups. A, B, C and T, and the three subgroups have distinct cell tropism. The 
main determinant of the cell tropism of virus is the interaction between the envelope 
glycoprotein of the virus and a cellular reception. FeLV-C is the subgroup that causes 
a fatal pure red cell aplasia (PRCA) in the cat and it has been shown that mutations in 
a single region of the envelope glycoprotein of FeLV-A reproduce the anaemogenic 
phenotype of FeLV-C, suggesting that the interaction between the virus and the 
receptor underlies the development of PRCA.
1.2 Structure and classification of the retroviridae
Retroviruses are a large family of viruses that cause many different diseases, 
including immunodeficiency, neurological disorders and tumours. Infection with the 
virus can also lead to a viraemia with no obvious signs of disease, an “inapparent” 
infection. The name is derived from the opposite way of working of the viruses: all 
pathogens translate their DNA into RNA whereas the retroviruses have an RNA 
genome that gets translated by the enzyme "Reverse Transcriptase” (RT). The virion 
structure, genome organisation and replication strategies are similar for all of the 
retroviridae, despite the diversity of host species and host-virus interactions. 
Retrovirus virions are enveloped particles that are approximately 100 nm in diameter. 
Contained within each particle is the viral genome consisting of two linear single 
stranded (SS) RNA molecules encoding for the gag, pol and env genes, arranged 
from the 5’ capped end to the 3’ polyadenylated end of the genome. The envelope 
gene (env) encodes for the surface glycoprotein of the virus. The internal structural 
proteins, the capsid, or core, and nucleocapsid are encoded for by the group-specific 
antigen {gag) gene. The polymerase {pol) gene encodes for the proteins involved in 
viral replication.
A number of retroviruses (such as the spuma- and ientiviruses) contain additional 
genes that are involved in the regulation of virus replication, these viruses are referred 
to as complex retroviruses; viruses lacking these additional genes are referred to as 
simple retroviruses, such as the oncovirinae.
Until recently, the retroviridae were classified in accordance with their 
morphology in electron microscopy images, however this classification has been 
modified as more is known about their structure and the diseases they cause. The 
oncovirinae have been regrouped into 5 new genera, depending on virus structure 
and outcome of infection in the host (see table 1 ). Most of the retroviruses that were 
previously classified as oncovirinae, cause cancer in their host species, however 
there are some oncovirinae that are non-pathogenic. The lentivirinae have long 
incubation periods and cause lifelong, persistent infections regardless of an extensive 
immune response. They induce two different types of diseases, they either induce a 
degenerative and inflammatory disease of specific connective tissues (for example 
the Maedi Visna viruses) or they cause pathological changes in the immune system, 
which result in severe immunodeficiency syndromes (the most well known example 
being Human Immunodeficiency Virus (HIV)). These differences in disease are due to 
the differences in main target cells: the first group mainly infects macrophages 
whereas the second group are able to infect both macrophages and lymphocytes 
(Jindrak L. and Grubhoffer L., 1999). In contrast, the spumavirinae cause non- 
pathogenic lifelong infections in naturally or accidentally infected hosts although they 
do cause vacuolation of cells in vitro.
Genus
a-retrovirus
p-retrovirus
y-retrovirus
5-retrovirus
s-retrovirus 
Le nti virus 
Spumavirus
Morphology
C type
B and D type 
C type
Examples
RSV, ASLV.
JSRV, MMTV. 
FeLV, MuLV, PERV, 
RD114, GALV. 
BLV, HTLV-1, STLV- 
1 .
WPSD.
HIV, SIV, FIV 
HFV, SFV
Table 1.1: Classification of the retroviruses.
RSV. Rous Sarcoma Virus; ASLV. avian sarcoma/leukosis virus; JSRV. Jaagsiekte 
Sheep Retrovirus; MMTV. mouse mammary tumour virus; FeLV. Feline Leukaemia 
Virus; PERV. Porcine Endogenous RetroVirus; GALV. Gibbon Ape Leukaemia Virus; 
MuLV. Murine Leukaemia Virus; BLV. Bovine Leukaemia virus; HTLV. Human T-cell 
Leukaemia Virus; STLV. Simian T-cell Leukaemia Virus; WPSD. Walleye Dermal 
Sarcoma Virus; HIV. Human Immunodeficiency Virus; FIV. Feline Immunodeficiency 
Virus; SIV. Simian Immunodeficiency Virus; HFV. Human Foamy Virus; SFV. Simian 
Foamy Virus
1.3 Y-Type retroviridae
The y-type retroviridae were previously classified as C-type mammalian 
retroviruses and contain the following retroviruses; feline leukaemia virus (FeLV), 
murine leukaemia virus (MuLV), porcine endogenous retrovirus (PERV), Gibbon ape 
leukaemia virus (GALV) and the endogenous feline retrovirus RD-114. Of this group, 
MuLV is perhaps the most well studied retrovirus, indeed it is commonly used to study 
leukaemogenesis and carcinogenesis in general. Furth et al (Furth J. et al., 1933) 
originally identified the virus by breeding high-leukaemia-incidence mouse strains in 
1933. Independent isolates of the agent were successfully identified by a number of 
people, such as Gross, Friend, Moloney and Rauscher (Fan H., 1999). Each isolate 
induces distinct leukaemias, for instance Moloney MuLV induces T cell lymphoma, 
whereas Friend MuLV induces an erythroleukemia. The predominant infection sites of 
MuLV are the haematopoietic tissues, such as bone marrow and lymph nodes. The 
latency of these viruses in mice ranges from 2  months to 18 months, dependent on 
virus strain and mouse strain. The MuLV have been classified using host range 
studies and the principle of interference (discussed in more detail in section 1.4.3), 
determining the differences in the interaction of the viral surface glycoprotein with the 
cell surface receptor, this has led to the following five subtypes. Ecotropic MuLV (e- 
MuLV) is an exogenous virus that is capable only of infecting murine cells. Xenotropic 
MuLV (X-MuLV) is an endogenous virus and is capable of infecting non-murine cells 
only. Amphotropic and polytropic MuLV (A-MuLV and P-MuLV) are capable of 
infecting both murine and non-murine cells. GALV is a retrovirus of the gibbon ape 
that causes T-cell leukaemia. It is transmitted horizontally and is closely related to the 
endogenous virus of the Asian mouse Mus Caroli, which suggests trans species 
transmission (Reitz Jr M.S., 1999). The virus most closely resembles a new world 
monkey virus, simian sarcoma associated virus (SSAV) (Delassus S. et al., 1989). 
However it also bears resemblance to both MuLV and FeLV. All pigs carry several 
copies of the RNA genome of porcine endogenous retroviruses (PERV) (Patience C. 
et al., 1997). Although PERV is not known to cause any disease in pigs, the virus can 
be activated to produce virions that are infectious for human cells and thus could have 
severe implications for the use of pig organs for xenotransplantation (Akiyoshi D.E. et 
al., 1998). There are three subgroups know to date, PERV-A, PERV-B and PERV-C, 
as determined by host range and interference studies (Takeuchi Y. et al., 1998).
RD-114 is an endogenous, xenotropic retrovirus with multiple copies of the complete 
viral genome present in all domestic cats (Hardy W.G.Jr., 1993). RD-114 is not known 
to cause any disease and does not recombine with either FIV or FeLV to cause 
recombinant, infectious retroviruses.
1.4 Feline leukaemia virus
1.4.1 Discovery and origins of feline leukaemia virus
FeLV was first discovered in 1964 by Jarrett et al in Scotland (Jarrett W.F.H. et 
al., 1964). An increased Incidence of lymphosarcomas in a multiple cat household had 
been reported, suggesting that a contagious agent caused these. In order to 
determine if a contagious agent was the cause of these lymphosarcomas, four kittens 
were injected with material from a lymphosarcoma (Mackey L. et al., 1975). All kittens 
developed symptoms and died or were euthanised at different times. Analysis of 
tissue from a kitten euthanised after 18 months showed virus-like particles in 
intracellular vesicles. The virus-like particles resembled particles observed in mice 
and chickens infected with leukaemia-causing virus. FeLV is thought to originate from 
an ancestral rodent virus and shows striking similarities both in sequence and in 
genetic structure with murine leukaemia virus, a leukaemogenic y-type retrovirus of 
the laboratory mouse (Benviste R.E. et al., 1975; Neil J.C. and Onions D.E., 1985).
1.4.2 Structure of the virus
FeLV is a y-type retrovirus with two linear single stranded (8 8 ) RNA molecules 
surrounded by a protein core, an inner protein coat and a viral envelope. The genome 
is approximately 8  kilobases (kb) in length and consists of the genes gag, pol and 
env, arranged from the 5’ capped end to the 3’ polyadenylated end of the genome 
(Hardy W.G.Jr, 1983a), (Hardy W.G.Jr, 1983b).
The gag gene (group-specific antigen) encodes the structural proteins plO (10 kDa), 
p i 2 (12 kDa), p i 5 (15 kDa) and p27 (27 kDa), which are similar in all FeLV Isolates. 
P10 is the nucleocapsid (NC) and is associated with the virion RNA, p i 5 is the matrix 
protein (MA) that forms the outer layer around the core and p27 is the internal capsid 
protein (GA) that Is the major component of the core. The precise function of p i2 (an 
unnamed protein) is unknown. P27 is the protein that is recognised by all the available 
diagnostic FeLV tests. The pol gene (polymerase) encodes the replication enzymes 
protease (PR), integrase (IN) and reverse transcriptase (RT). RT is involved in the 
transcription of RNA into double stranded DNA. This DNA integrates into the cellular 
chromosome, forming the provirus. The virus genome then gets translated alongside 
the cellular genome. The env gene (envelope) encodes the viral precursor protein 
gp85, which the enzyme protease subsequently cleaves into the glycosylated 
extracellular surface glycoprotein gp70 (70 kDa), the non-glycosylated 
transmembrane protein p15E (15 kDa) and a signal peptide. The viral envelope is a 
phospholipid membrane with spikes formed by the gp70 protein, these spikes are held 
in place by the hydrophobic p15È protein. The receptor on the cell surface recognises 
these spikes and this results in cell entry. A cartoon of the structure of the virus and 
the location of its antigens Is depicted in figures 1.1  and 1 .2 .
P15 Matrix
Transmembrane 
protein p15E
RNA with 
associated RT 
enzyme 
and p10 
nucleoprotein
Major
glycoprotein
protein
Major core 
protein p27
Figure 1.1: FeLV particle and ifs antigens.
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1.4.3 Subgroups of FeLV
There are four known subgroups of the virus, FeLV-A, FeLV-B, FeLV-C and 
FeLV-T; FeLV-A, FeLV-B and FeLV-C were identified first using viral interference and 
neutralisation assays (Sarnna P.S. and Log T., 1973). Subsequently, FeLV-T was 
described as an immunodeficiency causing FeLV isolate by Overbaugh et al 
(Overbaugh J. et al., 1988a) and Moser et al (Moser M. et al., 1998) showed the 
interference properties of two closely related FeLV variants. Interference was first 
demonstrated in avian type 0  viruses and has since then been used to identify 
subgroups of many viruses. Reciprocal receptor interference is the process whereby 
cells chronically infected with one virus remain resistant to superinfection by viruses 
that use the same cell surface receptor. These infected cells remain susceptible to 
infection by viruses that use different receptors. Non-reciprocal interference (see 
figure 1.3) has been observed in murine and avian retroviruses and after identification 
of the receptors, It was shown that some viruses could use more than one receptor 
and therefore were able to sustain multiple infection (Sommerfelt M.A., 1999). Viral 
subgroups are defined by differences in the amino acid sequence of the envelope 
glycoprotein and therefore their host ranges and cell surface receptor usage.
1.4.3.1 FeLV-A
FeLV-A is the only subgroup that can be transmitted between cats and 
therefore is present in all isolates (Jarrett O. et al., 1984). FeLV-A can infect only 
feline ceils (Jarrett O. et ai., 1973; Sanaa P.S. et al., 1975; Hardy W.G.Jr., 1993). It is 
minimally pathogenic in the absence of other subgroups (Roy-Burman P., 1996). 
Recently, Moser et al has shown that their prototypic FeLV-A isolate, 61E, is capable 
of infecting not only feline cells, but also some canine and human ceil lines (Moser M. 
et al., 1998). None of the FeLV subgroups are able to infect either mouse or rat ceil 
lines.
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1.4.3.2 FeLV-B
FeLV-B is the result of recombination between FeLV-A and endogenous FeLV 
(Eider J.H. and Muliins J.I., 1983; Stewart M.A. et al., 1986; Overbaugh J. et al., 
1988a; Overbaugh J. et al., 1988b). The FeLV-B env sequences differ in five regions 
of the gp70 (Neii J.C. et ai., 1987). Probes derived from these divergent regions of the 
envelope glycoprotein were used to show that the FeLV-B env gene is derived from 
endogenous proviral DNA (Stewart M.A. et ai., 1986). There are approximately 15 
copies of the enFeLV in the genome of the domestic cat (Benviste R.E. et ai., 1975; 
Roy-Burman P., 1996). However, these endogenous FeLV sequences do not 
generate infectious virus and do not cause disease (Roy-Burman P., 1996). FeLV-B is 
present in approximately 40% of ail natural isolates and causes mild, non-fatai 
anaemia and is also linked to the occurrence of lymphosarcomas and other lympho- 
or myeloproliferative diseases (Jarrett O. et ai., 1984). It has a broader in vitro host 
range than FeLV-A as it is capable of infecting both feline and non-feline ceils (Jarrett
O. et ai., 1973; Sarma P.S. etal., 1975; Hardy W.G.Jr., 1993).
1.4.3.3 FeLV-C
FeLV-C is the result of point mutations in the envelope glycoprotein of FeLV-A 
and shows a close similarity with FeLV-A. The majority of the differences are located 
in the variable regions of the envelope glycoprotein. The determinants of the FeLV-C 
subgroup and disease phenotype have been located to the 3’ pol and 5' env region of 
the virus, which includes the VRA region of the envelope glycoprotein (Riedel N. et 
al., 1988). In a study by Rigby et al (Rigby M.A. et al., 1992), the region of the 
envelope glycoprotein that is involved in receptor recognition and pathogenesis has 
been narrowed down to a single cysteine bounded domain encompassing the VR1 
region. The FeLV-C strains known to date differ in this region, suggesting that each 
isolate arose independently from FeLV-A. FeLV-C is the most rare subgroup; it is 
present in only 1% of all natural isolates (Jarrett O. et al., 1984). This subgroup has 
the broadest in vitro host range; it can infect both feline and non-feline ceil lines and it 
Is the only subgroup capable of infecting guinea pig cells (Jarrett O. et ai., 1973; 
Sarma P.S. et al., 1975; Hardy W.G.Jr., 1993).
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FeLV-C causes aplastic anaemia, a disease that is characterised by 
the fatal erythroid hypoplasia or pure red cell aplasia (PRCA). The main 
haematoiogical symptoms of PRCA are a normal number of early erythroid precursor 
ceiis (BFU-E), but a decreased number of late erythroid precursor ceiis (CFU-E).
These symptoms suggest a defect in the maturation from BFU-E to CFU-E (Abkowitz 
J.L et ai., 1985). Clinical signs are not obvious until the anaemia is severe, they 
include weight loss, fever and listiessness (Hoover E.A. et ai., 1974; Onions D.E. et 
ai., 1982; Abkowitz J.L et al., 1985; Abkowitz J.L et ai., 1998). it has been shown that 
new-born specific pathogen-free (SPF) kittens that are infected with FeLV-C develop 
pure red ceil aplasia within eight weeks, however 8-week-oid kittens that are infected 
with FELV-C do not become infected, and showing that the infection is age related 
(Hoover E.A. et ai., 1974; Riedel N.O. et ai., 1986). Previous research has shown that 
inserting the point mutations, which distinguish FeLV-C from FeLV-A, into the 
envelope gene of FeLV-A generates a virus with an expanded cell tropism, including 
non-feline ceil lines. These results suggest that the interaction between the virus and 
its ceil surface receptor underlie the development of PRCA (Onions D.E. et al., 1982; 
Abkowitz J.L et al., 1987; Rigby M.A. et al., 1992; Brojatsch J. et al., 1992; Abkowitz 
J.L et ai., 1998).
1.4.3.4 FeLV-T
In 1988, Overbaugh et al (Overbaugh J. et ai., 1988a) described a naturally 
occurring FeLV isolate that induces a fatal immunodeficiency similar to AIDS In 
humans. In this study, it was shown that the isolate could not induce a disease without 
the help of a replication-competent virus. Later studies showed that there is a 98% 
sequence homology between their two isolates, suggesting they are closely related 
isolates that were cloned from a single virus (Overbaugh J. et al., 1992). It was shown 
that there are two regions with differences in the amino acid sequence essential for 
the conversion into the cytopathic virus, namely a region near the N-terminus and a 
region of 7 amino acids near the C-terminus. More recently, Rohn et al (Rohn J.L. et 
al., 1998) showed that the immunodeficiency-inducing isolate is unable to establish 
superinfection interference against a homologous challenge, suggesting that the 
cytopathic properties of this isolate might be due to the lack of interference against 
superinfection.
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When the cell tropism of both the immunodeficiency-inducing isolate and the non- 
cytopathic isolate was studied, Moser et al (Moser M. et al., 1998) found no 
interference occurs between the two clones, suggesting they use distinct receptors for 
viral entry and therefore these isolates are distinct subgroups.
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1.4.4 Determinants of host range and pathogenicity
1.4.4.1 y-Type retroviruses envelope glycoproteins
The SU domains of FeLV, MuLV and GALV are composed of three distinct, 
highly variable domains; two variable regions VRA and VRB and a proline rich region 
PRR. The remainder of the SU envelope glycoprotein is highly conserved between 
species (figure 1.4a and 1.4b). The virus subtype variations are mainly found in VRA 
and VRB. VRA begins approximately 50 amino acids from the amino terminal end of 
the SU envelope glycoprotein, is 35 to 80 amino acids long and is flanked by two 
conserved cysteine residues. A conserved region consisting of 38 amino acids 
separates VRA and VRB; this region contains a cysteine residue. The second variable 
region, VRB, is 6 to 30 amino acids is size and contains a conserved cysteine residue 
(Battini J-L. et al., 1992).
1.4.4.2 MuLV envelope glycoprotein studies
In order to investigate the domains of the envelope gene that are involved in 
host range and pathogenicity, Battini et al (Battini J-L. et al., 1995) and Gray et al 
(Gray K.D. and Roth M.J., 1993) studied the envelope glycoprotein of MuLV. Both 
studies concluded that the VRA region is the main determinant in receptor 
recognition, although VRA alone is not sufficient for efficient entry into the cell. The 
PRR is necessary for efficient virus entry, but mutations in this region do not alter 
receptor recognition. Therefore, it is thought that the PRR is involved in maintaining 
the correct conformational shape of the receptor binding domain and therefore 
allowing efficient binding of the virus.
1.4.4.3 FeLV envelope glycoproteins studies
Riedel et al (Riedel N. et al., 1988) investigated the main determinants 
involved in the induction of pure red cell aplasia (PRCA) as a result of FeLV infection 
and found an 886 base pair region that encodes 72 amino acids of the 3’ end of the 
pol gene and 241 amino acids of the N-terminal region of the envelope glycoprotein.
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After infection of SPF cats with the chimaeras made, these cats developed anaemia, 
confirming that this region is involved in the onset of PRCA. The chimaeras also had a 
wider host range, proving that this region is also involved in the determination of host 
range of the virus. A few years later Brojatsch et al (Brojatsch J. et al., 1992) and 
Rigby et al (Rigby M.A. et al., 1992) constructed chimaeras in order to narrow down 
the domains involved. Brojatsch et al looked into 3 anaemia-inducing FeLV-C isolates, 
FA27, FS246 and FZ215. Sequence analysis showed that FA27 and FS246 isolates 
were more closely related to FeLV-A, however there was a single amino acid 
difference between FZ215 and FeLV-C, suggesting that this was not an independent 
isolate. Chimaeras were made by inserting the previously determined region into a 
FeLV-A backbone. The chimaeras that included the SU domain of the envelope 
glycoprotein of FeLV-C all had a broader host range, including guinea pig cells, 
proving that the host range determinant is situated in this region of the envelope. After 
examining the sequences of the different isolates, it was observed that there was only 
one consistent amino acid change in the FeLV-C isolates; this is a KgaL change in the 
VR1 region, affecting the secondary structure. However, this structural change on its 
own was insufficient to alter the host range specificity. Rigby et al narrowed down the 
subgroup specificity; host range and pathogenicity determinants to a cysteine 
bounded region of gp70, including the VR1 region. The cysteine residues are not only 
conserved amongst all FeLV isolates, but also amongst other y-retroviruses, such as 
MuLV. The isolates studied varied in sequence, showing that they had arisen 
independently from FeLV-A. The chimaeras that were constructed induced anaemia 
in neonates, although this anaemia was less virulent and progressed more slowly 
than the PRCA induced by FeLV-C.
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1.4,5 Replication and life cycle
FeLV is thought to be transmitted predominantly by biting and licking (the virus 
is present in saliva). Following exposure to the virus, the epithelial surfaces of the eye, 
mouth and nose are penetrated and the virus enters the local lymph nodes, where It 
replicates In lymphocytes. At this stage, most cats are able to fight off infection and 
become immune to the virus. After replication in lymphocytes, the virus enters the 
bone marrow where it is able to replicate to high titres. The virus binds to specific cell 
surface receptors on the target cell, after which It enters the cell and uncoats to reveal 
the RNA genome. The RNA genome is transcribed into cDNA by the RT enzyme of 
the virus. This cDNA is flanked by two long terminal repeats (LTR) and Integrates into 
the host cellular DNA, this process is mediated by the viral protein IN. The LTR 
regions contain enhancers that drive the transcription of the viral RNA and promoters 
that have processing signals for the cleavage and poly-adenylation of RNA 
transcripts. The viral mRNA (both spliced and unspliced mRNA) is then transported to 
the cytoplasm and translated into viral proteins. These initial products are 
polyproteins, which contain all the protein domains for the genes. At this stage, the 
virus particles are assembled at the cell surface from where they derive a host cell 
derived outer membrane and virus encoded spikes. Cleavage of the polyproteins by 
the viral PR results in mature viral particles, which are subsequently released into the 
bloodstream without damage to the infected cell (see figure 1.5). At this point the 
structural protein p27 is detectable in the blood. The virus spreads to the salivary 
glands and the infection cycle can start again from the beginning. This cycle takes 
approximately 4 weeks (Hardy W.G.Jr, 1983a; Hardy W.G.Jr, 1983b; Jarrett O., 1994; 
Jarrett O., 1999). Transmission through the placenta is rare, as most queens that are 
infected with the virus are infertile (Caney S., 2000), however, Infection can occur 
from an infected queen to her new-born kitten via the milk (Hardy W.G.Jr et al., 1976; 
Jarrett O., 1999).
19
I1p
ep
01 s
I
II
8?
5
0
O  Q)
2 0
1.4.6 Epidemiology and immune response
Infection with FeLV is a significant cause of death amongst young adult cats 
and most infections occur between one and five years of age. In the United Kingdom, 
the prevalence of FeLV is 18% in sick cats and 5% in healthy cats, compared to 19% 
in sick cats and 6% in healthy cats for FIV (Hosie M.J. et al., 1989). Similar results 
were found in the United States, where the prevalence of FeLV is 13% in sick cats 
and 4% in healthy cats, compared to 24% in sick cats and 4% in healthy cats for FIV 
(Shelton G.H. et al., 1989). There is a distinct difference between the outcome of 
infection in multiple cat households and in free-roaming cats, due to the close contact 
cats in multiple cat households have with each other and their shared usage of bowls 
and litter pans. Of these cats, approximately 30 to 40% become viraemic, whereas 
approximately 70% of FeLV negative cats have virus neutralising (VN) antibodies, 
indicating that they have been in contact with the virus (Jarrett O., 1994). Of free- 
roaming cats that are exposed to the virus, 28% become persistently infected, 42% 
become transiently infected and 30% remain uninfected (Hoover E.A. and Mullins J.L, 
1991; Hardy W.G.Jr., 1993). Persistently infected cats have high levels of viral capsid 
protein p27 in their blood and this can be used to diagnose their FeLV infection. 
Transiently infected cats are able to fight off the infection and become immune to 
subsequent FeLV infection. Within four to eight weeks after infection, virus expression 
is brought to a halt, although the virus is not completely eliminated and unexpressed 
non-replicating FeLV is present in the bone marrow. “Latent” FeLV in bone marrow is 
distinct from endogenous FeLV (Hardy W.G.Jr., 1993). The latent FeLV can be 
reactivated in vitro, although this is uncommon (Rojko J.L. et al., 1982). Pacitti et al 
(PacittI A.M. and Jarrett O., 1985) looked at the long-term effects of latent infection. In 
a previous study, 4 viraemic cats were placed in a household consisting of 19 
susceptible 4-month-old kittens. The virus neutralising antibody titre and the anti-feline 
oncornavirus-associated cell membrane antigen (FOCMA) antibody titre was 
determined, as well as virus isolation from the blood and bone marrow.
It was shown that the period of latency is short; within months of infection the bulk of 
cats is able to clear the infection from the bone marrow. However, a small portion of 
cats remained latently infected for a longer period. At 138 weeks, when the study was 
concluded, only 14% of the cats remained latently Infected.
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Similar results were found by Hoover et al (Hoover E.A. et al., 1976) when 
comparable experiments were carried out. It is not known why the latent stage of the 
virus comes to an end, however there are 2 possible reasons for this:
1. The virus infects a small portion of the immature cells in the bone marrow. 
Therefore, after a period of time, these cells gradually differentiate, leaving 
the bone marrow free of virus.
2. The latently infected cells are eliminated by the immune response of the 
cat.
The cats remain negative for the presence of p27 in serum; they develop persistent 
VN antibodies and FOCMA titres. FOCMA is a cell membrane antigen that is 
produced by cells infected with either FeLV or feline sarcoma virus FeSV (these 
viruses are antigenically indistinguishable). Studies have shown that cats which 
develop FeLV malignancies do not have high FOCMA antibody titres and that 
inadequate anti-FOCMA response is a cause, rather than an effect, of ensuing FeLV 
lymphosarcoma (Essex M. et al., 1975; Essex M. et al., 1979). Some cats produce 
antibodies against FOCMA, but these antibodies are not capable of neutralising the 
virus (Essex M. et al., 1971; Hardy W.G.Jr., 1993). However, the true nature and 
function of FOCMA remains illusive and needs to be studied in more detail to 
ascertain its role in FeLV infection. Whether the FeLV infected cat is able to fight off 
infection appears to be dependent on several factors, including the age of the cat, 
status of the immune system at the time of exposure and the amount of virus at the 
time of infection. Susceptibility to infection decreases with age; cats that are infected 
with FeLV at an early age are more likely to develop persistent viraemia and FeLV- 
related disease than cats infected later in life. Similar results were observed in FeSV 
(Hoover E.A. et al., 1976). The outlook for persistently infected cats is very poor, most 
viraemic cats die within 3 years from infection, mostly from non-neoplastic disease 
(Hardy W.G.Jr etal., 1976).
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1.4.7 Clinical signs
Infection with the virus can cause both neoplastic and non-neoplastic diseases 
such as immunodeficiency, reproductive failure, haematopoietic tumours and anaemia 
(see table 1.2) (Jarrett O. et al., 1984). Studies by, amongst others, Mullins et al 
(Mullins J.l. et al., 1984) and Neil et al (Neil J.C. et al., 1987) have shown that the 
different types of cancer caused by FeLV infection is due to the activation of cellular 
oncogenes, resulting in the unlimited proliferation of cells characteristic of leukaemia. 
Similarly, It has been shown previously that the haematoiogical abnormalities 
characteristic for pure red cell aplasia are Induced by the specific FeLV-C viral strains 
(Linenberger M.L. and Abkowitz J.L, 1995). Interestingly, Infection with FeLV-A alone 
does not appear to cause disease, leading to the conclusion that FeLV-A evolves in 
order to generate pathogenic variants of the disease.
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Malignant haemapoietic diseases
Lymphosarcoma
Leukaemias
Tissues affected
thymic lymphosarcoma, multicentric 
lymphosarcoma, alimentary 
lymphosarcoma.
Lymphoid leukaemia, myeloid 
leukaemia, erythroleukaemia.
Non-maiiqnant haemapoietic 
diseases
Anaemia
Immunodeficiency
Marrow aplasia
Symptoms
Haemolytic anaemia, pure red cell 
aplasia.
Comparable to AIDS in humans, thus 
susceptible to a range of opportunistic 
infections.
Hypoplasia of the bone marrow cells
Non-maiiqnant non-haemapoietic 
diseases
Symptoms
Reproductive failure
Enteritis
Spontaneous abortion or death soon after 
birth
Degeneration of the epithelial cells 
located in villous crypts
Table 1.2: Diseases associated with FeLV infection.
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1.4.7.1 Pure red cell aplasia
FeLV-C causes aplastic anaemia, a disease that is characterised by the fatal 
erythroid hypoplasia or pure red cell aplasia (PRCA). The main haematoiogical 
symptoms of PRCA are similar to the PRCA in humans which are a normal number of 
early erythroid precursor cells (BFU-E), but a decreased number of late erythroid 
precursor cells (CFU-E), suggesting a defect in the maturation from BFU-E to CFU-E 
as can be seen in figure 1.6 (Abkowitz J.L et al., 1985). However, two separate 
studies by Testa et al (Testa N. et al., 1983) and Boyce et al (Boyce J.T. et al., 1981) 
have reported a significant drop in BFU-E. This could be the result of different 
techniques or different amounts of virus. Other symptoms associated with PRCA are 
severe anaemia with haematocrit levels of 4 to 15%, absence of reticulocytes in 
blood, no haemoglobinised cells in the bone marrow, high levels of erythropoietin and 
a severely diminished erythropoiesis (Linenberger M.L. and Abkowitz J.L, 1995). 
However, the red cell survival is normal. Clinical signs are not obvious until the 
anaemia is severe; they include weight loss, fever and listlessness (Hoover E.A. et al., 
1974; Onions D.E. et al., 1982; Abkowitz J.L et al., 1987; Abkowitz J.L et al., 1998). 
Feline PRCA does not respond well to immunosuppressive treatments, such as 
prednisone or cyclosporine (Linenberger M.L, and Abkowitz J.L, 1995). As the onset 
of anaemia is more acute in neonatal and immunosuppressed cats then in adult cats, 
the PRCA results from viral replication rather then as a consequence of the immune 
response of the host (Hoover E.A. et al., 1974; Riedel N.O. et al., 1986; Linenberger 
M.L. and Abkowitz J.L, 1995).
Several groups have tried to identify the viral components that are Involved in 
the development of PRCA, however to date the regions that are essential in the onset 
of PRCA still remain to be identified (Riedel N. et al., 1988; Rigby M.A. et al., 1992; 
Brojatsch J. et al., 1992). Rigby et al (Rigby M.A. et al., 1992) have shown with their 
chimaeras that the VRA region of the envelope is the major determinant of tropism of 
the virus as a chimaera of the VRA region of FeLV-C in FeLV-A backbone renders 
guinea pig cells susceptible. They have also shown that this region is important in the 
onset of acute anaemia, suggesting that the cell surface receptor is necessary for 
normal erythroid maturation.
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1.5 Viral receptors
The identification of viral receptors is important for two reasons. Firstly, as the 
receptor plays an important role in virus entry, the expression of the receptor on 
tissues and cells is a major determinant in the pathogenesis and cell tropism of the 
virus. Secondly, once receptors have been identified, novel drugs that inhibit virus-cell 
interactions can be designed. Receptors are components on the cell surface to which 
a virus binds specifically and this interaction result in virus entry. This is in contrast to 
a virus-binding site, which is a component on the cell surface that permits virus 
attachment, but binding of the virus does not result in virus entry. It was previously 
thought that the binding of a ligand to its receptor was a one step process, dependent 
on temperature, pH and ionic strength. With the discovery of large numbers of 
receptors and their subsequent characterisation, it is now believed that virus binding 
is a multi-step process. Each step involves conformational changes in either host or 
receptor or viral envelope glycoprotein, allowing subsequent steps to take place. The 
secondary interactions between virus and target cell strengthens adhesion, enabling 
virus uptake by either of the two following pathways:
1. Fusion of the viral envelope with the plasma membrane.
2. Cellular uptake of virions by endocytosis.
1.5.1 Identification and characterisation of virai receptors
There are several methods to identify and characterise viral receptors; the 
most common approach is to transfer the gene of a potential receptor Into non- 
permissive cell line and demonstrate the ability of this gene to render the cell line 
permissive for infection. An alternative method is to screen a panel of monoclonal 
antibodies against cell surface antigens to determine whether any of the antibodies 
protect the cells against viral infection (Haywood A.M., 1994; Jindrak L. and 
Grubhoffer L , 1999). A range of cell surface molecules has been identified as viral 
receptors, ranging from immunoglobulin-like molecules to multi transmembrane 
transporter proteins. In certain cases (for example the retroviral receptors) binding of 
the viral envelope glycoprotein severely disrupts normal cellular function of the 
molecule.
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1.5.2 Retroviral receptors
Over the years, there has been considerable interest In identifying and 
characterising retroviral receptors. Retroviral infection leads to serious disease in both 
humans and animals. Similarly, retroviruses can be used for the delivery of DMA in 
gene therapy. Over the years, a number of retroviral receptors have been identified 
and characterised. There are many types of cell surface proteins that can act as 
retroviral receptors; however, it is thought that members of the same genera use 
similar cell surface molecules as their receptor. As described previously, retroviral 
envelope glycoproteins are oligomers of SU anchored to the viral membrane by the 
TM. The SU bears epitopes for specific receptor recognition. Binding of the virus to 
the cellular receptor leads to conformational changes in the SU, exposing a 
hydrophobic peptide in the TM domain. Fusion between the virus and the cell is 
catalysed by the exposed peptide. It is thought that fusion is a multi-step process, 
however the exact mechanism is not yet fully understood. The conformational 
changes to expose the peptide are pH-independent. The level of receptor expression 
does not always correspond with the level of infection, suggesting there are other 
cellular factors involved in virus entry (Sommerfelt M.A., 1999).
The structure of retrovirus receptors can be divided into 5 general groups 
(figure 1.7). Protein receptors that have been identified for y-type retroviruses are 
generally multiple transmembrane spanning proteins (multiple TM receptor). The 
number of times a receptor spans the membrane is variable in the different receptors. 
Examples of this group are Pit1 (FeLV-B), FLVCR (FeLV-C) and mCAT-1 (E-MuLV) 
(figure 1.7a). Several retroviruses (for instance HIV) require an additional co-receptor 
for efficient entry in the cell. For example, CD4 is the main receptor for HIV-1 with the 
chemokine CCR5 acting as a co-receptor or fusion receptor. After initial binding of the 
HIV SU to CD4, conformational changes occur in the viral SU, uncovering the binding 
site for CCR5 and allowing fusion to occur between virus and cell. To date, several 
chemokines, that can act as co-receptor for HIV, have been identified, such as CCR3, 
CCR5, CXCR4 and SDF-1 (figure 1.7b). FeLV-T appears to be the only y-type 
retrovirus that requires an additional factor for successful entry; it uses Pit1 as a 
primary receptor and the secreted protein FeLIX as an additional factor (figure 1.7c).
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Cell membrane
TVA
a. Multiple TM d. Single TM
CD4 CCR5 HYAL2?
b. Single TM with multiple TM e. GPI anchor
FeLIX?
Pit1?
c. Multiple TM with secreted factor
Figure 1.7: Different classes o f proteins utilized as a receptor by the y-type 
retroviridae.
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Most a-retroviruses use single transmembrane spanning proteins (single TM) as a 
receptor. To date, the receptors for the avian sarcoma/leukosis viruses (ASLV) 
subgroups A, B, D and E have been identified. They are all member of the tumour 
necrosis factor (TNF) family (figure 1.7d). To date the receptor for Jaagsiekte sheep 
retrovirus (JSRV), HYAL-2 is the only glycosylphosphatidylinositol-anchored (GPI- 
anchored) protein identified for retroviruses. These receptors have an amino terminal 
endoplasmic reticulum signal sequence and a hydrophobic carboxy terminal end. The 
hydrophobic end is removed during anchor addition, allowing the tail part of the 
receptor to anchor the protein to the cell membrane (figure 1.7e) (Overbaugh J. et al., 
2001 ). Eleven receptor groups of retroviruses have been identified on human cells on 
the basis of receptor Interference studies. These receptors have distinct structures 
and functions in the cell (Weiss R.A. and Tailor C.S., 1995).
1.5.3 Receptors of the y-type retroviruses
1.5.3.1 MuLV receptors
The first y-type retrovirus receptor that was identified was the receptor for e- 
MuLV, which is a cationic amino acid transporter, mCAT-1 (Albritton L.M. et al., 1989). 
It has been shown previously that the gene encoding mCAT-1 plays a critical role in 
the haematopoiesis and growth in the development of mice, resulting in death when 
this gene is non functional (Perkins C.P. et al., 1997). The A-MuLV receptor has been 
identified as Pit2, a sodium dependent inorganic phosphate transporter with 10 
transmembrane spanning domains (Miller D.G. et al., 1994). This molecule is closely 
related to the FeLV-B receptor Pit1 (discussed in more detail in section 1.5.3); there is 
62% amino acid homology and both molecules are expected to have 10 
transmembrane spanning domains and 5 extracellular loops (Fan H., 1999). A 
putative human receptor for X-MuLV has been identified and characterised; X- 
receptor is a protein with eight transmembrane spanning domains and is widely 
expressed in both haematopoietic and non- haematopoietic tissues (Battini J-L. et al., 
1999; Tailor C.S. et al., 1999a).
30
Infection studies on Chinese Hamster Ovary cells (OHO cells), a cell line that is not 
susceptible to infection with both X-MuLV and P-MuLV, showed that when these cells 
were transfected with the X-receptor, these cells were not only susceptible to X-MuLV 
infection, but also susceptible to infection with P-MuLV. These findings lead to the 
conclusion that X~MuLV and P^MuLV are indeed a single family of retroviruses, 
despite the differences in infectivity of mice. The viruses have co-evolved due to 
differences in the receptor genes of the host (Tailor C.S. et al., 1999a).
1.5.3.2 RD114 receptors
RD114, human endogenous retrovirus type W, all strains of simian 
immunosuppressive type D retroviruses and the avian reticuloendotheliosis group 
(including spleen necrosis virus and baboon endogenous) virus utilise the same 
receptor, ASCT2 (Rasko J.E.J. et al., 1999; Tailor C.S. et al., 1999b; Marin M. et al., 
2000). This receptor is a sodium-dependent neutral-amino-acid transporter that has 
10 transmembrane spanning domains (Tailor C.S. et al., 1999b). The majority of 
these viruses were also capable of utilising the reiated transporter ASCT1, possibly 
due to the high degree of conserved sequence in the receptor binding domain (Marin 
M. et al., 2000; Lavillette D. et al., 2002).
1.5.3.3 PERV receptors
Recently, Ericsson et al (Ericsson T.A. et al., 2003) identified the receptors 
utilised by PERV-A; PhuR-AI and PhuR-A2. In keeping with the y-type retrovirus 
receptors identified previously, the proteins are thought to have 10 to 11 
transmembrane spanning domains, however the exact number of TM domains and 
the function of the protein remains to be confirmed.
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v-tvpe Receptor Transmembrane Function of the
retrovirus spanning domains protein
FeLV-C
FeLV-B, GALV, 
WMSV 
FeLV-T
A-MuLV
E-MuLV
RD114
PERV-A
FeLV-A
FLVCR
Pit1
FeLIX and 
Pit1
X-MuLV, P-MuLV X-receptor
Pit2
mCAT-1
ASCT-2
HuPARI/
HuPAR2
9
12
12
Soluble (FeLIX)
10
14
10
10- 11?
Organic anion 
transporter 
Na-dependent inorganic 
phosphate transporter 
Env-like protein. 
Na-dependent inorganic 
phosphate transporter.
G-protein-coupled
signalling?
Inorganic phosphate 
transporter? 
Na-dependent inorganic 
phosphate transporter 
Na-independent basic 
amino acid transporter 
Na-independent neutral 
amino acid transporter 
?
Table 1.3: y-type retroviruses and their receptors
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1.5.4 Identification of receptors used by FeLV
A putative receptor on feline cells for FeLV-A has been identified using 
immuno-precipitation, revealing a 70 kDa molecule (Ghosh S.K. et al., 1992). To date, 
however, this receptor has not been characterised. However, the receptors for FeLV- 
B, FeLV-C and FeLV-T have been identified and characterised.
1.5.4.1 FeLV-B receptor
FeLV-B shares its receptor with gibbon ape leukaemia virus (GALV) (Takeuchi 
Y. et al., 1992). Their receptor, pit1, has 10 transmembrane domains and 5 
extracellular loops; it is a Na^-dependent inorganic phosphate transporter. The 
function of Pit1 is inhibited when Na^ is replaced with either or LF. Chimaeric 
studies with the functional human pit1 and the non-functional mouse pit1 have 
identified the region involved in receptor binding (Johann S.V. et al., 1993). These 
differences are also found in the characterised Pit1 from different species. Amino acid 
sequence differences of this molecule account for the differences in permissivity of 
human, rat and murine Pit1 (Weiss R.A. and Tailor C.S., 1995). Amphotropic murine 
leukaemia virus (A-MuLV) uses the related transporter Pit2 as its receptor. There is 
approximately 60% homology between Pit1 and Pit2 and both are widely expressed in 
tissues, although the level of expression varies between tissues. Interestingly, the 
envelope glycoproteins of FeLV-B and GALV show few similarities, even though they 
use the same receptor. In contrast, FeLV-B and A-MuLV share a high homology in 
their envelope glycoproteins (van ZeijI M. et al., 1994). Recent studies by Sugai et al 
(Sugai J. et al., 2001 ) tried to clarify the usage of Pit1 and Pit2 by the different viruses. 
Studies on MuLV have shown that the N-terminal domain of the SU is a major 
determinant for receptor specificity. In this region, there are 2 variable regions (VRA 
and VRB) and a proline rich region (PRR). The VRA region of FeLV-B Is sufficient to 
be able to use Pit1 as a receptor, whereas VRB and PRR are secondary determinants 
for Pit2 usage. It was shown that an arginine in the VRA region is sufficient to change 
the usage of Pit2 by a virus. This amino acid is found in all viruses that are able to use 
Pit2 as a receptor.
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As there are amino acid sequence differences between the receptor binding sites of 
the different species, the receptor-binding site is not conserved between species and 
these differences contribute to control in the tropism of the virus. Both pit1 and pit2 
are widely expressed in vivo and the viruses that use them mainly cause leukaemias, 
it is thought that other post-entry factors are involved in causing pathogenic effects 
(Sommerfelt M.A., 1999).
1.5.4.2 FeLV-C receptors
Both the human and the feline homologue of the FeLV-C receptor have been 
identified and characterised (Tailor C.S. et al., 1999c), (Quigley J.G. et al., 2000). The 
feline homologue, feFLVCR, is a protein with a molecular mass of 60 kDa; the cDNA 
encoding the protein has a size of 1.8kb. The protein has twelve membrane spanning 
domains and shows a high similarity to a hypothetical protein in Caenorhabditis 
Elegans that encodes a putative D-glucarate transporter. It is suggested that the 
FeLV-C envelope SU protein can act as a dominant negative protein, which inhibits 
the function of the FLVCR, resulting in PRCA. Consequently, it is thought that FLVCR 
plays a crucial role in erythopoiesis (Quigley J.G. et al., 2000). The human 
homologue, huFLVCR, has been identified by Tailor et al (Tailor C.S. et al., 1999c). 
The cDNA has a predicted size of 2.0 kb. In accordance with feFLVCR, huFLVCR has 
12 membrane spanning domains and shows a high similarity to a hypothetical protein 
in Caenorhabditis Elegans that encodes a putative D-glucarate transporter. Northern 
blot analysis showed that the protein is widely expressed in haematopoietic tissues, 
most abundantly in foetal liver. Relatively little is expressed in non-haematopoietic 
tissues. This is consistent with evidence that FeLV-C infects different lineages of 
haematopoietic cells in vivo (Dean G.A. et al., 1992). There is 83% amino acid 
similarity and 89% protein similarity between the human and feline homologue of 
FLVCR. The majority of differences are found in the N-terminal domain. The putative 
D-glucarate transporter is a member of the major facilitator superfamiiy of transporters 
(MFS), suggesting that the receptor for FeLV-C is a member of the same family. 
There is further evidence that the FeLV-C receptor is a member of this superfamiiy as 
the predicted structure is similar to the structure of members of this family. As FeLV-A 
is closely related to FeLV-C, it is proposed that FeLV-A use another member of the 
MFS family as a receptor (Tailor C.S. et al., 1999c).
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The MFS is an ancient superfamiiy with at least 17 distinct branches. There are only 
slight similarities between the different branches since they have separated shortly 
after the origin of the superfamiiy (Pao S.S. et al., 1998). The prediction of the FeLV-A 
receptor also being related to the FeLV-C receptor is strengthened by the findings 
described by Bupp et al (Bupp K. and Roth M.J., 2002). Bupp et al describe the 
screening of a library containing Env variants with random amino acids in the host 
range determining region of the enveiope glycoprotein of FeLV-A, resulting in the 
identification of a functional variant (EF) with an altered in vitro tropism. The host 
range was distinct from both FeLV-A and FeLV-C and interference assays on the 
canine cell line D17 indicated that EF utilised a distinct receptor from FeLV-A. It was 
shown that FeLV-C interfered with both FeLV-A and EF infection on D17 celis, but 
neither FeLV-A nor EF was capable of interfering with FeLV-C infection (thus this is 
non-reciprocal interference). These findings indicate that there are two receptors 
present on D17 cells; FeLV-C is capable of using both receptors, whereas FeLV-A 
and EF are capable only of utilising one of the molecules present on the cell surface.
1.5.4.3 FeLV-T receptors
FeLV-T appears to be the only y-type retrovirus that requires an additional 
factor for successful entry. It uses Pit1 as primary receptor and the secreted protein 
FeLIX as a co-receptor (Anderson M.M. et al., 2000). FeLIX is a soluble FeLV-B 
related glycoprotein that is either expressed by feline T-lymphocytes or by 
endogenous FeLV glycoproteins (Anderson M.M, et al., 2000; Lauring A.S. et al., 
2002).
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1.6 Main aims
The aims of the project described in this thesis were threefold; they were:
o To amplify env gene products representative of a mix of subgroups 
within a panel of primary isolates, 
o To examine the expression of the feline FeLV-C receptor in a panel of 
both haematopoietic and non-haematopoietic tissues 
o To identify and characterise the FeLV-A cellular receptor.
1.6.1 Amplification of representative env gene products
In order to identify amino acid sequence motifs that define the subgroup 0  
phenotype and thus the in vitro cell tropism of the env genes studied, env gene 
products representative of a mix of subgroups within a panel of primary isolates were 
isolated and characterised. Previous studies indicated that FeLV-A had the most 
restricted cell tropism (it was capable only of infecting feline cells), whereas both 
FeLV-B and FeLV-C were capable of infecting both feline and non-feline ceils (Jarrett 
O. et al., 1973; Sarma P.S. et al., 1975; Hardy W.G.Jr., 1993). Thus, an expanded cell 
tropism would indicate the presence of subgroup C viruses.
1.6.2 Expression of the FeLV-C receptor feFLVCR
The expression of the feline FeLV-C receptor feFLVCR was studied in a panel 
of both haematopoietic and non-haematopoietic tissues to establish if the detrimental 
effect FeLV-C infection has is a result of preferential expression of the receptor on 
cells that are involved in erythroid maturation or if binding of the virus results in 
inhibition of the normal function of the molecule in the production of erythrocytes.
1.6.3 Identification of the FeLV-A receptor
To date, the FeLV-A receptor has not been identified and characterised. 
Therefore, attempts were made to identify this receptor using methods that have been 
used successfully for the Identification of, amongst others, the feline FeLV-C receptor 
FLVCR (Tailor C.S. et al., 1999c).
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CHAPTER TWO
METHODS
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Methods used throughout the thesis are described in this chapter, whereas methods 
specific to one area are described in the appropriate chapters. Many of the methods 
are based on standard techniques and can be found in laboratory manuals such as 
Current Protocols in molecular biology and Sambrook (Ausubel F .A. et al., 1992) 
(Sambrook J. et al., 1989).
2.1 GROWTH AND MANIPULATION OF MAMMALIAN CELLS 
2.1.1. Basic techniques
All procedures involving manipulation of mammalian cells were performed 
using standard aseptic procedures and, where possible, were performed in a 
microbiological safety cabinet, class II.
2.1.1.1 Cryopreservation o f cells
In order to preserve stocks of ceil lines for iong term use, ceiis were stored in 
the vapour phase of liquid nitrogen. Cells to be frozen were grown to mid-log phase 
(as described below) and removed into a sterile 50ml centrifuge tube (using trypsin- 
EDTA where necessary). The cells were centrifuged at 400xg for five minutes, the 
supernatant discarded and the cells resuspended in freezing medium to a 
concentration of approximateiy 2x10® cells/ml. The celi suspension was transferred 
in 1ml aiiquots, to labelled cryoviais and brought to -130°C in a controlled rate cell 
freezer (Kryo 10 - Planer Products Ltd., Sunbury on Thames, U.K.). The vials were 
then transferred to a liquid nitrogen freezer. Cell stocks were revived by rapid thawing 
in a 37°C waterbath, resuspended In 10% DMEM growth medium to remove the 
DMSO and subsequently cultured using standard techniques (described below).
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2.1.1.2 Cell counting
Ceils were counted using a haemocytometer (Weber Scientific Internationai) 
as follows. Cells were resuspended in the appropriate growth medium and introduced 
to the haemocytometer chamber and cells were counted under an inverted 
microscope with 4X or 10X objective. Cells lying on the top and right hand perimeter 
of each large (one millimetre) square were included; those on the bottom or left hand 
were excluded. Cell concentration (cells/ml) was calculated by multiplying the mean 
number of cells per large square by lO^and correcting for the dilution factor.
2.1.1.3 Cell growth and maintenance
Cells were maintained in 10% DMEM growth medium and grown at 37°C with 
5% COg unless otherwise stated. The growth medium contained 10% foetal caif 
serum, 2mM glutamine; the antibiotics penicillin and streptomycin, which were added 
to a final concentration of lOOIU/ml and 100p.g/ml respectively to prevent 
contamination. When cells reached 80-90% confluency, which was typically every 3-4 
days, cells were subcultured by adding a 1:10 dilution of trypsin-EDTA, spinning the 
celis at 10OOrpm and resuspending the celi pellets in growth medium.
2.1.1.4 Routinely used cell lines 
* 293T cell line (HEK293T)
This is a human embryonic kidney line transformed with adenovirus El a and 
carrying a temperature sensitive T antigen to enhance gene expression (Graham F.L. 
et al., 1977). The T antigen allows for episomal replication of plasmids that contain the 
SV40 origin and early promoter region. The cells are maintained in 10% DMEM 
growth medium in the presence of 400|ag/ml G418. Prior to setting up ceils for 
transfection assays, the G418 is omitted from the growth medium and cells are 
detached from the flask by gentle tapping.
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* 3T3 cell line (NIH 3T3)
This is a cell line of Swiss albino mouse fibroblasts that grow as a monolayer 
with contact inhibition. The cell line was established in 1962 by disaggregating Swiss 
albino mouse embryos and is described by Todaro et al (Todaro G.J. et al., 1965).
* 104C1 cell line
104C1 are guinea pig foetal cells that grow in an epithelial like monolayer and 
were a kind gift from Prof. D.E. Onions (Q1 Biotech, Glasgow, U.K.). Evans et al 
(Evans G.H. et al., 1975) first described this cell line in 1975.
* H06T1 cell line
This ceil line is a derivative of the Crandeli feline kidney (GrFK) ceil line, which 
was first described by Grandell et ai In 1973 (Grandell R.A. et al., 1973) (Grandell R.A. 
et al., 1973). The GrFK cell line is an epithelial-like cell line derived from the kidney of 
a female cat. H06T1 ceils were generated by transfecting GrFK cells with the plasmid 
pH06T1 carrying an activated Ha-ras oncogene (Spandidos D.A. and Wilkie N.M., 
1984).
* HeLa cell line
The HeLa cell line is a cell line derived from a cervical tumour and cells grow 
in an epithelial like monolayer. This cell line was estabiished by Gey et al and first 
described in 1952 (Gey G.O. et al., 1952).
* ST Iowa cell line
This cell line was originally derived from porcine testes from an eighty to ninety 
day old foetus and was first described in 1966 by McGlurkin et al (McGiurkin A.W. and 
Norman J.O., 1966).
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* Mv1Lu cell line
This cell line was derived from the lungs of several near full term foetuses of 
the mink, Mustella vison, and grows in an epithelial like monolayer. This cell line was 
first described in 1974 by Henderson et al (Henderson I.C. et al., 1974).
* MDCK cell line
This celi line is also known as Madin-Darby canine kidney cells and was 
derived from the kidneys of a normal, healthy female cocker spaniel. The cells grow in 
a heteroploid epithelial monolayer and are maintained in MEM supplemented with non 
essential amino acids and 5% foetal calf serum. The cells were first described in 1958 
by Madin et ai (Madin S.H. and Darbey N.B.Jr., 1958) and characterised in more 
detail in 1966 by Gaush et al, (Gaush C.R. et al., 1966).
2.1.2 Transfection of mammalian cells
2.1.2.1 Calcium Phosphate transfection method
Cells were transfected using the CaP0 4  method as described previously by 
Gorman (Gorman G.M. et al., 1985) using 24^ig of each of the plasmids. The plasmids 
used for transfections were the FeLV env of interest in the retrovirai vector VR1012, 
pHit60 and mfg LacZ. PHit60 contains the gag and pol of murine ieukaemia virus, 
therefore enabiing the production of infectious particies and therefore infection of the 
target cells. The marker gene mfg LacZ encodes for p-galactosldase. When staining 
the transfected ceiis with x-gal, the x-gal will be converted into an insoluble blue 
compound by the enzyme p-galactosidase. A subsequent plate was transfected with 
vector only, Hit60 and mfg LacZ to determine negative background. This negative 
control plate was treated similarly to the plates with the gene of interest.
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On day 1, 6x10® 293T cells were plated in 150mm dishes in 16mls 10% DMEM. The 
following day, chloroquine was added to the cells to a final concentration of 25p,M 
chioroquine to enhance DNA uptake. The DNA to be transfected was made up to 
1752p,i with distiiied water and 248^1 2M CaClg was added. 2000jil 2xHBS was added 
slowly whilst blowing air in the mixture and this DNA mixture was added to the cells. 
After an 8 to 9hr incubation, the transfection mixture was replaced with fresh 10% 
DMEM growth medium and celis were incubated overnight at 37°C. On day 3, the 
cells were washed twice with PBS and fresh growth medium was added. The 
following day, the supernatant of the transfected 293T cells was removed and filtered 
using a 0.45micron filter. The supernatants were titrated to determine the titre and 
subsequently stored at -70°G until further use. The 150mm 293T dishes were stained 
for transfection efficiency by fixing the ceils for 10 minutes in PBS containing 0.5% 
giutaraldehyde, washed three times with PBS and p-gaiactosidase activity was 
determined by incubation with x-gai buffer (5mM potassiumferrocyanide, 5mM 
potassiumferricyanide, 2mM MgGIg) containing 1 mg/ml x-gal (5-bromo-4-chloro-3- 
indolyl p-D galactopyranoside).
2.1.2.2 Assay to determine virus titre using J3-galactosidase
The day prior to collection of supernatants, H06T1, FEA and 104G1 cells were 
seeded In 24 well plates at a final concentration of 2*10'^  cells per well and incubated 
overnight at 37°G in the presence of 5% GOg. Five fold dilutions of the filtered 
supernatants were prepared in 10%DMEM, polybrene was added to a final 
concentration of 4|ig/ml and 900^1 of the dilutions was added to a well each of 
H06T1, FEA and 104G1. After 72hr incubation, the 24 well plates were fixed for 10 
minutes in PBS containing 0.5% giutaraldehyde, washed three times with PBS and p- 
galactosidase activity was determined by incubation with x-gal buffer (5mM 
potassiumferrocyanide, 5mM potassiumferricyanide, 2mM MgGIg) containing 1 mg/ml 
x-gal (5-bromo-4-chloro-3-indolyl p-D galactopyranoside) in dimethylformamide. The 
titre of the supernatants was determined using the following formula;
Number of colonies * dilution plated 
ml plated per well
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2.1.2.3 Antibody staining
To establish the efficient uptake of the FeLV envelope glycoprotein constructs, 
the transfected 293T ceiis were stained with the anti-gp70 monoclonal antibody 6-15 
(Weijer K. et al., 1986). After removal of the supernatant, ceiis were washed with PBS 
and subsequently fixed with ice cold methanol for approximately 10 minutes. Cells 
were scraped off the wells using a cell scraper and transferred to tubes, pelleted for 5 
minutes at lOOOrpm and washed twice in PBS containing 1% (w/v) BSA and 0.1% 
(w/v) azide. Subsequently, cell pellets were resuspended in 40fxl KW1 (1:100 dilution 
in PBS/1 % BSA/ 0.1% Azide) and incubated for 30 minutes at 4°C. Again, cell pellets 
were washed twice in PBS containing 1% (w/v) BSA and 0.1% (w/v) azide and 
subsequently resuspended in 40^1 FITC a-mouse (1:50 dilution in PBS/1 % BSA/ 
0.1% Azide), after which the cells were incubated for 30 minutes at 4°C. After a 
further two washes in PBS containing 1% (w/v) BSA and 0.1% (w/v) azide, cell pellets 
were resuspended in a small volume of PBS. Simultaneously, an additional sample of 
the cells was treated and stained similarly with an antibody against FIV (AE11) to 
establish the background. Stained cells were examined under a fluorescent 
microscope (Das Mikroskop, Leica , Solms, Germany) using 40x magnification and 
ultraviolet light of a wavelength of approximately 250nm. To ensure the presence of 
cells in the field examined, the cells were also examined using bright field microscopy.
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2.2 RECOMBINANT DNA TECHNIQUES
2.2.1 Storage and growth of bacteria
Plasmids were maintained in E.coli strain INVaF'. To enable storage of these 
E.coli host strains and of transformants obtained during this work, glycerol stocks 
were prepared. The desired bacterial culture was streaked onto a 1.5% agar plate 
(1.5% agar in LB medium), in cases where the bacterial stock contained a plasmid 
conferring ampicillin resistance the medium was supplemented with 50^g/ml ampicillin 
and in cases where the bacterial stock contained a piasmid conferring kanamycin 
resistance the medium was supplemented with 20 ^ig/ml kanamycin. The plate was 
incubated overnight at 37°C and the following day single colonies were picked using a 
sterile toothpick, into 2.5ml LB medium (supplemented as appropriate with kanamycin 
or ampicillin) in sterile bijoux. The cultures were incubated at 37°C overnight in an 
orbital incubator. Confirmation that the overnight culture was derived from bacteria 
containing the desired recombinant plasmid was achieved by DNA extraction and 
restriction digest (section 2.2.2.4). Glycerol stocks were prepared by the addition of 
200^1 of glycerol to one millilitre of culture and were stored at -70°C. Bacterial stocks 
were revived for subsequent work by using a sterile toothpick to scratch the surface of 
the stock, following which it was grown in the appropriate medium as described 
above.
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2.2.2 Extraction and purification of DNA
Plasmid DNA was isolated using a modification of the alkaline lysis technique 
described by Birnboim and Doly (Birnboim H.C. and Doly J., 1979).
2.2.2.1 Small Scale Plasmid Preparations
Small-scale plasmid preparations were performed using QIAprep® Spin 
Miniprep. One and a half millilitres of an overnight culture of the desired transformant 
was removed to an eppendorf tube and spun at IS.OOOrpm in a microcentrifuge for 5 
minutes to pellet the bacteria. The supernatant was discarded and the bacterial pellet 
was resuspended in 250|il buffer PI, lysed in 250^1 buffer P2 and neutralised in 350^1 
buffer N3. The lysate was cleared from denatured cellular components by 
centrifugation at 13.000rpm in a microcentrifuge for 10 minutes. The cleared lysate is 
applied to the QIAprep spin column and the solution is drawn through the columns by 
applying a vacuum. The QIAprep spin columns contain silica-gel membrane to adsorb 
plasmid DNA in a high salt buffer. The column is washed once with buffer PE and 
spun once at 13.000rpm in a microcentrifuge for 1 minute to remove all residual buffer 
PE. To elute the DNA 30^1 of the low salt buffer EB is added to the column, incubated 
for 1 minute and spun at 13.000rpm in a microcentrifuge for 1 minute.
22.2.2 Large Scale plasmid Preparations using a Caesium Chloride Gradient
A 200ml overnight culture of E.coli containing plasmid DNA was grown in the 
presence of 20|ig/ml kanamycin and incubated overnight at 37°C with shaking. 
Bacteria were spun down in a Beckman J2-21 centrifuge (JA10 rotor) at 8671 xg for 10 
minutes and supernatant was removed. The bacterial pellet was resuspended in 5m! 
50mM TRIS containing 25% sucrose. 1ml of 20mg/ml lysozyme in 0.25 mM TRIS 
pH8.0, mixed by inversion and incubated on ice for 10 minutes. 8ml TRITON mix was 
added quickly, mixed by inversion and incubated on ice for 15 minutes, after which 
the bacterial debris was pelleted by spinning in a Beckman J2-21 centrifuge (JA20 
rotor) at 48384xg for 30 minutes.
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The supernatant was removed, caesium chloride was added to a final concentration 
of 1 g/ml and 100pt ethidium bromide (iOmg/ml) was added. The tubes were spun for 
18 hours at 60,000rpm in an ultracentrifuge (TI70 rotor). The plasmid band was 
removed using a 24-gauge needle and a second gradient spin was loaded. The 
samples were spun in a benchtop ultracentrifuge for 4 hours at 100,000rpm. Again, 
the plasmid band was removed using a 24-gauge needle and the ethidium bromide 
was removed through several extractions with butanol. DNA was then ethanol 
precipitated by adding 2 volumes of IxTE (lOmM TRIS.CI, 1mM EDTA pH7.5), 1/10**^  
volume of 3M NaOAc and 2 volumes of ethanol at 4°C for 30 minutes. The nucleic 
acid concentration was determined as described in section 2.2.3.3.
2.2.23 Large Scale plasmid Preparations using QIAGEN’s endofree™ plasmid maxi 
kit
A 100ml overnight culture of E.coli containing plasmid DNA was grown in the 
presence of 20|ig/mi kanamycin and incubated overnight at 37°C with shaking. 
Bacteria were spun down in a Beckman J2-21 centrifuge (JA14 rotor) at 7518xg for 10 
minutes and supernatant was removed. The bacterial pellet was resuspended in 10ml 
resuspension buffer PI and 10ml lysis buffer P2 was added, mixed gently by 
inversion and incubated at RT for 5 minutes. 10ml Ice-cold neutralisation buffer P3 
was added, mixed gently by inversion and this was added to the resuspended 
bacteria. The lysate was applied to a QIAfilter cartridge to remove bacterial debris, 
proteins, genomic DNA and detergent and incubated for 10 minutes after which the 
cell lysate was filtered into a 50ml tube. To remove endotoxins, 2.5ml buffer ER was 
added and incubated on ice for 30 minutes. In this time, the QIAGEN-tip 500 was 
equilibrated by addition of 10ml buffer QBT. After the endotoxin removal, the filtered 
lysate was applied to the QIAGEN-tip and allowed to enter the resin by gravity flow. 
The QIAGEN-tip was washed twice with buffer QC after which the DNA was eluted 
from the QIAGEN-tip with 15ml buffer QN and precipitated with 10.5ml isopropanol. 
The DNA was precipitated in a Beckman J2-21 centrifuge (JA20 rotor) at 48384xg for 
30 minutes and supernatant was removed.
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After a wash with endotoxin-free 70%EtOH, the DNA pellet was air-dried briefly and 
resuspended in 200^1 endotoxin-free buffer TE, The nucleic acid concentration was 
determined as described in section 2.2.3.3.
2.2.3 Determination of nucleic acid concentration by 
spectrophotometry
The sample was diluted 1:200 by addition of 2.5|xl of nucleic acid to 497.5pl of 
dHgO. The optical density was measured at 260nm and 280nm, in comparison to a 
blank containing dHgO. An OD reading of 1.0 at 260 nm corresponds to an 
approximate nucleic acid concentration of 50pg/ml for double stranded DNA or 
40).ig/ml for RNA. The ratio of the OD readings at 260 nm and 280 nm (ODgeo/ODgeo) 
was used to estimate the purity of the nucleic acid. Pure preparations of DNA and 
RNA have an ODgeo/ODgso of 1.8 and 2.0, respectively; a lower value suggesting 
possible protein contamination.
2.2.4 Restriction endonuclease digestion
Typically, 0.5-1 )ig of DNA was digested in a lOpI reaction mix containing 10 
units of the desired restriction enzyme and the appropriate buffer. The reactions were 
incubated at 37°C for a minimum of one hour and separated on an agarose gel as 
described in section 2.2.3.5. When the isolation of restriction fragments was required, 
5-10|ig of DNA was digested in a 50p.l reaction mix containing 10 units of the desired 
restriction enzyme and the appropriate buffer. The reactions were then incubated at 
37°C for a minimum of one hour and separated on an agarose gel as described in 
section 2.2.3.5.
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2.2.5 Electrophoresis of DNA
DNA fragments of 1.0 - 10 kb were separated and identified by agarose gel 
electrophoresis using a Bio-rad wide mini sub® cell GT gel kit (Hybaid). All analysis 
was carried out on agarose gels, which varied from 0.8% to 1.5% depending on the 
size of the fragment to be visualised. Gels were cast in IxTBE and 0.5^g/ml EtBr was 
added to the gel. DNA samples were prepared by adding the appropriate volume of 
10X DNA Gel Loading Buffer and loaded into the wells. Gels were run at QOvolts in 
1xTBE for 60 minutes to 90 minutes. The separated DNA was visualised using a short 
wave UV transilluminator and photographed using a gel print 2000i (MWG biotech 
AG, Ebersberg, Germany).
2.2.6 Purification of restriction enzyme fragments
The DNA fragment of interest was purified from an agarose gel using the 
QIAquick® Gel Extraction Kit that uses a silica-gel membrane. The adsorption of the 
DNA only takes place in the presence of high salt buffers. The DNA is eluted from the 
column by the addition of low salt buffer. The DNA was digested with the desired 
restriction enzyme and separated by electrophoresis on an agarose gel as described 
previously (sections 2.2.3.4 and 2.2.3.5). The DNA fragment of Interest was excised 
from the gel using a sterile scalpel and placed in an eppendorf tube. Three volumes of 
binding and solubilization buffer QC was added and the mixture was incubated at 
50°C for 10 minutes or until the fragment was dissolved completely. The mixture was 
then applied to a QIAquick column and washed once with buffer PE to remove 
impurities such as agarose, restriction enzymes or primers. An additional 
centrifugation step was included to remove any residual buffer PE as this may 
interfere with subsequent enzymatic reactions. The purified fragment was eluted with 
30|il buffer EB, incubated for 1 minute and spun down at maximum speed for 1 
minute. To establish the efficiency of the gel purification, a small aliquot of the sample 
was run on an agarose gel as described in section 2.2.3.5.
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2.2.7 Ligation of vector and target DNA
Equal quantities of vector and insert were mixed with an appropriate volume of 
ligation buffer and 4 units of DNA ligase in a 10|xl reaction. The ligation reaction was 
incubated at 14°C overnight and stored thereafter at -20°C if not used immediately.
A negative control, omitting insert DNA, was generally set up in parallel to check for 
background when performing the subsequent bacterial transformations.
2.2.8 Transformation of INVaF’ cells with plasmid DNA
Cells were thawed on wet ice, mixed gently and 25j.il of cells were used per 
transformation. One microlitre of ligation reaction (containing either the recombinant 
plasmid or the negative control as described previously) was added to the cells whilst 
mixing carefully. Cells were incubated on ice for 30 minutes and subsequently heat 
shocked in a 42°C waterbath for 30 seconds. After cells were placed on ice for 2 
minutes, 250\x\ SOC medium was added and the cells were incubated at 37°C for 1 
hour with shaking at 225rpm. Typically, 50^1 and 200|il cells were plated on LB plates 
containing 20|ig/ml kanamycin and incubated overnight at 37°C.
2.2.9 Preparation of a [a-^^P]-dCTP probe
Invitrogen’s RadPrime DNA Labelling System was used to prepare [a-®^Pj- 
dCTP labelled DNA probes. Approximately 50ng of the gel-purified fragment was 
denatured at 100°C for 10 minutes and immediately chilled on ice. Random primers 
were annealed to the denatured DNA template, extended by the klenow fragment in 
the presence of 50 fj,Ci [a-®^P]-dCTP and incubated at 37°C for 10 minutes. The probe 
was applied to a NICK ™ column (Amersham Pharmacia Biotech) to remove 
unincorporated [a-®^P]-dCTP. The column was washed once with 350^1 IxTE pHS.O. 
This flow through was discarded. The second flow through of 400^1 was collected.
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The radioactivity was determined by counting 2pl of the prepared probe in liquid 
scintillation counting and the total counts/ml was determined by multiplying the counts 
by 200 to take the dilution into account. The [a-®^P]-dCTP probe was stored at -20°C 
until required. Before use, the probe was denatured at 100°C for 10 minutes and 
immediately chilled on ice.
2.2.10 Automated sequencing using the LI-COR 4000
The LI-COR model 4000 automated sequencer (LI-COR inc., Lincoln, USA) 
utilises an infrared detection system, whereby DNA fragments are detected following 
labelling with IRD41 labelled primers, as they run through the denaturing 
polyacrylamide gel. In addition, sequencing reactions were performed using a 
thermostable DNA polymerase (SequiTherm DNA polymerase), allowing reactions to 
be performed in a thermal cycler. This variation on the original method of chain 
termination sequencing, known as 'cycle sequencing', was first described by Innis et 
al (Innis M.A. et al., 1988). This method allows direct sequencing of dsDNA without 
alkaline dénaturation, requires less template and is more efficient at sequencing 
templates that are G/C rich or have high secondary structure. Custom made IRD41 
labelled primers were designed and ordered from MWG Biotech, see figure 2.1 for the 
position of the primers in the FeLV-A/Giasgow-1 envelope glycoprotein (Accession 
number P08359) (Stewart M.A. et al., 1986).
Primer name Primer binding site
FeLV env F69 5 -GTC CAA CGC ACC CAA AAC C-3'
FeLV env F795 5 -ATC AAA AAC CCC CAT CCC-3’
FeLV env F974 5 -ACC CCA ACA AAA CTA AAG AC-3'
FeLV env R1019 5’-GTC GAG AAA CCA GGC AGA GC-3’
FeLV env R1482 5’-GCT TTA GTC CCT GTT CCG ACC-3’
FeLV env F I737 5’-TAA AAC AGC GGC AAC AAC-3’
FeLV env R1858 5'-TAG GAG TAG GAT TAG TAA GGG-3’
Table 2.1: Primers used for sequencing the envelope glycoprotein.
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2.2.10.1 Sequencing reactions
Protocols for cycle sequencing were provided by LI-COR. The dsDNA was 
diluted by adding 1^g to 40pl in 1mM TRIS-HCI pH 8.5. The following were combined 
in a 250(^ 1 micro-amp reaction tube: 1p,l 5’ IRD 800 labelled primer, 2|il of A, T, G, or C 
long read termination mix (45 )j,M each of dATP, dCTP, dTTP and 7-deaza-dGTP and 
either 0.03 mM ddGTP, 0.3 mM ddCTP, 0.45 mM ddATP or 0.45 mM ddTTP as 
appropriate) and 5p.l of diluted dsDNA stock. The tubes were placed in a thermal 
cycler (Perkin Elmer) and subjected to an initial dénaturation step of 95°C for two 
minutes followed by 30 cycles of 95°G for 30 seconds; 60°C for 30 seconds; 70°C for 
30 seconds; terminating in a 4°G soak. The annealing temperature used was 
dependent on the melting temperature of the primer used; generally the annealing 
temperature was 2°G below the melting temperature of the primers used. After cycling 
was complete, four microlitres of stop solution (95% (w/v) formamide, 10 mM EDTA 
(pH 7.6), 0.1% xylene cyanol and 0.1% bromophenol blue) was added to each of the 
reaction mixes. Reactions were stored at - 20°G for up to one week prior to gel 
electrophoresis; whilst exposure to light was avoided.
2.2.10.2 Gel electrophoresis
Sequencing reactions were run on 4% denaturing polyacrylamide gels, as 
detailed in the manufacturer’s instructions. Glass plates (66cm) were used with a 32 
well rectangular toothed comb. The plates were cleaned thoroughly before use and 
340jLil bind-silane was added to the notched glass plate at the area to be in contact 
with the comb (to aid the formation of wells) and at the bottom of the plate (to aid the 
formation of a plug). Bind-silane contains lOjal 10% acetic acid and 330^1 silane 
solution (40|il y-methacryloxy-propyltrimethoxysilane in 10 ml 100% ethanol). After 
this had dried, the plates were assembled and placed in a casting stand. A gel mix 
was prepared using 27.7gr urea, 5.3ml millilitres Long Ranger™ polyacrylamide gel 
mix (AT Blochem.), 7.9ml lOx TBE and dH20 was added to a final concentration of 
65ml. To the gel mix was added 440pl 10% APS. To prepare a plug, 3ml of the gel 
mix were removed and 40^1 10% APS plus 4|xl TEMED was added to the mix.
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A pasteur pipette was used to inject the mix between the bottom of the glass plates to 
form a plug. After polymerisation of the plug, 40jil TEMED was added to the 
remainder of the gel solution, which was mixed and the gel was poured using a 50ml 
syringe. The comb was inserted and the gel was left to polymerise for approximately 
2hrs at an angle. The gel was then transferred to the electrophoresis apparatus, both 
buffer tanks were filled with 1x TBE, the comb was removed and wells were flushed. 
The gel was pre-electrophoresed for 30 - 45 minutes, during which time the scanning 
microscope was focussed and the gain controls were adjusted. Sequencing reactions 
were denatured at 95°C for three minutes prior to loading; generally 1.5 |il was loaded 
per well. The gel was run at 45.0 W, with the scanner programmed to collect 32 
frames (approximately 1000 bp). Sequence data was read automatically: base 
ambiguities were checked by visual inspection of the gel image.
2.2.11 Sequencing using the ABI PRISM 3100 genetic analyser
During the later stages of this project an ABI PRISM 3100 genetic analyser 
(Applied biosystems, Warrington, U.K.) became available, which considerably 
increased the ease and throughput of sequencing. The kit used (ABI PRISM BigDye 
Terminator Cycle Sequencing Ready Reaction Kit version 2.0) to generate the PGR 
products required for the ABI PRISM 3100 genetic analyser contains AmpliTaq ® 
DNA Polymerase BigDye terminators and all required components for the sequencing 
reactions. The BigDye terminators are labelled with high-density dyes, allowing the 
laser in the ABI PRISM 3100 genetic analyser to determine the correct sequence. 
Primers were designed and ordered as previously, see figure 2.1 for primer binding 
sites of the primers used.
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2.2.11.1 Sequencing reactions
dsDNA to be sequenced was prepared as described previously (section 
2.2.3.2.1) and the dsDNA was eluted in SOpI elution buffer. The PCR reactions 
contained 4 \x \ dsDNA, 4|o.l ABI Prism® BigDye™ Terminator Cycle Sequencing Ready 
Reaction Kit, version 2.0, 2\x\ 5x sequencing buffer, 3.2pmol primer and dH^D was 
added to a final volume of 20pl. The tubes were placed in a thermal cycler (Perkin 
Elmer) and subjected to 25 cycles of 96°C for 10 seconds; 50°C for 5 seconds; 60°C 
for 4 minutes; terminating in a 4°C soak. The PCR reactions were purified using 
Performa DTR gel filtration system columns (EDGE biosystems, U.K.) as described In 
the product protocol. Spinning at 750*g for 2 minutes re hydrated the columns and the 
PCR reactions were added to the middle of the column and subsequently spun at 
750*g for 2 minutes. The purified reactions were dried in a vacuum drier for 
approximately an hour and resuspended in 25^1 HiDi formamide (Applied biosystems, 
Warrington, U.K.), a 96 well plate (ABgene, U.K.) was loaded and stored at 4°C until 
required.
2.2.11.2 Sample collection and sequence analysis
The analysis of the sequencing reactions was carried out as described by the 
manufacturers. A septa (Applied biosystems, Warrington, U.K.) was placed on the 96 
well plate and this was inserted in the box. Conditions were chosen depending on the 
polymer used and the length of the capillary used and were as described by the 
manufacturers. To obtain approximately 800bp of reliable sequence, 80cm capillaries 
were used with the polymer P0P6, again as described by the manufacturers.
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2.2.12 Analysis of sequences obtained from either the LI-COR 4000 
or the ABI PRISM 3100 genetic analyser
The sequences obtained were analysed using the NCBI blast nucleotide 
search on their website (http://www.ncbi.nlm.nih.qov/BLAST/) to ensure the isolates 
were indeed FeLV-related. Ambiguities were checked and corrected where possible 
and the sequences were further analysed using the following software: Wisconsin 
Package Version 10.0, Genetics Computer Group (GCG) (Madison, Wise.). The 
sequences were translated into protein sequences and a pileup analysis was done to 
compare the sequences to published sequences.
2.2.13 Envelope glycoprotein structure predictions
FeLV env structures were generated using "Swiss model" fwww.expasv.ora. 
hosted by the Swiss Institute of Bioinformatics, Basel, Switzerland). Envelope 
glycoprotein structure predictions were prepared using PDB-viewer (www.expasv.ora. 
as above). The FeLV env structures were based on the Friend MuLV gp70 (Fass D. et 
al., 1997), (Accession number AAA46478, accession code in the Protein Data Bank 
(PDB): 1AOL).
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CHAPTER THREE
CLONING AND SEQUENCING OF 
NOVEL ISOLATES OF FELV-C
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3.1 Introduction
FeLV-A is present in all naturally occurring isolates of FeLV, FeLV-B is present 
in approximately 40% of naturally occurring isolates and FeLV-C is the subgroup that 
is isolated least frequently and it is present in approximately 1% of isolates (Jarrett O. 
et al., 1984). FeLV-C Is the subgroup that causes a fatal pure red cell aplasia (PRCA) 
in the cat and it has been shown previously (Hoover E.A. et al., 1974) that mutations 
in a single region of the envelope glycoprotein of FeLV-A reproduce the anaemogenic 
phenotype of FeLV-C, suggesting that the interaction between the virus and the 
receptor underlies the development of PRCA.
A panel of primary isolates of FeLV, some of which have been described 
previously by Brojatsch et al (Brojatsch J. et al., 1992) and Rigby et al (Rigby M.A. et 
al., 1992), were examined in this study. These primary isolates of FeLV (see table 3.1 
for a description and origin) were classified previously into subgroups A, B or C by 
interference assays [described by Sarma et al (Sarma P.S. and Log T., 1973)] and 
contained either an A/C mixture or and A/B/C mixture. Three of these isolates (FA27, 
FS246 and FZ215) have been partially characterised previously. However 
discrepancies were found between the sequences published in both studies. 
Furthermore, the envelope glycoprotein genes were only sequenced partially in the 
studies described previously.
Therefore, the aim of this study was to identify and characterise env gene 
products representative of the mixture of subgroups present in the primary isolates in 
order to identify amino acid sequence motifs that define the subgroup C phenotype 
and thus the in vitro cell tropism of the env genes studied. Previous studies indicated 
that FeLV-A had the most restricted cell tropism of the FeLV subgroups and that is 
was capable of infecting feline cells only (Jarrett O. et al., 1973). In contrast, FeLV-B 
and FeLV-C were found to have a broader tropism and were capable of infecting both 
feline and non-feline cells (Jarrett O. et al., 1973; Sarma P.S. et al., 1975; Hardy 
W.G.Jr., 1993). Thus, an expanded cell tropism would indicate the presence of 
subgroup C viruses.
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Isolate Description of isolate
FA27 Isolated by limiting dilution from an A/C complex obtained from an
anaemic cat in Great Britain. Passaged in FEA cells and 
anaemogenic in neonatal cats. (Onions D.E. et al., 1982)
FY981 Isolated by limiting dilution from an /K/B/C complex obtained from
an anaemic cat in Great Britain in 1980. Passaged in FEA cells 
and anaemogenic in neonatal cats.
FS246 Isolated by limiting dilution from an A/C complex obtained from an
anaemic cat in Scotland in 1977. Passaged in FEA cells and 
anaemogenic in neonatal cats. (Onions D.E. et al., 1982)
FA621 Isolated by limiting dilution from an A/C complex obtained from an
anaemic cat in Scotland and passaged in FEA cells.
FX343 Isolated by limiting dilution from an A/C complex obtained from an
anaemic cat in Scotland and passaged in FEA cells.
FZ215 Isolated by limiting dilution from an A/B/C complex obtained from
an anaemic cat in Great Britain in 1979. Passaged in FEA cells 
and anaemogenic in neonatal cats.
L3728F Isolated by limiting dilution from an A/C complex obtained from an
anaemic cat in Scotland in 1994 and passaged in FEA cells.
L3950F Isolated by limiting dilution from an A/C complex obtained from an
anaemic cat in Scotland in 1994 and passaged in FEA cells.
Table 3.1: Source and description o f primary FeLV isolates.
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3.2 Methods
3.2.1 Expansion of primary isolates
Isolates that were classified previously as subgroups A/C or A/B/C were used 
to infect the non-restrictive cell line FEA (FEA cells do not select for the A, B or C 
subgroups). The day prior to infection, FEA cells were seeded in 12 % cm^ flasks at a 
concentration of 1x10® cells per flask. The following day, supernatants were collected, 
clarified by centrifugation and 2ml of SN was added to each flask of FEA cells and 
incubated overnight at 37°C. The remainder of the supernatant was stored at -70°C 
until required. The following day, FEA cells were re-infected with the frozen 
supernatant and incubated for a further 4 hours, after which they were washed once 
with PBS and fresh 10% DMEM was added. Supernatant samples of the FEA-infected 
cells were collected and stored at -70°C at regular intervals. These supernatants were 
assayed for FeLV p27 by ELISA (FeLV p27 ELISA IDEXX Laboratories Limited, 
Buckinghamshire, U.K). If cultures were positive by ELISA, cells were expanded to 
prepare DNA (as described previously in section 3.2.2) and to enable storage In the 
vapour phase of liquid nitrogen (as described previously in section 2.2.1.2.1).
3.2.2 Preparation of High Molecular Weight DNA from cell pellets
DNA was prepared from p27-positive cell cultures by the method of Boom et al 
[(Boom R. et al., 1990), (QIAamp® DNA blood mini kit, QIAGEN)]. To prepare DNA, 
10  ^cells were resuspended in 200pt PBS and added to a sterile 1.5ml microcentrifuge 
tube containing 20pl protease. The cells were lysed by adding 200pl buffer AL and 
vortexed to ensure efficient mixing and thus lysing of the cells. Buffer AL contained 
25|ig/ml RNAse A to ensure RNA-free DNA. The mixture was incubated at 56°C for 
10 minutes before spinning briefly to remove drops from the inside of the lid. An equal 
volume of 100% ethanol was added before the lysate was applied to a spin column 
and was allowed to enter the silica gel resin.
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After binding of the DNA, the column was washed with 750p.l buffer AW1 and 750jal 
buffer AW2 subsequently to remove residual debris. The column was then centrifuged 
at 13000 rpm to remove all traces of wash buffer and DNA was eluted by adding 
200|il buffer AE to the column. The columns were incubated for 5 minutes at room 
temperature and subsequent centrifugation at 13000 rpm to release the DNA from the 
columns.
3.2.3 Amplification of envelope glycoprotein gene by PCR
Envelope glycoprotein genes were amplified from total cellular genomic DNA 
by using the polymerase chain reaction (PCR). Oligonucleotide primers were 
synthesised corresponding to the 5’ start codon and 3’ stop codon and incorporating 
Sail and Notl restriction sites, the oligonucleotide primers are shown in figure 3.1. A 
Kozak-sequence was included in the sequence of the 5’ primer to improve expression 
levels as described previousiy by Kozak (Kozak M., 1987). In each PCR reaction, the 
final concentrations of the components were the following: 1x buffer 2 (Roche applied 
science. East Sussex, U.K.), 1 mM dNTP (Promega, U.K.), 37.5 pmol of each primer 
(MWG, U.K.) and 50U of enzyme 1 (Roche applied science, East Sussex, U.K.). The 
amplification was performed under the following conditions: dénaturation at 94°C for 3 
minutes, followed by 30 cycles of dénaturation at 94‘"C for 30secs, annealing at SO'^ C 
for 1 minute and extension at 72°C for 3 minutes after which there was an additional 
10 minutes extension step at 72°C. The PCR gave a 1.8kb product, as predicted from 
the FeLV-A sequence and the samples were visualised by agarose gel 
electrophoresis as described previously (section 2.2.3.5).
62
Sail site Start codon of mature protein
FeLV env 5’ Sail: 5’-GC^.TCGJtÇ A Ç Ç A TG  GAA AGT CCA ACG CAC CCA AAA C-3’
Kozak sequence
Notl site
FeLV env 3’ Notl: 5 '-CCECGGlC^ CAA TCA TGG TCG GTC CG GAT CGTA TT-3’
End codon of 
mature protein
Figure 3.1: Structure of primers used to amplify the envelope glycoprotein of FeLV.
3.2.4 Molecular cloning of FeLV env gene products
The PCR products were ligated into the pCR1 vector (Invitrogen NV, Leek, 
The Netherlands) using the TA cloning system as described previously (section 
2.2.3.7) and transformed into E.coli INVaF' competent cells (section 2.2.3.8) as 
described previously. Colonies were picked, inoculated in 2.5ml L-broth containing 
50pg/ml ampicillin and grown overnight at 37°C. DNA was prepared using the “small- 
scale plasmid preparation” method (section 2.2.3.2.1) and the plasmid DNA was 
digested using 10 units of the restriction enzyme EcoRI to establish the presence of 
an insert as described previously (section 2.2.3.5).
3.2.5 Molecular cloning into the vector VR1012
Prior to ligation into the eukaryotic expression vector VR1012, the positive 
“miniprep” DNA’s were digested in a 50pl reaction mix containing 25 units of the 
restriction enzyme Sail and 25 units of the restriction enzyme Notl. The reactions 
were incubated at 37°C for a minimum of one hour and subsequently separated by 
agarose gel electrophoresis as described previously (section 2.2.3.6). Again, the 
fragment of interest was excised from the agarose gel and purified as described 
previously.
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Simultaneously, 5pg of the eukaryotic expression vector VR1012 was digested and 
purified. Insert and vector were then ligated and transformed, after which small-scale 
plasmid preparations were performed to identify positive colonies.
3.2.6 Nucleic acid sequencing of the novel env genes
The cloned envelope gene products were sequenced using either a LICOR 
model 4000 automated sequencer (section 2.2.3.10) or an ABI PRISM 3100 genetic 
analyser (section 2.2.3.11) using a panel of primers based on the published sequence 
of FeLV-A/Glasgow-1 (accession number P08359, (Stewart M.A. et al., 1986)). Primer 
design utilised the Omiga 2.0 software package (Oxford Molecular Ltd.), the primer 
binding sites are described in table 2.1 and figure 2.1. The sequences obtained were 
analysed using Wisconsin Package Version 10.0, Genetics Computer Group 
(Madison, Wisconsin) as described previously in section 3.2.5. Each nucleic acid 
sequence was translated using the “Translate” component of the GCG software 
package and the predicted amino acid sequence examined for integrity of the env 
open reading frame.
The novel env sequences were compared to the published sequences of 
FeLV-A/Glasgow-1 (Accession number P08359, (Stewart M.A. et al., 1986)), FeLV-B 
Gardner-Arnstein (Accession number P03391, (Wunsch M. et al., 1983)) or FeLV-C- 
Sarma (Accession number M14331, (Riedel N.O. et al., 1986)) using the "Bestfit” 
component of the GCG software package according to the local homology algorithm 
of Smith et al (Smith T.F. et al., 1985). Both nucleotide and amino acid alignments 
were performed using the "Pileup” component of the GCG software package 
according to the progressive alignment method described by Feng and Doolittle (Feng 
D.F. and Doolittle R.F., 1987).
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3.2.7 Preparation of FeLV/MuLV pseudotypes in 293T celis by 
transient transfection
Cells were transfected using the CaP0 4  method as described previously by 
Gorman (Gorman C.M. et al., 1985). On day 1, 3x10® 293T cells were plated In 
100mm dishes in lOmIs 10% DMEM. On day 2, chloroquine was added to the cells to 
a final concentration of 25|iM (the pH is increased by this endosomalytic agent, which 
in turn inhibits lysosomal hydrolytic enzymes and thus decreases the risk of 
degradation of endocytosed material (Luthman H. and Magnusson G., 1983)), 9pg of 
the FeLV env of interest, 9|ig pHitGO (which contains MuLV gag-pol to enable 
formation of FeLV env/MuLV gag-pol pseudotypes (Soneoka Y. et al., 1995)) and 9|ig 
mfg LacZ, (carrying the p-galactosidase marker gene (Dranoff G. et al., 1993)) were 
combined and the total volume made up to 1314|il with distilled water. 168pl of 2M 
CaCIa was then added without mixing. 1500p1 2xHBS was added slowly and the DNA 
mixture was added to the cells. After a 9 hour incubation, the transfection mixture was 
replaced with fresh 10%DMEM and the cells were then incubated overnight at 37°C. 
On day 3, the cells were washed twice with PBS and fresh growth medium was 
added. The following day, the supernatant of the transfected 293T cells was removed 
and filtered using a 0.4micron filter. The filtered viral pseudotypes were titred on 
H06T1 cells and then used to infect a range of cell lines in order to establish the 
tropism of the novel envelope glycoprotein. In parallel with the viral pseudotype 
studies, 293T cells transfected with each VR1012-env construct were fixed using ice- 
cold methanol and stained with the 6-15 monoclonal antibody (anti-gp70) first 
described in 1986 by Weijer et al (Weijer K. et al., 1986). Expression of mature 
envelope glycoprotein was then evaluated by immunofluorescence as described 
previously (section 2 .2 .1 .2 .2 .).
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3.3 Results
3.3.1 Isolation, PCR amplification and characterisation of novel 
envelope glycoprotein genes {envs)
Partial nucleic acid sequences of the envelope glycoproteins of FA27, FZ215 
and FS246 have been described previously by Brojatsch et al (Brojatsch J. et al., 
1992) and Rigby et al (Rigby M.A. et al., 1992). However, the sequences of the 
envelope glycoprotein genes of the three isolates did not cover the entire SU region 
and discrepancies were found between the sequences published by Brojatsch et al 
and Rigby et al. In order to identify a representative sequence of each primary isolate 
covering the entire SU and TM regions and to clarify the discrepancies described 
previously, a representative env clone of each primary isolate was amplified, cloned 
and sequenced. The env clones were then translated and the predicted amino acid 
sequence was examined for integrity of the env open reading frame. Amino acid 
alignments were performed on these sequences and are shown in figure 3.2.
FA27
Differences were apparent when comparing the three envelope glycoprotein 
sequences of primary isolate FA27. Three changes clustered in the VRA region and 
altered the polarity of the envelope glycoprotein. These substitutions were RegW, S7 2 R 
and A8 4T. Outwith the VRA region, the sequence published by Rigby et ai contains an 
additional aspartate residue and a glycine residue has been deleted (D i# and G1 22  
respectively). When compared with both the sequence published by Brojatsch et ai 
and the sequence described in this study, the alterations in the sequence described 
by Rigby et al result in an isolate that is slightly more polar than the isolates described 
by Brojatsch et al in this study. However, as only part of the envelope glycoprotein 
was sequenced by Rigby et ai and Brojatsch et ai, it was conceivable that mutations 
further on in the envelope glycoprotein may counteract the slight change in polarity 
and subsequently the infectivity of this isolate.
66
FS246
The amino acid sequences described previousiy for FS246 and the amino acid 
sequence characteristic of the FS246 isolate in this study were very similar. The 
overall polarity of this region of the envelope glycoprotein differed between the 
sequence published by Rigby et ai and the sequence published by Brojatsch et al and 
the sequence described in this study as there was a KgyE substitution resulting in a 
change from a positively charged residue to a negatively charged residue and a H1 0 1Y 
substitution which resulted in a change from a positively charged residue to a neutral 
residue. Therefore, the overall polarity predicted for the env described by Rigby et al 
was slightly lower than for the two other env sequences. As described for isolate 
FA27, it is conceivable that mutations further on in the envelope glycoprotein 
counteract this change in polarity in order that the isolate remains capable of infection. 
The addition and deletion of two amino acids in the FA27 sequence published by 
Rigby et al can also be found In the FS246 sequence described in the same paper, 
these are an additional aspartate residue and a deleted glycine residue, as is 
described for isolate FA27 (D114 and G1 2 2 respectively).
FZ215
The amino acid sequence of the FZ215 envelope glycoprotein described by 
Brojatsch et al is virtually identical to the published FeLV-C/Sarma sequence, bar one 
amino acid difference (L2 9 8 S) outwith the region shown in figure 3.2. Therefore, 
Brojatsch concluded that this isolate was not an independent isolate, but rather both 
this isolate and the FeLV-G/Sarma were derived from the same virus isolate. The env 
clone isolated in this study for the FZ215 isolate was very similar to the FZ215 isolate 
described by Brojatsch et al, however when compared with the published amino acid 
sequence of FeLV-C/Sarma, there were more differences in the sequence described 
in this thesis, therefore it was conceivable that this env clone was indeed an 
independent isolate and not derived from the same isolate as FeLV-C/Sarma. The 
sequence published by Rigby et al is significantly different from the two other FZ215 
isolates, having gained a stretch of three amino acids (®®RSW®®) at the start of the 
VRA region, this stretch is very similar to the sequence found in FeLV-A/Glasgow-1.
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FY981
In order to compare the unique envelope glycoproteins Identified in this study, 
an env clone of the primary isolate FY981 was amplified, cloned and subsequently 
sequenced. This env clone was considered characteristic of the FY981 isolate. An 
amino acid alignment of this representative FY981 clone, FeLV-A/Glasgow-1 and 
FeLV-C/Sarma is shown in figure 3.2. There were few differences in the VRA region 
of this FY981 env clone, when compared with FeLV-A/Glasgow-1, however the VRA 
region of this representative env clone was shorter than the VRA region of FeLV- 
A/Glasgow-1, indicating it was a C component of this isolate.
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At present, three sequences that represent FeLV-A have been published; they 
are FeLV-A/Giasgow-1 (accession number P08359, (Stewart M.A. et al., 1986)), 61E 
(accession number M18247, (Donahue P.R. et ai., 1988)) and FeLV strain Rickard, 
subgroup A (accession number AF052723, (Chen H. et al., 1998)) The published 
FeLV-A sequences show a high degree of homology in the envelope glycoprotein and 
have a VRA region of a similar length. Therefore, two criteria were used to define a 
unique env clone as the C-component of the primary isolate. The criteria were, firstly, 
a high degree of sequence divergence in the VRA region of the env clone when 
compared with FeLV-A/Giasgow-1 and secondly, the presence of length 
polymorphisms in the VRA region of the envelope glycoprotein. Conversely, sequence 
conservation and the absence of length polymorphisms in the VRA region of the env 
clones when compared with FeLV-A/Glasgow-1 indicated that the clone constituted 
the "A component" of the primary isolate. As FeLV-B/Gardner Arnstein is highly 
divergent from both FeLV-A/Glasgow-1 and FeLV-C/Sarma, subgroup B components 
were identified based on similarity to FeLV-B/Gardner Arnstein.
After small scale plasmid screening, thirty four small scale plasmid preps 
contained an insert of the expected size and thus were sequenced using the FeLV 
env primer F69, the primer binding site of which is described in figure 2.1 and table 
2.1. This primer binds prior to the start of the mature protein and therefore provides 
the sequence of the VRA region, enabling the identification of novel env clones. In 
order to classify each env clone as either the A-component or the C-component of the 
primary isolate, the predicted amino acid sequence was examined. Similarly, the 
integrity of the env open reading frame was confirmed in order to determine whether 
the env gene had the potential to encode a viable Env. The sequences were 
compared with both FeLV-A/Glasgow-1 and FeLV-C/Sarma and changes in the amino 
acid sequence relative to the published FeLV-A/Giasgow-1 sequence were Identified. 
All of the unique envelope glycoproteins isolated had intact open reading frames. 
Table 3.2 lists the similarities found when comparing the env clones with both FeLV- 
A/Glasgow-1 and FeLV-C/Sarma and figure 3.3 shows the amino acid alignment. 
Amino acid 1 in the amino acid sequence compares to amino acid 2026 in the 
published FeLV-A genome.
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E n v  c lo n e  # %  S im ila r ity  to  
V R A  reg io n  o f  
F e L V -A
%  S im ila r ity  to  
V R A  reg io n  o f  
F e L V -C
S u b g ro u p  
p re d ic te d  by  
s e q u e n c in g
F u rth e r
c h a ra c te ris a tio n
F A 27-17 97.4% 94.7% C Y e s
F A 27-19 85.5% 79.9% A N o
F A 27-53 99.0% 94.4% A Y e s
F A 27-55 98.7% 94.7% C Y e s
F A 621-15 77.6% 72.2% 8 (98.1% ) N o
F A 621-17 98.2% 92.4% A N o
F A 621-42 77.8% 79.6% B (96.3% ) N o
F A 621-43 98.8% 90.4% A N o
F A 621-44 67.1% 97.8% B (89.0% ) N o
F S 246-1 99.4% 92.5% A N o
F S 246-4 98.7% 93.7% C Y e s
F S 246-37 98.9% 93.9% C Y e s
F S 246-38 89.6% 82.9% A N o
F S 246-39 87.1% 82.1% A N o
F S 246-40 99.3% 94.2% A Y e s
F X 343-26 99.0% 93.9% A Y e s
F X 343-28 98.2% 93.6% A Y e s
F Y 981-9 87.4% 80.7% 0 (v a r ia n t 1) N o
F Y 981-10 97.4% 93.2% C  (v a r ia n t II) Y e s
F Y 981-12 94.1% 88.9% C  (v a r ia n t 1) N o
F Y 981-13 95.9% 90.7% C  (v a r ia n t 1) N o
F Y 981-14 97.9% 93.7% C  (v a r ia n t 1) Y e s
F Y 981-22 94.8% 90.4% C  (v a r ia n t II) N o
F Y 981-24 95.9% 89.8% C  (v a r ia n t 1) N o
F Z 215-9 98.2% 93.4% A Y e s
F Z215-10 39.4% 55.4% 8 (61.5% ) N o
F Z 215-11 71.9% 71.9% 8 (92.3% ) N o
F Z 215-12 77.0% 89.1% 8 (98.9% ) Y e s
F Z 215-46 66.8% 65.3% 8 (91.5% ) N o
L3128F-49 96.8% 91.1% A N o
L3128F -50 97.8% 92.6% A N o
L3950F -32 82.3% 76.7% A N o
L3950F -52 85.7% 80.8% C N o
L3950F -66 99.6% 92.6% A N o
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As shown in figure 3.3, the env genes that were classified as the A-components of the 
primary isolates display a high degree of similarity to the published FeLV-A/Glasgow- 
1 sequence. With the exception of the env clones derived from primary isolate FS246, 
in which the VRA region is three amino acids longer than the VRA region of FeLV- 
A/Giasgow-1, the env clones that appear to be C-components of the primary isolates 
ail contain a VRA region that is shorter than the FeLV-A/Glasgow-1 VRA region. This 
shows that the criteria used to classify the unique envelope glycoproteins are valid.
FA27
Isolate FA27, an A/C mixture in the original isolate, yielded four env gene 
clones. Both FA27-17 and FA27-55 appeared to be the C components of the mixture, 
whereas env clone FA27-53 was thought to be the A component. The fourth env 
clone, FA27-19, was identical to FA27-53 and therefore was not studied further.
FS246
Isolate FS246 was an A/C mixture of which six env genes were identified; 
three of the env clones identified were the A-component (FS246-1, FS246-38 and 
FS246-40), three of the env clones identified appeared to be the C component 
(FS246-4, FS246-37 and FS246-39). The three env clones thought to be the A 
component were identical, therefore only env clone FS246-40 was characterised 
further. Of the C component env clones, FS246-39 was identical to FS246-4 and 
therefore not characterised further.
FY981
Although the original FY981 isolate contained an A/B/C mixture, neither the A 
component nor the B component were isolated following expansion on FEA celis, 
suggesting that the C component of this isolate was relatively abundant. In total, 
seven envelope clones were isolated, five of which (FY981-9, FY981-12, FY981-13, 
FY981-14 and FY981-24 were identical to the representative FY981 sequence and 
were termed "variant I". Clones FY981-10 and FY981-22 had two amino acid 
differences (P7 4S and PyeS respectively when compared with the representative 
FY981 amino acid sequence and were termed "variant II” . Thus, only two FY981 env 
clones were characterised further, they were FY981-10 and FY981-14, representative 
of variant II and variant I respectively.
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FX343
Isolate FX343 again was an A/C mixture of which two env clones (FX343-26 
and FX343-28) were identified. Both of these clones appeared to be the A 
component, however, amino acid differences were observed in both sequences of 
these env clones, therefore the two sequences were characterised further.
FZ215
Isolate FZ215 was an A/B/C mixture, of which five env gene clones were 
identified, four of which (FZ215-10, FZ215-11, FZ215-12 and FZ215-40) were the B- 
component while the fifth clone, FZ215-9, was the A-component. These results 
suggested that the B-component was relatively abundant in this isolate.
FA621
Primary isolate FA621 was an A/C mixture, however when sequencing the five 
envelope genes obtained, three were similar to FeLV-B/Gardner Arnstein (FA621-15, 
FA621-42 and FA621-44) and two appeared to be the A-component (FA621-17 and 
FA621-43). These env clones were not characterised further, as the regions of the 
env clones sequenced were identical to the sequences published of FeLV-A/Glasgow- 
1 and FeLV-B/Gardner Arnstein. One env clone, FA621-44 contained two stop 
codons prior to the VRA region, suggesting this protein would be non-functional.
L3128F
When the two env genes obtained from primary isolate L3128F were 
sequenced, the env genes (L3128F-49 and L3128F-50) appeared to be the A- 
component of the primary isolate. Env clone L3128F-50 had a stop codon prior to the 
VRA region, suggesting this clone would be non-functional. These clones were not 
characterised further.
L3950F
Similarly, primary isolate L3950F yielded three envelope genes, L3950F-32, 
L3950F-52 and L3950F-66. One env clone, L3950F-52 appeared to be the C- 
component and two env clones (L3950F-32 and L3950F-66) were the A-components 
of his primary isolate. However, these clones were not characterised further as they 
appeared to be identical to the published FeLV-A/Glasgow-1 sequence.
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As summarised in table 3.3, when the nucleic acid sequences of the novel 
isolates were compared with FeLV-A, five nucleotide sequences were similar to FeLV- 
A/Glasgow-1, (FA27-53; 95.5%, FS246-40; 98.7%, FX343-26; 98.3%, FX343-28; 
97.9% and FZ215-9; 97.5% similarity to FeLV-A respectively), while six nucleotide 
sequences were similar to FeLV-C/Sarma (FA27-17; 90.2%, FA27-55; 89.2%, FY981- 
10; 88.9%, FY981-14; 89.5% FS246-4; 92.3% and FS246-37; 90.8% similarity to 
FeLV-C/Sarma respectively). One nucleotide sequence was similar to FeLV- 
B/Gardner Arnstein (FZ215-12; 98.4% similarity). A multipie nucieotide sequence 
alignment was performed on these sequences, with the exception of the isolate that 
was related to FeLV-B/Gardner Arnstein. The alignment is shown in figure 3.4 and 
position 1 in this nucleotide sequence correlates with nucleotide 6079 in the published 
FeLV-A genome. The majority of the sequence variation clusters in the VRA region of 
the envelope glycoprotein. It is striking that on examining the nucieotide alignment, 
the majority of changes in the nucleotide sequence are found in similar positions in 
the VRA region of the env gene.
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A separate nucleotide alignment was performed on the isolate that was related 
to FeLV-B/Gardner Arnstein, this alignment is shown in figure 3.5. Position 1 in this 
nucleotide sequence correlates with nucieotide 211 in the published FeLV-B genome. 
At present, two sequences that represent FeLV-B have been published; they are 
FeLV-B/Gardner Arnstein (Accession number P03391, (Wunsch M. et ai., 1983)) and 
FeLV-B/Snyder Theilen (Accession number KOI208, (Nunberg J.H. et al., 1984)). In 
order to maintain the nucleotide alignment, an adenine on position 380 in the 
published FeLV-B/Snyder Theilen sequence was deleted. The nucleotide alignment 
was lost from nucleotide 1510 in the published sequence of FeLV-B/Snyder Theilen 
and thus this sequence was deleted from that position onwards. When FZ215 was 
compared with the published sequences of the FeLV-B/Gardner Arnstein and FeLV- 
B/Snyder Theilen env genes, the majority of the differences were localised to the VRA 
and the VRB regions. A third cluster of changes was present from nucleotide 1115, 
however these changes did not affect the amino acid sequence (synonymous 
changes) and thus were discounted.
The sequences were then translated into amino acid sequences to establish 
the integrity of the env open reading frame and changes from the published FeLV A 
sequence. All of the novel env gene clones had intact open reading frames and figure 
3.6 shows the amino acid alignment using the “Pileup” component on GCG. Position 1 
in the amino acid sequence correlates with position 6079 in the published FeLV-A 
genome. The percentage similarity found for the novel env clones compared to FeLV- 
A/Glasgow-1 and FeLV-C/Sarma were equivalent to those found for the nucleic acids, 
albeit slightly higher, and are summarised in table 3.3. This higher degree of amino 
acid similarity suggests that some of the mutations detected in the nucleic acid 
sequence are “synonymous” (i.e. not affecting the coding sequence). When the 
sequence comparisons were restricted to the VRA region, the degree of amino acid 
similarity was considerably lower, consistent with this region being the major site for 
variation; the results of these comparisons are illustrated in table 3.4.
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Env clone 
#
Nucleotide 
similarity to 
FeLV-A 
Glasgow 1
Amino acid 
similarity to 
FeLV-A 
Glasgow 1
Nucleotide 
similarity to 
FeLV- 
C/Sarma
Amino acid 
similarity to 
FeLV- 
C/Sarma
Subgroup
predicted
by
sequencing
FA27-17 94.9% 97.4% 90.2% 94.7% C
FA27-53 95.5% 99.0% 88.4% 94.4% A
FA27-55 96.1% 97.4% 89.2% 94.7% C
FS246-4 98.5% 98.7% 92.3% 93.7% C
FS246-37 98.1% 98.9% 90.8% 93.9% C
FS246-40 98.7% 99.3% 90.1% 94.2% A
FY981-10 95.7% 97.4% 88.9% 93.2% C
FY981-14 96.5% 97.9% 89.5% 93.7% C
FX343-26 98.3% 99.0% 90.0% 93.9% A
FX343-28 97.9% 98.2% 89.9% 93.6% A
FZ215-9 97.5% 98.2% 89.9% 93.4% A
FZ215-12 77.4% 77.0% 90.1% 89.1% B (98.6% 
and 98.9%)
Table 3.3: Nucleotide and amino acid sequence homology of the complete env genes 
relative to the published sequences of the envelope glycoproteins of FeLV- 
A/Glasgow-1 and FeLV-C/Sarma.
8 0
Env clone # Amino acid 
similarity to 
FeLV-A 
Glasgow 1
Amino acid 
similarity to 
FeLV-C/Sarma
Predicted 
subgroup 
determined by 
sequencing
FA27-17 95.4 93.2 C
FA27-53 97.3 92.5 A
FA27-55 93.9 91.9 C
FS246-4 96.6 90.9 C
FS246-37 95.9 90.2 C
FS246-40 98.6 92.4 A
FY981-10 92.5 88.5 C
FY981-14 94.6 90.5 C
FX343-26 99.3 93.1 A
FX343-28 98.0 91.2 A
FZ215-9 97.3 91.8 A
FZ215-12 75.4 75.0 B
Table 3.4: Amino acid sequence homology of the VRA region of the novel env genes 
relative to the published sequences of FeLV-A/Glasgow-1 and FeLV-C/Sarma. The 
VRA region is a stretch of fifty-six amino acids starting from amino acid 50, relative to 
the published sequence of FeLV-/VGIasgow-1 (^DTWEPI to PKGTH^^°).
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FA27
Clone FA27-53 appeared to be the A-component of FA27, however FA27-53 
differed from FeLV-A/Glasgow-1 at six amino acids. As these amino acids were also 
present in the representative FA27C amino acid sequence, the data suggested that 
these amino acids were indeed representative of the FA27 isolate. Clones FA27-17 
and FA27-55 appeared to be C components of the FA27 isolate. When compared with 
the A-component of FA27 (FA27-53), there were three amino acid differences outwith 
the VRA region that were not present in clone FA27-53. A Q2 1 8 R substitution was 
present in both unique env clones and in the FA27 sequence published previously, 
therefore this substitution can be considered representative. There were also two 
amino acid substitutions present in both clones that were not present in the sequence 
published previously; these were I3 0 1V and IsiaD. The latter was a change from a 
hydrophobic residue without polarity (isoleucine) to an acidic negatively charged 
residue (aspartate). There were two changes in the VRA region compared with the 
published FA27 sequence, these were F6 2 L and SayR. The first substitution yields an 
amino acid with an aromatic side chain while the latter substitution resulted in a 
change in polarity of the residue from an uncharged polar residue (serine) to a 
positively charged polar residue (arginine).
FS246
When FS246-40, the A-component of the primary Isolate FS246, was 
compared to the published FeLV-A/Glasgow-1 sequence, three amino acid changes 
were found. Two of these amino acids (Q1 4 9P and A2 4 6G) were present in the 
representative FS246 sequence and thus they were considered to be consistent with 
FS246, whereas one substitution, D1 5 0G, was unique to FS246-40. The two env 
clones thought to be 0  components of primary isolate FS246, FS246-4 and FS246- 
37, were very similar to one another, however there were differences between these 
two env clones. Clone FS246-37 was Identical to the representative FS246 sequence, 
with the exception of a three amino acid stretch at the start of the mature peptide; the 
published sequence has a T2 4 P2 5 K2 6 . whereas the clone identified has a similar 
sequence to FeLV-A, namely N2 4T2 5Q2 6 . This amino acid stretch appeared to be a 
loop that links p-sheets and also resulted in an increase in the overall polarity; 
therefore the change in this stretch of sequence could alter the structure and 
subsequent function of the protein.
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Clone FS246-4, which also appears to be a C component, was very similar to 
the published FS246 sequence, with the exception of a S6 4 N substitution in the centre 
of the VRA region (similar to the sequence found in the published FeLV-A/Glasgow-1 
sequence) and a S2 9 0F substitution, neither of which resulted in a change in polarity of 
the overall amino acid sequence.
FX343
Both clones characterised for primary isolate FX343 were similar to FeLV- 
A/Glasgow-1 , suggesting that they were the A component of this primary isolate. As 
the parent FX343 sequence was not known, it was difficult to identify residues in the 
amino acid sequence that conferred the tropism of the clones characterised. There 
were four amino acid changes between the A-components and FeLV-A/Glasgow-1, 
suggesting these residues were unique to the primary isolate. However, there were an 
additional six changes present in FX343-28 when FX343-26 and FX343-28 were 
compared to one another, these were; Q2 2P, TiseA, N2 4 0T, TaeoA, S4B9T and As^V, 
none of these amino acid substitutions altered the polarity of the sequence. However, 
the amino acid substitution N2 4 0T resulted in the loss of a glycosylation site. 
Interestingly, there was also a change in the FX343-26 sequence compared to FeLV- 
A, namely Q2 2 4 K, which was not found in the FX343-28 amino acid sequence, altering 
the polarity from uncharged to positively charged.
FY981
The env clones identified from isolate FY981 were very similar to the FY981p 
amino acid sequence. Indeed, when compared to the FY981p amino acid sequence, 
there was only one amino acid difference in env clone FY981-14 (termed “variant I”). 
The threonine residue present at position 23 was also present in the FeLV- 
A/Glasgow-1 amino acid sequence. Clone FY981-10 (termed "variant 11”) differed from 
FY981-14 and FY981p at a stretch of three amino acids; P7 4 S7 5 P7 6 in contrast to 
S7 4S7 5 S7 6 . The polarity of the P7 4 S7 5 P7 6 and S7 4S7 5S76 is the same. However, although 
this variation in the amino acid sequence may not alter the overall polarity of this 
region of the protein, proline residues are predominantly found in the folds of a protein 
chain, therefore the presence of these proline residues may significantly alter the 
structure of the protein.
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FZ215
Isolate FZ215 consisted of two unique env clones, FZ215-9 and FZ215-12. 
The A component, FZ215-9, was virtually identical to the previously described FZ215 
sequence. However, there were four amino acids that were not present in the 
representative FZ215 sequence, these were D1 5 0G, I3 9 2A, IsgsT and S5 9 9 I, these amino 
acid changes should not affect the overall polarity of the protein. These amino acids 
were similar to those found In the FeLV-A/Glasgow-1 Env, suggesting that these 
amino acids were characteristic of the A component of this isolate. A separate 
nucleotide sequence alignment and amino acid sequence alignment was performed 
for the isolates that resembled FeLV-B Gardner-Arnstein; these are shown in figures 
3.5 and 3.7. The majority of unique amino acids were also found in the representative 
FZ215 clone, with the exception of two changes namely L4 1 I just prior to the VRA 
region and T 1 6 5 I (compared to the FeLV-B/Gardner Arnstein sequence) in the VRB 
region. Ties! results in a change of polarity from uncharged polar to hydrophobic non­
polar, a change that might result in a change in structure.
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3.3.2 Assaying the production of mature envelope glycoproteins by 
immunofluorescence
In order to assess whether the novel env genes produced polypeptides that 
were folded correctly, 293T cells were transfected with VR1012-env constructs, fixed 
with ice-cold methanol and stained using 6-15, a monoclonal antibody recognising the 
FeLV envelope glycoprotein. FeLV-A/Glasgow-1, FeLV-B/Gardner Arnstein and 
FeLV-C/Sarma were included as controls. The results of the antibody staining are 
shown in figure 3.8. From the twelve novel env gene products assessed, nine 
produced envelope glycoproteins that could be detected with the 6-15 antibody, 
namely FA27-17, FA27-53, FA27-55, FS246-4, FS246-37, FS246-40, FY981-14, 
FX343-28 and FZ215-9. The remaining three did not produce envelope glycoproteins 
that were recognised by the 6-15 antibody, namely FZ215-12, FX343-26 and FY981- 
10. Cells that were successfully transfected were clearly distinguishable as the 
fluorescence localised on the membrane of these cells, indicating the production and 
export of the envelope glycoprotein from the cells. The three env gene products that 
were unable to produce a protein that was recognised by the antibody were 
indistinguishable from the background cells, as can be seen in figure 3.8. To ensure 
the presence of cells in the field examined, a second image was recorded using bright 
field microscopy, the results of which can be seen in figure 3.8. As there were cells 
present in the field photographed, the negative antibody staining was due to the env 
constructs producing a protein that was no longer recognised by the antibody. Two 
possible explanations for the production of a protein that is not recognised by the 
antibody are firstly, mutations in the amino acid sequence disrupt the conformational 
structure of the protein and therefore the protein is no longer recognised by the 
antibody. Secondly, the mutations in the amino acid sequence are located in the 
antibody-binding site, therefore the antibody is no longer able to recognise the protein.
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FA27-17 FA27-53 FA27-55
FS246-4 FS246-37 FS246-40
FZ215-9 FZ215-12 FZ215-12
FX343-26 FX343-26 FX343-28
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FY981-10
4  A u
FY981-10 FY981-14
FeLV-A/Glasgow-1 control
FY981 control FeLV-C/Sarma control
FeLV-B/Gardner Arnstein control
Figure 3.8: Evaluation o f the expression of the mature envelope glycoprotein. 
The 2937 cells that were transiently transfected with the FeLV env constructs, a 
plasmid containing MuLV gag-pol and a marker gene were stained with the anti- 
gp70 monoclonal antibody 6-15 and examined by immunofluorescence.
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3.3.3 Cell tropîsm of the FeLV enWMuLV gag-pol pseudotypes
FeLV env/MuLV gag-pol pseudotypes were prepared by transfection of 293T 
cells with the VR1012 env constructs. The supernatants containing the pseudotypes 
were filtered through a 0.45pM filter and dilutions were prepared and subsequently 
plated onto a range of cell lines to determine the titres and in vitro cell tropism, the 
results of which are summarised In table 3.5. Pseudotypes bearing the FeLV-A, FeLV- 
B and FeLV-C env proteins were capable of infecting the cell lines predicted by 
previous studies, with FeLV-A having the most restricted in vitro cell tropism and 
FeLV-C the broadest in vitro cell tropism (Jarrett O. et al., 1973; Sarma P.S. et al., 
1975; Hardy W.G.Jr., 1993). FeLV-A infected the feline cell line H06T1 and Mink cells 
to titres of 10^ CFU/ml. FeLV-B infected the feline cell line H06T1 (1.1x10® CFU/ml) 
and In agreement with previous studies, the human cell line HeLa (6.8x10® CFU/ml), 
the canine cell line MDCK (1.2x10'^ CFU/ml) and the porcine cell line ST (1.5x10^ 
CFU/ml) (previous studies have shown that porcine cells are permissive for FeLV-B 
infection but not FeLV-A or FeLV-C infection (Hardy W.G.Jr., 1993)). FeLV-B/Gardner 
Arnstein infected Mink cells poorly (26 CFU/ml). Similarly, FeLV-C infected the feline 
cell line H06T1 (4.6x10^ CFU/ml) and in agreement with previous studies, the human 
cell line HeLa (5.7x10^ CFU/ml) and the guinea pig cell line 104C1 (1.5x10® CFU/ml) 
(guinea pig cells are known to be permissive to FeLV-C infection alone (Hardy 
W.G.Jr., 1993)). The titres of the FeLV-C/Sarma control were lower than the titres for 
the other controls included in the studies, on average the titres were five to ten fold 
lower than other titres (for example H06T1; FeLV-A 7.4x10® CFU/ml, FeLV-B 1.1x10® 
CFU/ml and FeLV-C 4.6x10^ CFU/ml). In agreement with previous studies, no FeLV 
subgroups were capable of infecting the murine cell line 3T3 (Jarrett O. et al., 1973).
The constructs, which were not recognised by the monoclonal antibody 6-15, 
namely FZ215-12, FX343-26 and FY981-10, did not produce pseudotypes capable of 
infecting the panel of cell lines, suggesting that the proteins formed were non­
functional. An additional three constructs, FS246-4, FS246-40 and FX343-28, also did 
not produce infectious pseudotypes, suggesting that, although the envelope 
glycoprotein was synthesised, there were further changes in the envelope 
glycoprotein that rendered these proteins non functional.
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H06T1 104C1 Mink HeLa
CB
MDCK ST Iowa 3T3
FS246-4 0 0 0 0 0 0 0
FS246-37 4.3x10® 5.6x10® 9.3x10® 2.5x10® 0 0 0
FS246-40 0 0 0 0 0 0 0
FA27-17 9 0 4.6x10" 0 0 0 0
FA27-53 9.6x10^ 0 5.6x10® 0 0 1.5x10® 0
FA27-55 9.3x10® 1.0x1 O'* 1.5x10'* 7.4x10® 0 0 0
FY981-10 0 0 0 0 0 0 0
FY981-14 7.1x10® 1.7x10'* 1.6x10'* 2.5x10® 5.7x10" 4.6x10® 0
FZ215-9 9.6x10® 0 6.2x10® 0 0 0 0
FZ215-12 0 0 0 0 0 0 0
FX343-26 0 0 0 0 0 0 0
FX343-28 0 0 0 0 0 0 0
CL29A 7.4x10® 0 4.0x10® 0 0 0 0
FeLV-
B/GA
1.1x10® 0 26 6.8x10® 1.2x10^ 1.5x10" 0
Sarma C 4.6x10" 1.5x10® 1.9x10® 5.7x10" 0 0 0
FY981 8.6x10® 1.9x10'* 2.0x10^ 7.1x10® 0 4.1x10" 0
Table 3.5: Titres (CFU/ml) of the unique env constructs established by infection of a 
panel of cell lines. The cell lines tested are: the feline kidney cell line H06T1, the 
guinea pig cell line 10401, the mink lung cell line MvlLu (Mink), the human cervical 
carcinoma cell line Hela OB, the canine kidney cell line MDCK, the porcine testes cell 
line ST IOWA and the murine cell line NIH 3T3.
1 1 2
The env constructs most closely resembling FeLV-A and which were shown to 
produce functional env protein (FA27-53 and FZ215-9) were able to infect the same 
cell lines as the control FeLV-A construct to comparable titres (9.6x10® CFU/ml and 
9.6x10® CFU/ml respectively for H06T1 infection and 5.6x10® CFU/ml and 6.2x10® 
CFU/ml respectively for Mink infection). Interestingly, FA27-53 was capable also of 
infecting the porcine cell line ST Iowa, a cell line thought to be permissive to FeLV-B, 
but not FeLV-A or FeLV-C infection, to a comparable titre as FeLV-B/Gardner 
Arnstein, 1.5x10" CFU/ml. When the amino acid alignment (see figure 3.6) was 
examined, one amino acid change ( D 5 3 N )  was present at the start of the VRA region 
in env clone FA27-53 and similarly present in FeLV-B/Gardner Arnstein. Therefore it 
is possible that this single amino acid substitution is responsible for the extended in 
vitro cell tropism of this clone. There are two possible explanations for this altered 
tropism of clone FA27-53. Firstly, the FeLV-A receptor present on ST cells is in an 
alternative conformational structure than the FeLV-A receptor present on H06T1 
cells. Secondly, similar to the proposition by Bupp et al (Bupp K. and Roth M.J., 2002) 
that FeLV-C is capable of utilising two receptors, there are two FeLV-A receptors and 
ST cells express a second FeLV-A receptor used by FA27-53. The amino acid 
substitution described above ( D 5 3 N )  is present also in the other FA27 constructs 
(FA27-17, FA27-55 and FA27p), however these constructs are not capable of 
infecting porcine cells. This could be due to the fact that there are numerous other 
changes in the VRA region when compared to FeLV-A/Glasgow-1 that may affect the 
conformational structure of the envelope glycoprotein and subsequently prevent 
infection of porcine cells.
The env constructs that were thought to be C components and were capable 
of producing functional env protein (FA27-55, FY981-14 and FS246-37) showed a 
similar host range to FeLV-C/Sarma. The titres of the unique env clones were slightly 
higher than the titres of the control construct, but comparable to titres found for the 
other constructs. Env clone FA27-17, which was also thought to be the 0  component 
of primary isolate FA27, was not able to infect the guinea pig cell line 10401 (a cell 
line permissive for infection with FeLV-C), however the overall titres of pseudotypes 
produced from this construct were at least 10 fold lower than the titres achieved with 
the other constructs (1.5x10'* CFU/ml, 1.6x1 O'* CFU/ml and 9.3x10® CFU/ml 
respectively compared to 4.6x10" CFU/ml when comparing the titres of mink
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infection). Therefore it is conceivable that the failure of pseudotypes derived from 
FA27-17 to infect 104C1 cells was due to the low titres generated and not due to the 
env being unable to support Infection of this cell line. Interestingly, construct FY981- 
14 had an extended in vitro cell tropism and was capable of infecting not only the 
porcine cell line ST, but also the canine cell line MDCK (5.7x10" CFU/ml). When 
pseudotypes derived from the representative FY981 clone (FY981p) were plated on 
the same panel of cells, it was capable also of infecting the porcine cell line ST 
(4.1x10" CFU/ml), suggesting that this a genuine trait of this isolate. However, 
FY981 p was not capable of infecting the canine cell line MDCK. This was considered 
to be a valid observation as the titres achieved when Infecting other cell lines were 
comparable, if not slightly higher for FY981p when compared to the other FY981 
clones. Therefore, an additional amino acid change present in FY981-14 and possibly 
FeLV-B/Gardner Arnstein, but not present in FY981p, could be responsible for the 
altered tropism of FY981-14. There was one amino acid difference (N2 3T) present in 
FY981-14, relative to FY981p, but this threonine residue was present also in the 
published FeLV-A/Glasgow-1 amino acid sequence (FeLV-A is incapable of infecting 
MDCK cells). When comparing the FY981 and the FA27 constructs, the D 5 3 N  
substitution discussed for construct FA27-53 was present in both the FY981p and the 
FY981-14 amino acid sequence, strengthening the involvement of this single amino 
acid substitution. The deletion in the VRA region of the FY981 constructs was smaller 
than the deletion in the FA27 constructs that were considered to be C components, 
suggesting that the unique sequence of the FA27 VRA region is responsible for the 
lack of infection of ST cells.
Rather surprisingly, only few isolates (FS246-37, FA27-55 and FY981-14) 
were capable of infecting the human cell line HeLa. With the exception of the FeLV-B 
control, only Isolates that were capable of Infecting 10401 cells were capable of 
infecting HeLa cells, leading to the conclusion that only pseudotypes that were the C 
component of a primary isolate were capable of infecting the human cell line HeLa. 
Given that previous studies have shown that FeLV-A infects the human cell line 293T, 
It is likely that these findings reflect differential receptor expression on 293T cells and 
HeLa cells.
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Virus
isolate
Original 
mixture of 
subgroups
Env clone 
number
Subgroup
predicted
by
sequencing
Antibody 
staining 
using 6-15 
monoclonal 
antibody
Subgroup 
established 
by virus 
infection
FA27 A/C 17 C + A or C*
53 A + A?
55 C + C
FS246 A/C 4 C + -
37 C + C
40 A + -
FX343 AJC 26 A - -
28 A + -
FZ215 A/B/C 9 A + A
12 B - -
FY981 AJB/C 10 C - -
14 C + C
Table 3.6: Subgroups determined of the unique envelope glycoproteins through both 
sequencing and infection on a panel of different cell lines.
* Titres of pseudotypes derived from FA27-17 were too low to confirm that FA27-17 
had the cell tropism of an A or C component.
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3.4 Discussion
FeLV can be classified Into three main subgroups, A, B and C as determined 
by interference assays (Sarma P.S. and Log T., 1973). The three subgroups have a 
distinct cell tropism; subgroup A has the most restricted cell tropism and is capable of 
infecting feline cells only, whereas subgroups B and C have a broader tropism and 
are capable of Infecting both feline and non feline cells (Hardy W.G.Jr., 1993; Jarrett 
O. et al., 1973; Sarma P.S. et al., 1975). Thus, an expanded cell tropism could be a 
useful tool in identifying subgroup 0  viruses. The main determinants of cell tropism 
and receptor binding of the virus are located in the N-terminal domain of the envelope 
glycoprotein, as was found for the murine retroviruses (Gray K.D. and Roth M.J., 
1993; BattinI J-L. et al., 1995; Bae Y. et al., 1997; Han J-Y. et al., 1997). Previous 
studies by Brojatsch et al and Rigby et al examined a number of FeLV-C isolates in 
order to establish the amino acids in the envelope glycoprotein that were responsible 
for the altered in vivo pathogenicity and in vitro cell tropism of FeLV-C (Brojatsch J. et 
al., 1992; Rigby M.A. et al., 1992). In both studies, the envelope glycoproteins of 
FeLV-C/Sarma, FeLV-C/FA27, FeLV-C/FS246 and FeLV-C/FZ215 were examined, 
however, the envelope glycoprotein was not sequenced fully In either study and there 
were discrepancies when the sequences were compared between the two studies 
(see figure 3.2 for the amino acid alignment of the published sequences and a 
representative clone of each isolate). As described in section 3.3.1, the differences 
found between the sequences altered the predicted polarity of the protein only slightly 
and were not expected to alter the overall structure of the protein. Furthermore, the 
specific amino acids or the stretch of amino acids involved in determining the in vivo 
pathogenicity and in vitro cell tropism were not identified. In order to locate the 
determinants of the in vitro cell tropism, we aimed to clone a representative of the 0- 
phenotype of each of the isolates and subsequently sequence the entire envelope 
glycoprotein gene to establish the determinants for the C-phenotype. Secondly, we 
aimed to investigate whether the envelope glycoproteins of subgroup A FeLVs were 
as conserved as has been suggested previously by screening a selection of A- 
components of the primary isolates studied.
116
In the course of these studies, thirty-four novel FeLV env clones were 
identified and were classified into either the A component or the C component of the 
isolate using the criteria described in section 3.3.1. Accordingly, fifteen clones 
appeared to be the A-component of the primary isolate and twelve clones appeared to 
be the C-component of that particular primary isolate. As the envelope glycoprotein of 
FeLV-B/Gardner Arnstein is highly divergent from both FeLV-A and FeLV-C, it was 
relatively easy to establish that the remaining seven clones were the B-component of 
those specific primary isolates.
3.4.1. The sequence of the novel FeLV-C envelope glycoproteins
3.4.1.1. Envelope glycoproteins described in this study are divergent from 
published envelope glycoprotein sequences
When the envelope glycoprotein sequences published by Brojatsch et al and 
Rigby et al were compared, contradictions were found in the two versions of the env 
sequences (Brojatsch J. et al., 1992; Rigby M.A. et al., 1992). Therefore, a clone of 
each of the isolates was sequenced and an amino acid alignment was performed to 
identify a representative envelope glycoprotein sequence. This alignment (see figure 
3.2) showed that there were some discrepancies between the studies; however, the 
overall polarity of each of the sequences was altered only slightly by the 
Inconsistencies between the studies. Therefore, it is conceivable that the 
discrepancies found previously did not have a significant effect on the overall 
structure of the envelope glycoprotein. However, as only fragments of the envelope 
glycoprotein were sequenced, It was possible that additional changes were present In 
regions outwith the VRA and VRB domains described previously (see section 1.4.4) 
which may have affected the structure in such a way that the isolates became non­
functional, as described by Rigby et al. Natural Isolate FZ215 was described as being 
FeLV-C/Sarma by Brojatsch et al, as there was only one amino acid difference in the 
region sequenced.
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However, both the FZ215 clone described by Rigby et a! and the representative clone 
sequenced in this thesis were significantly different from FeLV-C/Sarma; therefore the 
clones used in both the study described by Rigby et al and the study described in this 
thesis were Indeed, novel clones in their own right. When the novel envelope 
glycoproteins characterised in this thesis were compared with the published FeLV 
envelope glycoproteins, it became clear that the C component of each primary isolate 
was represented by more than one sequence.
3.4.1.2. Each primary Isolate is represented by multiple envelope glycoprotein 
sequences
When all the FeLV env A and C sequences identified in this study were 
compared, the majority of the env sequence was conserved. However, for each 
Independent isolate, there were characteristic differences throughout the sequence 
that were unique to that isolate. The majority of these differences were clustered in 
the variable regions of the envelope glycoprotein, though additional sequence 
polymorphisms were scattered throughout the entire envelope glycoprotein. For 
example, the primary isolate FY981 yielded seven env clones, five clones of which 
were termed “variant I” whereas the remaining two env clones were termed “variant 
II", due to a substitution from a stretch of S7 2S7 3S7 4 in "variant I" to a stretch of 
P 7 2 S 7 3 P 7 4  in “variant II". The FY981 “variant 11" clones produced an env protein that 
was not recognised by the 6-15 antibody, suggesting that “variant II" was defective. 
When comparing clone FY981-10 (variant II) and clone FY981-14 (variant I), no 
additional changes were found in the amino acid sequence, thus it is likely that the 
P 7 2 S 7 3 P 7 4  substitution in clone FY981-10 is responsible for this loss of infection. 
Similarly, primary isolate FS246 yielded two variant C components, namely FS246-4 
and FS246-37. When the amino acid sequences of FS246-4 and FS246-37 were 
compared, there were only three amino acid differences present in the entire 
envelope glycoprotein, nevertheless clone FS246-4 was no longer recognised by 
monoclonal antibody 6-15 and was incapable of Infecting the panel of cell lines tested. 
Of the three amino acid differences, the first difference (NszS) was situated at the start 
of the VRA region, whereas the remaining two differences were outwith the VRA 
region (S2 9 1 F and S4 2 8 P).
118
Thus, minor differences resulted in clone FS246-4 no longer being recognised by the 
monoclonal antibody 6-15 and incapable of infecting the panel of cell lines tested. 
When the amino acid sequences of the C components of primary isolate FA27 were 
compared, there was a single amino acid difference when comparing FA27-17 and 
FA27-55. Clone FA27-55 contained a serine residue at position 61, whereas clone 
FA27-17 contained an arginine residue at this position, consistent with the sequence 
found in FeLV-C/Sarma. However, the altered amino acid sequence of clone FA27-17 
resulted in a diminished titre when used to infect a panel of cell lines. Thus, the results 
described in this thesis lead to the conclusion that indeed there are multiple envelope 
glycoprotein sequences present in the viral pool of each primary isolate.
3.4.1.3. The abundance of the C-component within each primary isolate pool
When the number of subgroup C envs identified for each primary isolate was 
compared, it was clear that the C phenotype was more abundant in some primary 
isolates than in other primary isolates. For example, with isolate FY981 seven out of 
seven env clones were the C component, suggesting a relatively abundant C 
phenotype within this viral pool. Although this isolate was classified previously as an 
A/B/C mixture, neither the A component nor the B component were isolated. The 
primary isolate FZ215, which was originally classified as an A/B/C mixture, yielded 
five unique env clones. Of these five clones, one appeared to be the A component, 
four appeared to be the B component and no C component was identified, suggesting 
that the B component was abundant in this isolate while the C component was scarce. 
Although both primary isolates FX343 and L3728F were classified as A/C mixtures, 
only the A components were isolated, suggesting that the C component was rare in 
these viral pools. Both isolate FA27 and isolate FS246 yielded two out of four clones 
and two out of six clones respectively that were the C component, suggesting that the 
C component was relatively abundant in these pools. Interestingly, although isolate 
FA621 was previously classified as an A/C mixture through interference assays, the 
majority of clones (three out of five clones) appeared to be subgroup B, suggesting 
that either this original classification was incorrect, or that the C component was rare.
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3.4.2. Characteristics of the 0  phenotype of FeLV
3.4.2.1. The common features of the C-component
To date, no single amino acid or amino acid motif has been identified as a 
consistent feature of viruses with a subgroup C phenotype. Brojatsch et al proposed 
that a single lysine to arginine substitution at position 64 in the published FeLV-A 
sequence was sufficient to alter the in vitro host range (Brojatsch J. et ai., 1992). 
However, this Ke4 R substitution was not present consistently in the clones described 
in this thesis. Indeed, with the exception of the clones characterised from isolate 
FS246, this substitution was absent. The lack of this single substitution in the Isolates 
described in this study could be due to differences in the method used to perform an 
amino acid alignment. The amino acid alignment described in this thesis (see figure 
3.6) centred on a conserved alanine residue on position 66 in the published FeLV- 
A/Glasgow-1 sequence, which was present in all env clones identified in this study. 
Consequently, the lysine to arginine substitution described by Brojatsch et al was 
absent from the amino acid alignment. Therefore, it was highly likely that this amino 
acid was not the sole determining factor of the altered phenotype of the clones 
representing the 0  component.
When Rigby et al studied the receptor specificity and pathogenicity of the 
same natural FeLV-C isolates described by Brojatsch et al, it was found that the VRA 
region (referred to as V ri ) was sufficient to alter the receptor specificity from an A 
phenotype to a C phenotype (Rigby M.A. et al., 1992). The majority of changes found 
in the envelope glycoproteins described by Rigby et al were in the N-terminus of the 
envelope glycoprotein; in agreement with other studies (Bae Y. et al., 1997; Riedel N. 
et al., 1988; Riedel N.O. et al., 1986). Indeed as expected, the majority of changes 
described in this thesis can be found in the first variable region, the VRA region. The 
VRA region is predicted to be located on the surface of the envelope glycoprotein, as 
deduced from the MuLV env structure proposed by Fass et al (Fass D. et al., 1997). 
Therefore changes in the VRA region may alter the surface of the env and 
subsequently receptor recognition by the envelope glycoprotein.
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Figure 3.9 shows a possible structure of the FeLV env receptor-binding domain as 
deduced from the structure of the corresponding region of Friend MuLV according to 
Fass et al (Fass D. et al., 1997).
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Figure 3.1. Comparison of the predicted structures of the envelope glycoproteins of the feline and 
murine leukaemia viruses.
When examining both the nucleotide and the amino acid alignment, a pattern 
emerges in the sequence of the C components of the primary isolates. Whereas the A 
components are very similar, indeed there are few differences throughout the entire 
envelope glycoprotein (these will be discussed in more detail in section 3.4.3), the C 
components are highly divergent, as can be seen in figures 3.3 and 3.6. Deletions 
appear to cluster In similar areas of the envelope glycoprotein and there appear to be 
two common motifs found only in the C components, they are the lack of a stretch of 
six amino acids (®*TNVKHG®®) and a VeaW substitution.
3.4.2.1.1. Deletions In the VRA region of the envelope glycoprotein
When the nucleotide sequences of subgroup C envs were aligned, it was 
apparent that the mutations in the VRA region occurred at the same nucleotide 
position and consisted of common deletions and mutations (see figure 3.4). The 
deletions in the nucleotide sequences present in all subgroup C envs occurred from 
position 173 and consisted of:
a) Seventeen mutated nucleotides
b) Nine deleted nucleotides
c) Three nucleotides that were fairly conserved to account for the
conserved alanine residue
d) Three deleted nucleotides in all envs except FS246 env clones to
account for the two extra amino acids in FS246
The retroviral RNA genome is transcribed into a proviral DNA copy in a 
complex process called “reverse transcription” driven by the enzyme “reverse 
transcriptase" (which is encoded for by the retroviral pel gene). Reverse transcription 
in retroviruses is subject to a relatively high occurrence of errors due to the complexity 
of the process and the lack of an error correcting function of the enzyme (see also 
(Varela-Echavarrla A. et al., 1992), (Temin H.M., 1993) and (Mansky L.M., 2002)). 
Due to the presence of an additional enzyme, RNAse H, only a limited stretch of RNA 
is “unzipped" at any given time in the process. The majority of mistakes during this 
process occur due to the enzyme dislocating itself from the RNA and rejoining the
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structure at a different location. Two possible locations for the occurrence of such a 
mistake can be seen in figure 3.10, where in position A, the adjacent RNA strands are 
relatively close or position B where the RNA structure is stressed by adjacent areas of 
intrastrand hairpin formation. Thus it is highly likely that the clustering of mutations in 
the nucleotide sequence alignment of the novel FeLV envelope glycoproteins may be 
the result of mistakes during the reverse transcription process.
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Figure 3.10: Secondary structure o f RNA and possible positions where errors in the 
transcription could occur.
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3.4.2.1.2. Motifs in the envelope glycoprotein
When the env sequences of the C components are compared, there are two 
main features present in the envelope glycoprotein that are consistent with a C 
phenotype. Within the VRA region of the C components, a series of amino acids 
consisting of '^’TNVKHG®® starting at position 61 in the FeLV-A/Giasgow-1 envelope 
glycoprotein amino acid sequence is mutated resuiting in the disruption of the 
®'*TNVKHG®®. A second feature present in ail C components is the substitution VsaW. 
This series of amino acids may be a critical determinant in the A phenotype and 
usage of the A receptor as clones that contained " '^'TNVKHG®®” had an A tropism, 
whereas clones that lacked "®''TNVKHG®®” had a tropism consistent with the C 
phenotype. As discussed previously (see figure 3.10 and section 3.4.2.1), this stretch 
of amino acids is predicted to lie on the exposed surface of the protein and is situated 
in the putative receptor binding domain, therefore changes in this region of the 
envelope glycoprotein are likely to alter the region of the protein that determines the 
ability of the virus to bind its receptor. The valine and the tryptophan residues have 
hydrophobic side chains and thus may form a hydrophobic pocket on the surface of 
the envelope glycoprotein; a tryptophan residue at position 142 has been linked 
previously to the formation of a hydrophobic pocket and subsequent binding of the 
viral receptor by the envelope glycoprotein of ecotropic MuLV (Zavorotinskaya T. and 
Albritton L.M., 1999). Thus, even though the tryptophan residue described in this 
thesis is not the tryptophan residue described by Zavorotinskaya and Albritton, it is 
conceivable that the tryptophan residue present in the C components has a similar 
role in the receptor recognition and thus Is involved in the altered receptor binding of 
the C components.
As is clear in figure 3.11, the addition or deletion of even a small number of 
amino acids can have a major impact on the exposed receptor recognition site on the 
surface of the envelope glycoprotein. When three amino acids are deleted (as is the 
case in the C components of the primary isolates), the amino acid sequence after this 
shifts to the left and thus exposes a novel receptor recognition site (see figure 3 .1 1 a). 
Similarly, the addition of three amino acids (such as in the 0  components of primary 
isolate FS246) results in the amino acid sequence shifting to the right and thus the 
exposure of an additional receptor recognition site (see figure 3.11b).
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A: Deletion of three amino adds
A
B: Addition of three amino adds
B
B
Figure 3.11: The effects a deletion or an addition o f a stretch of three amino acids 
can have on amino acids involved in for example receptor binding.
3.4.2.2. The occurrence of clustered mutations within the envelope glycoprotein
When the nucleotide and amino acid sequences were compared, differences 
between the sequences were clustered within a number of regions of the env. The 
majority of the sequence changes were present in the first twenty-five amino acids of 
the VRA region (stretching from D5 3  to G 7 9 )  while fewer changes were clustered in the 
VRB region. There were additional amino add changes throughout the entire 
envelope glycoprotein and it is possible that these changes occurred to counteract 
amino acid changes in other regions of the envelope glycoprotein and therefore were 
there to maintain the structure of the protein, as also discussed briefly by Pass et ai 
(Pass D. et al., 1997).
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The clustering of amino acid changes In the envelope glycoprotein sequence 
rather than the random occurrence of these changes throughout the entire envelope 
glycoprotein indicates that the accumulation of mutations in the sequence is not 
random. While the mechanism of acquisition of the mutations (e.g. errors in reverse 
transcription) is largely random in nature, the process of selection for mutant envelope 
glycoproteins is likely to be driven by:
a) Pressure to escape the humoral immune response against exposed
epitopes
b) Selective pressure for mutations that are tolerated by the envelope
glycoprotein structure
c) Selection for mutations that give rise to a variant virus with a
replicative advantage, for example a broader ceil tropism.
3.4.3. The envelope glycoprotein sequences of the A components
Of the thirty-two envelope glycoproteins identified, fifteen env clones were 
classified as the A component of the primary isolate, using the criteria described 
previously (lack of both variability and length polymorphisms in the VRA region of the 
envelope glycoprotein). Comparisons of the FeLV-A envelope glycoprotein sequences 
that have been published to date (FeLV-A/Glasgow-1 and 61E) revealed few 
differences between the envelope glycoprotein sequences. However, when the env 
clones identified in this study were compared, there appeared to be a small number of 
differences between the envelope glycoprotein amino acid sequences. These amino 
acids were present in other clones of the same primary isolate, for example a D^N 
substitution and a N 5 9 D  substitution (relative to the FeLV-A/Glasgow-1 sequence) In 
the VRA region of the clones derived from primary isolate FA27. As these amino acids 
were present in all clones sequenced from this particular primary isolate, it was likely 
that these amino acids were a conserved feature of the envelope glycoprotein. 
Further, these changes were also present in the published amino acid sequences of 
FA27 by both Brojatsch et al and Rigby et al (Brojatsch J. et al., 1992), (Rigby M.A. et 
al., 1992).
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These data suggested that although FeLV-A amino acid sequences were very similar, 
there might be amino acids that were specific for env clones derived from a particular 
isolate, rendering these changes unique to a specific primary isolate. Moreover, minor 
variations in the VRA region of independent isolates of FeLV-A might affect the cell 
tropism and immunogenicity of the virus, perhaps influencing the likelihood of 
producing a subgroup C variant in vivo.
3.4.4. Effects of the env sequence on antibody staining and 
biological function
In order to establish the function and the host range of twelve of the unique 
envelope glycoproteins isolated, FeLV/MuLV pseudotypes were generated and their 
cell tropism investigated in vitro (see table 3.5). Further, recognition of the viral env 
protein by the anti-gp70 antibody 6-15 was examined by immunofluorescence (see 
figure 3.8).
3.4.4.1. The production of mature envelope glycoprotein in vitro
Of the twelve envelope glycoproteins that were fully characterised, three env 
clones (FX343-26, FY981-10 and FZ215-12) failed to react with the anti-gp70 
monoclonal antibody 6-15. While the binding site for the monoclonal antibody 6-15 
has not yet been characterised, it Is known that the antibody recognises the three 
subgroups of the virus, suggesting that the antibody-binding site is located in a highly 
conserved region of the envelope glycoprotein. Two possible explanations for the 
production of a protein that is no longer recognised by this antibody are:
a) the mutations in the amino acid sequence disrupt the
conformational structure of the protein and therefore the antibody 
epitope is no longer available to the antibody.
b) the mutations are located in the antibody-binding site, destroying
the epitope and preventing antibody binding.
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In each of the three env clones that failed to bind the monoclonal antibody, there were 
a number of changes in the amino acid sequence that were not present in env clones 
identified from the same primary isolate that were recognised by the monoclonal 
antibody. The mutations for each env clone were as follows:
a) FX343-26: Q2 2 4 K
b)FY981-10: S ^ fa n d S ^ P
c) FZ215-12: T2 3A and T 1 6 5 I
When the three env clones were compared, the mutations appeared to fall in distinct 
regions of the envelope glycoprotein. Based on the structure of the MLV envelope 
glycoprotein (see figure 3.12), the predicted locations for these amino acids in the 
FeLV envelope glycoprotein lie in distinct regions of the protein, it is therefore unlikely 
that these amino acids form the 6-15 epitope on the envelope glycoprotein. Rather, it 
is likely that the mutations in the envelope glycoprotein alter the conformational 
structure of the protein and as a result, the 6-15 epitope is destroyed, leading to a 
protein no longer recognised by the monoclonal antibody.
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Figure 3.12: Predicted locations o f the T2 3A and TiesI mutations on the
FeLV A enveiope giycoprotein (structure is modelled on the published coordinates of 
MLV envelope glycoprotein, pdb number 1A0L).
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In a study by Burns et al (Burns C.C. et al., 1995) into the mutations 
responsible for an altered phenotype and the delayed onset of immunodeficiency, it 
was found that two amino acid changes, EsssK E 5 3 7 K ,  within a putative cysteine loop of 
the TM region were sufficient to interfere with enveiope glycoprotein processing. In 
env clones that did not produce detectable protein in this study, similar changes were 
not observed. These data suggested that distinct amino acids are responsible for 
interfering with the production of viable Env. As the epitope recognised by the 6-15 
monoclonal antibody has not yet been characterised, it is not possible to determine 
the precise residues responsible for the improper folding of these proteins. A further 
two Env clones (FS246-40 and FX343-28) produced a protein that was recognised by 
the anti gp70 monoclonal antibody 6-15 but did not produce pseudotypes capable of 
infecting of a panel of cell lines, suggesting that although correctly folded the 
mutations disrupted a region that affects the function of the Env, possibly by 
interfering with the receptor binding site (discussed in more detail in section 3.4.2.2.). 
Accordingly, these data may suggest that the antibody binding site and the receptor- 
binding site are distinct regions in the envelope glycoprotein.
3.4.4.2. Altered cell tropism of novel FeLV env clones
To determine whether the novel envelope glycoproteins were functional, the 
cell tropism of FeLV/MuLV pseudotypes prepared from each clone was investigated. 
Previous studies have examined the in vitro cell tropism of FeLV-A, FeLV-B and 
FeLV-C and have shown that FeLV-A has the most restricted in vitro ceil tropism and 
is capable of infecting feline cells alone (Jarrett O, et al., 1973), (Sarma P.S. et al., 
1975), (Hardy W.G.Jr., 1993). In contrast, FeLV-B and FeLV-C have a broader in vitro 
cell tropism and both viruses are capable of infecting a range of feline and non-feiine 
cells. FeLV-C is the only subgroup capable of infecting guinea pig ceils, whereas 
porcine cells can be infected by FeLV-B alone (Jarrett O. et al., 1973), (Hardy 
W.G.Jr., 1993).
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The three env clones that failed to produce protein recognised by the 6-15 
antibody (FX343-26, FY981-10 and FZ215-12) did not produce pseudotypes capable 
of infecting the cell lines examined, suggesting that the proteins produced were 
indeed non-functional. Furthermore, three viable env clones (FS246-4, FS246-40 and 
FX343-28) did not produce pseudotypes capable of infecting the cell lines tested, 
suggesting that although the protein was folded properly, it was non-functional and 
indicating that mutations outwith the antibody-binding site rendered the protein non­
functional. The receptor-binding domain has been identified previously for 
amphotropic MuLV by amongst others Bae et al and consists of the first two hundred 
and thirty amino acids of the enveiope glycoprotein (Gray K.D. and Roth M.J., 1993; 
Battini J-L. et al., 1995; Bae Y. et al., 1997; Han J-Y. et al., 1997). Thus, amino acid 
substitutions within this region may affect the function of the protein. When clone 
FS246-40 was compared with FeLV-A/Glasgow-1, five amino acid differences were 
identified; these were Q1 4 9P, D1 5 0G, Ag^aG, M3 3 3L and T3 7 1 P. As the Q1 4 9P and A2 4 8G 
mutations were present in the viable FS246 clones, it was unlikely that these amino 
acids were responsible for the loss of function of the protein. Furthermore, although a 
M3 3 3L substitution was present in FS246-40, the methionine residue at position 333 is 
present only in FeLV-A/Glasgow-1 and not in any other FeLV envelope glycoprotein. 
When FeLV-A/Giasgow-1 was sequenced, this methionine residue was present In the 
primary FeLV-A/Glasgow-1 clone, thus the residue was considered to be a unique 
feature of FeLV-A/Glasgow-1. In all other clones, this residue is leucine, thus this 
residue can be excluded from the possible mutations affecting the protein structure. 
Thus, two substitutions remain that may be involved in the loss of functional protein; 
these are D1 5 0G and T3 7 1P. D1 5 0G is located in the VRB region of the envelope 
glycoprotein and this substitution results in a change from a negatively charged 
residue (D) to an uncharged residue (G). Considering the location of this residue, this 
substitution could affect the interaction between the virus and its receptor. However, 
this substitution was present also in env clone FZ215-9, a clone that was capable of 
producing a protein that was recognised by the anti-gp70 monoclonal antibody 6-15. 
Thus It is unlikely that this residue is responsible for the loss of biological function 
although it is possible that FZ215-9 has mutations in adjacent regions of the structure 
that compensate for D1 5 0G while FS246-40 does not.
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I n  c o n t r a s t ,  T 3 7 1 P  i s  s i t u a t e d  i n  a  h i g h l y  c o n s e r v e d  r e g i o n  o f  t h e  e n v e i o p e  g i y c o p r o t e i n  
a n d  r e s u l t s  i n  a  c h a n g e  f r o m  a  n e u t r a l ,  h y d r o p h i l i c  r e s i d u e  t o  a  r e s i d u e  t h a t  i s  f o u n d  
p r e d o m i n a n t l y  i n  b e n d s  i n  t h e  c o n f o r m a t i o n a l  s t r u c t u r e  o f  a  p r o t e i n .  F u r t h e r m o r e ,  t h i s  
m u t a t i o n  i s  s i t u a t e d  t e n  a m i n o  a c i d s  r e m o v e d  f r o m  a  s t r e t c h  o f  a m i n o  a c i d s  t h a t  h a s  
b e e n  d e s c r i b e d  p r e v i o u s l y  t o  b e  i m p o r t a n t  i n  t h e  o n s e t  o f  i m m u n o d e f i c i e n c y  
( Q u a c k e n b u s c h  S . L .  e t  a l . ,  1990) .  T h u s  i t  i s  l i k e l y  t h a t  a m i n o  a c i d  m u t a t i o n s  i n  t h i s  
r e g i o n  o f  t h e  e n v e l o p e  g l y c o p r o t e i n  c a n  i n d e e d  a l t e r  t h e  p r o t e i n  s t r u c t u r e  s u f f i c i e n t l y  
t o  a c c o u n t  f o r  t h e  l o s s  o f  a  f u n c t i o n a l  p r o t e i n .  W h e n  t h e  s e q u e n c e  o f  c l o n e  F X 343-28 
w a s  c o m p a r e d  w i t h  F e L V - A / G l a s g o w - 1, t h e r e  w e r e  t w e l v e  a m i n o  a c i d  d i f f e r e n c e s  
b e t w e e n  t h e  c l o n e s .  O f  t h e s e  t w e l v e  a m i n o  a c i d s ,  f i v e  w e r e  a l s o  p r e s e n t  i n  c l o n e  
F X 343-26 ( a  c l o n e  t h a t  w a s  n o t  r e c o g n i s e d  b y  t h e  6-15 m o n o c l o n a l  a n t i b o d y ) ;  t h e s e  
w e r e  S 7 5 D ,  T s i s i ,  M 3 3 3 L ,  K 3 4 8 E  a n d  V 5 9 4 I .  A  f u r t h e r  s e v e n  a m i n o  a c i d  d i f f e r e n c e s  w e r e  
p r e s e n t  i n  c l o n e  F X 343- 28 , b u t  n o t  i n  c l o n e  F X 343- 26 , t h e s e  w e r e  Q 2 2 P .  T i g g A ,  N 2 4 0 T ,  
T 3 8 0 A ,  S 3 8 9 T ,  A 5 1 1 V  a n d  K g g g l .  F o u r  o f  t h e  s u b s t i t u t i o n s  w e r e  r e l a t i v e l y  m i n o r  
s u b s t i t u t i o n s  ( T i b b A ,  T s s o A ,  S s s q T  a n d  A 5 1 1 V )  a n d  w e r e  n o t  l i k e l y  t o  h a v e  a n  e f f e c t  o n  
t h e  o v e r a l l  s t r u c t u r e  o f  t h e  p r o t e i n .  H o w e v e r ,  t h e  r e m a i n i n g  t h r e e  s u b s t i t u t i o n s  ( Q 2 2 P ,  
N 2 4 0 T  a n d  K 5 9 5 I )  c o u l d  h a v e  a n  e f f e c t  o n  t h e  o v e r a l l  s t r u c t u r e  o f  t h e  p r o t e i n  a n d  
s u b s e q u e n t  l o s s  o f  a  f u n c t i o n a l  p r o t e i n .  P r o l i n e  i s  a  r e s i d u e  t h a t  i s  p r e d o m i n a n t l y  
f o u n d  i n  t h e  b e n d  o f  f o l d e d  p r o t e i n  c h a i n s ,  t h u s  t h e  p r e s e n c e  o f  t h i s  r e s i d u e  i s  l i k e l y  t o  
h a v e  a  m a j o r  e f f e c t  o n  t h e  p r o t e i n  s t r u c t u r e .  S i m i l a r l y ,  t h e  o c c u r r e n c e  o f  c h a n g e s  i n  a  
h i g h l y  c o n s e r v e d  a r e a  o f  t h e  e n v e l o p e  g i y c o p r o t e i n  ( K 5 9 5 !  a n d  N 2 4 0 T )  m a y  a f f e c t  t h e  
c o n f o r m a t i o n a l  p r o t e i n  s t r u c t u r e  a n d  r e s u l t  i n  t h e  l o s s  o f  t h e  p r o d u c t i o n  o f  a  f u n c t i o n a l  
p r o t e i n .  T h e  m u t a t i o n  K 5 9 5 I  i s  s i t u a t e d  i n  t h e  p 15E  p r o t e i n ,  a n d  m i g h t  a f f e c t  t h e  
i n t e r a c t i o n  b e t w e e n  p 15E  a n d  g p 70 a n d  t h u s  r e s u l t  i n  a  p r o t e i n  t h a t  i s  n o t  c a p a b l e  o f  
p r o d u c i n g  p s e u d o t y p e s  t h a t  c a n  i n f e c t  t h e  p a n e l  o f  c e l l  l i n e s  t e s t e d .
Pseudotypes bearing the Envs most closely resembling FeLV-A (FA27-53 and 
FZ215-9) were able to infect the feline cell line H06T1 and mink cells to comparable 
titres as those derived from the control FeLV-A (7.4x10^ CFU/ml for the control FeLV- 
A compared to 9.6x10® CFU/ml for both FA27-53 and FZ215-9 when infecting H06T1 
ceils). FA27-53, FZ215-9 nor the control FeLV-A derived pseudotypes were capable 
of infecting any other ceil line tested, including the human cell line HeLa and the 
canine cell line MDCK.
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The inability of pseudotypes derived from FeLV-A/Giasgow-1 and the novel FeLV-As 
to infect human cells, contradicts studies by Moser et al and Bupp et al, in which the 
host range of FeLV-A was studied (Moser M. et al., 1998), (Bupp K. and Roth M.J., 
2002). Both Moser et al and Bupp et al found that FeLV-A does indeed infect human 
cells. However, both of these studies used the human cell line 293T for infection 
assays while HeLa cells were used in this thesis. Moreover, the FeLV-A isolates used 
were distinct; 61E in contrast with FeLV-A/Glasgow-1 used in the infection assays 
described in this thesis. Indeed, 293T cells supported infection with the FeLV- 
A/Glasgow-1 isolate used in this study (data not shown). It is possible that distinct 
isolates of FeLV-A are capable of infecting different cell types and secondly although 
it is generally stated that FeLV-A is incapable of infecting human cells, the 
discrepancies when comparing the findings in this thesis and the studies described by 
both Moser et al and Bupp et al may be due to differences in the human cell line used 
for the infection assays.
Interestingly, pseudotypes derived from clone FA27-53 were capable of 
infecting the porcine cell line ST Iowa, in contrast to previous reports in which porcine 
ceils were shown to support FeLV-B infection alone. When the sequence of FA27-53 
was examined, there were relatively few differences between FA27-53 and FeLV- 
A/Glasgow-1. Relative to FeLV-A/Glasgow-1, they are D 5 1 N ,  N 5 9 D ,  V2 4 7 I, T3 1 8 I, M 3 3 3 L ,  
K&wE and Kq^R- With the exception of D^N and N^D, the amino acid differences lay 
outwith the region in the envelope glycoprotein associated with cell tropism 
(determined amongst others by Bae et al (Bae Y. et al., 1997)). When the FA27-53 
amino acid sequence was compared with the amino acid sequence of other 
constructs that were capable of infecting ST Iowa ceils (FY981-14, FY981 and FeLV- 
B/Gardner Arnstein), the D^N substitution alone was present in ail constructs which 
pseudotypes were capable of infecting ST Iowa cells. Thus it is likely that this single 
amino acid substitution may explain the tropism of FA27-53 env-bearing pseudotypes 
for the porcine cell line ST Iowa. The amino acid substitution discussed (DsiN) was 
present also in the other FA27 constructs (FA27-17, FA27-55 and FA27p), however 
pseudotypes derived from these constructs were not capable of infecting porcine 
ceils.
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This could be due to the fact that there were numerous other changes in the VRA 
region when compared to FeLV-A/Glasgow-1 and therefore altering the 
conformational structure of the proteins and subsequently the amino acids thought to 
be involved in infection of porcine ceiis were no longer available. Thus, the data 
presented in this thesis suggest that although it was thought that FeLV-A isolates had 
the same in vitro ceil tropism, FeLV-As derived from diverse primary isolates did have 
a unique in vitro cell tropism.
The env-construct that most closely resembled FeLV-B/Gardner Arnstein, 
FZ215-12, did not produce protein recognised by the monoclonal antibody 6-15, nor 
was it capable of producing functional protein as was shown by the lack of infection by 
FZ215-12 env/MuLV gag-po! pseudotypes. This suggested that the small number of 
changes compared to the published FeLV-B/Gardner Arnstein present in this 
envelope glycoprotein rendered this construct defective. There were two additional 
changes in the amino acid sequence of FZ215-12 that were found neither in the 
published FeLV-B/Gardner Arnstein sequence nor in the parent FZ215 sequence. 
These were a T2 3A substitution and a Ties! substitution; both substitutions resulted in a 
change from a residue with an uncharged polar side chain to a residue with a non­
polar side chain. The side chain of threonine is hydrophilic; whereas both alanine and 
isoieucine have hydrophobic side chains, thus leading to the conclusion that these 
minor changes could indeed lead to the production of a non-functional protein.
Pseudotypes derived from the env clones thought to be G components (FA27- 
55, FS246-37 and FY981-14) were capable of infecting both the feline ceil line H06T1 
and the guinea pig cell line 10401 to higher titres than the control FeLV-C/Sarma 
(4.6x10^ CFU/ml for the control FeLV-C compared to 9.3x10® CFU/ml for FA27-55, 
4.3x10® CFU/ml for FS246-37 and 7.1x10® CFU/ml for FY981-14 when infecting 
H06T1 cells). The ten fold difference in titres was most likely due to the poorer titres 
for the FeLV-C/Sarma construct, as the titres found for FA27-55, FS246-37 and 
FY981-14 were comparable with the titres found for the control FeLV-A/Glasgow-1 
construct. Furthermore, env clone FY981-14 had a broader tropism than the other C 
components and the control FeLV-C/Sarma. However, the tropism of FY981-14 was 
comparable to the tropism of clone FY981 p.
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Indeed, It was capable of infecting ail cell lines tested, including the porcine cell line 
ST Iowa thought to be restrictive to FeLV-B infection only. As discussed for FA27-53, 
the D5 1 N substitution that may be involved in altering the tropism to include infection 
of the porcine ceil line ST Iowa is present also in the amino acid sequence of FY981- 
14.
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CHAPTER FOUR
ENRICHMENT OF FeLV-C ISOLATES 
BY BIOLOGICAL SELECTION
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4.1 Introduction
The FeLV isolates described earlier (section 3.1) were classified into 
subgroups A, B or C by interference assay. Our initial aim was to amplify env gene 
products representative of the original mix of subgroups within the primary isolate. 
With some isolates, no C component was detected following the PGR reaction, 
therefore, in order to enrich for the 0  component, the primary isolate was plated onto 
the 10401 cell line, a guinea pig cell line which is known to be permissive for infection 
with subgroup 0  viruses, but restrictive to infection with the A and B subgroups. Thus, 
it was hoped that through biological selection, the 0  component would replicate 
preferentially and thus it would be represented in the pool of viral envs isolated.
Biological selection is the process whereby populations of organisms adjust to 
their environment through the accumulation of beneficial mutations. Through natural 
selection, these mutations will spread and ultimately the mutations that are the most 
advantageous will predominate in the viral population (Gerrish P., 2001). As the 
enzyme reverse transcriptase (encoded by the pel gene in the retroviral genome) 
does not have a proof-reading activity, these random mutations occur frequently and 
result in a population with a novel phenotype (Miralles R. et al., 2000), (Overbaugh J. 
and Bangham G.R., 2001).
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4.2 Methods
4.2.1 Isolation of FeLV -  C subgroups through biological selection
Isolates that were classified previously as subgroups A/C or A/B/C were 
expanded on the FEA cell line (non-restrictive). The supernatants were then used to 
infect 10401 cells. The day prior to infection, 10401 ceiis were seeded in 12.5 cm^ 
flasks at a concentration of 1x10® cells per flask. The following day, supernatant was 
collected from FEA stocks, clarified by centrifugation and 2m) of SN was added to 
each flask of 10401 cells and incubated overnight at 37°C. The remainder of the 
supernatant was stored at -70°O until required. The following day, 10401 cells were 
re-infected with the frozen FEA supernatant and incubated for a further 4 hours, after 
which they were washed once with PBS and fresh 10% DMEM was added. 
Supernatant samples of the 10401-infected cells were collected at regular intervals 
and stored at -70°O. The supernatants were then assayed for FeLV p27 by ELISA 
(FeLV p27 antigen ELISA kit, IDEXX Laboratories Limited, Buckinghamshire, U.K). If 
the cultures were positive by ELISA, then the cells were expanded to prepare DNA 
(as described previously in section 3.2.2) and to enable storage in the vapour phase 
of liquid nitrogen (as described previously in section 2.2.1.2.1).
4.2.2 Amplification of the enveiope glycoprotein by PCR
Total cellular DNA from the infected 10401 cells was subjected to POR using 
primers to introduce Sail and Notl restriction sites to enable direct cloning of the 
amplified product into the eukaryotic expression vector VR1012. The ligation reactions 
were subsequently transformed into E.coli INVaF' competent cells as described 
previously in section 3.2.4.
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4.2.3 Sequencing of new enveiope genes obtained through 
biological selection
The cloned envelope gene products were sequenced using either a LICOR 
model 4000 automated sequencer (section 2.2.3.10) or an ABI PRISM 3100 genetic 
analyser (section 2,2.3.11) as described previously using a panel of primers based on 
the FeLV-A env sequence (Stewart M.A. et ai., 1986). The sequences and locations 
of the primers are described in table 2.1 and figure 2.1. The env sequences were 
analysed using Wisconsin Package Version 10.0, Genetics Computer Group 
(Madison, Wisconsin) as described in section 3.2.5. Each nucleic acid sequence was 
translated and the predicted amino acid sequence analysed for integrity of the env 
open reading frame.
4.2.4 Production of FeLV pseudotypes in 293T cells by transient 
transfection
As described in section 3.2.7, FeLV env/MuLV gag-pol pseudotypes were 
generated by transient transfection of 293T cells with FeLV env/ MuLV gag-pol and 
MFG-LacZ plasmids. Viral pseudotypes were titred on FEA cells and then used to 
infect a range of cell lines in order to establish the tropism of the novel envelope 
glycoprotein. In parallel with the viral pseudotype studies, 293T cells transfected with 
each VR1012-env construct were fixed using ice-cold methanol and stained with the 
6-15 monoclonal antibody (anti-gp70). Expression of mature envelope glycoprotein 
was then evaluated by immunofluorescence as described previously in section 3.2.7.
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4.3 Results
4.3.1 Isolation, PCR amplification and characterisation of novel 
envelope glycoproteins
Following infection of 104C1 cells with the primary isolates FS246 and 
L3128F, the cultures remained negative for FeLV p27; therefore no DNA was 
prepared from these cultures. The remaining cultures tested positive for p27 and thus 
DNAs were prepared for PCR amplification of env. Following cloning of the amplified 
products and small scale plasmid screening, twenty three plasmid DNAs containing 
inserts were identified and were sequenced using the FeLV env primer F69, the 
primer binding site of which is described previously in figure 2.1 and table 2.1. This 
primer binds prior to the start codon of the mature gp70 protein and therefore yields 
the sequence of the VRA region, enabling the identification of novel env clones. Table
4.1 and figure 4.1 summarise the results. The sequence characteristics used to 
classify an env clone to be either subgroup A or 0  were described previously in 
section 3.3.1.
FA27
Ten novel env clones were identified from 10401-derived FA27, nine of which 
(FA27-C1, FA27-C2, FA27-C3, FA27-C5, FA27-C7, FA27-C9, FA27-C10, FA27-C11 
and FA27-C12) appeared to be subgroup C, whereas one env clone appeared to be 
the A-component (FA27-C6). Of the ten env clones, only four were characterised 
further, they were FA27-C5, FA27-G6, FA27-C7 and FA27-G12; these were unique 
amongst the clones identified.
FA621
Biological selection of primary isolate FA621 on 104G1 cells yielded six unique 
env clones, one clone (FA621-G4) was the A-component, whereas the remaining five 
clones (FA621-G1, FA621-G2, FA621-G3, FA621-G6 and FA621-G7) were very 
similar and appeared to be G components. As FA621-G1 and FA621-G3 Wjere not 
identical, these two clones were characterised further.
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FX343
When isolate FX343 was plated onto the selective 104C1 cell line, one unique 
env clone was isolated, FX343-C8, this was thought to be subgroup C.
FY981
Biological selection of isolate FY981 yielded one unique env clone, FY981- 
C11, which appeared to be a C component.
FZ215
Selection of isolate FZ215 yielded three unique env clones; one of the clones was the 
A-component (FZ215-C6), whereas two env clones resembled FeLV-B/Gardner 
Arnstein (FZ215-G7 and FZ215-G11). Attempts to obtain the complete sequence of 
FZ215-G11 failed and this isolate was not studied further.
L3950F
When primary isolate L3950F was biologically selected on 104G1 cells, one 
env clone was identified. L3950F-G18 was the A-component of the isolate and was 
not characterised further.
Of the env gene clones that were characterised further, three nucleic acid 
sequences were similar to FeLV-A/Glasgow-1 (FA27-G6; 98.5%, FA621-G4; 97.9% 
and FZ215-G6; 98.0% similarity to FeLV-A/Glasgow-1 respectively). Seven nucleic 
acid sequences satisfied the criteria for subgroup G (FA27-G5; 89.5%, FA27-C7; 
90.2%, FA27-G12; 89.5%, FA621-G1; 90.8%, FA621-G3; 89.2%, FA621-C4; 90.9%, 
FY981-G11; 89.6% and FX343-G8; 91.0% similarity to FeLV-G/Sarma respectively). 
One nucleic acid sequence was similar to FeLV-B/Gardner Arnstein (FZ215-G7; 
98.0% similarity).
A multiple nucleic acid sequence alignment was performed on the sequences, 
with the exception of the isolate that was similar to FeLV-B Gardner-Arnstein using 
the “Pileup" component on the software package GGG according to the progressive 
alignment method of Feng and Doolittle (Feng D.F. and Doolittle R.F., 1987). This 
alignment is shown in figure 4.2. Position 1 in this sequence correlates with position 
6079 in the published FeLV-A genome.
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The multiple nucleic acid sequence of the isolates that were similar to FeLV-B 
Gardner-Arnstein, including isolate FZ215-C7, is shown in figure 3.5.
The sequences were then translated into amino acid sequences to establish 
the integrity of the env open reading frame and changes from the published FeLV A 
sequence. All of the novel env gene clones had intact open reading frames and figure 
4.3 shows the amino acid alignment using the “Pileup" component on GCG. Position 1 
in the amino acid sequence correlates with position 5981 in the published FeLV-A 
genome.
The percentage similarity found for the novel env clones compared to FeLV- 
A/Glasgow-1 and FeLV-C/Sarma were equivalent to those found for the nucleic acids, 
albeit slightly higher, and are summarised in table 4.2. This higher degree of amino 
acid similarity suggests that some of the mutations detected in the nucleic acid 
sequence are “synonymous” (i.e. not affecting the coding sequence). When the 
sequence comparisons were restricted to the VRA region, the degree of amino acid 
similarity was considerably lower, consistent with this region being the major site for 
variation; the results of these comparisons are illustrated in table 4.3.
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Env clone # %  S im ila r ity  to  V R A  
re g io n  o f F e L V -A
%  S im ila r ity  to  V R A  
re g io n  o f F e L V -C
Subgroup 
predicted by 
sequencing
Further
characterisation
FA27-C1 93.7% 88.9% C No
FA27-C2 95.0% 90.4% C No
FA27-C3 97.2% 92.6% C No
FA27-C5 97.7% 95.1% C Yes
FA27-C6 99.3% 94.6% A Yes
FA27-C7 97.5% 94.9% C Yes
FA27-C9 96.8% 91.6% C No
FA27-C10 91.8% 86.8% C No
FA27-C11 92.2% 88.1% C No
FA27-C12 97.0% 97.0% C Yes
FA621-C1 98.0% 94.2% C Yes
FA621-C2 95.5% 91.8% C No
FA621-C3 98.0% 94.4% C Yes
FA621-C4 98.5% 94.0% A Yes
FA621-C6 96.9% 93.0% C No
FA621-C7 96.3% 92.2% C No
FY981-C11 97.7% 93.9% C Yes
FX343-C8 98.3% 94.1% C Yes
FZ215-C6 98.7% 93.9% A Yes
FZ215-C7 89.7% 88.4% B (98.4%) Yes
FZ215-C11 74.4% 59.1% B (87.2%) No
L3950F-18 99.6% 91.0% A No
Table 4.1: Amino acid sequence similarity of the novei env genes relative to the 
published sequences of the VRA regions of FeLV-A/Giasgow-1 and FeLV-C/Sarma. 
The simiiarities o f the env clones, which resembie FeLV-B/Gardner Arnstein, relative 
to the published sequence of FeLV-B/Gardner Arnstein, have been included in 
brackets in the table.
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FA27
When primary isolate FA27 was plated on the selective cell line 104C1, it 
yielded four unique env clones. The A-component, FA27-C6, differed at seven amino 
acids from the published FeLV-A/Glasgow-1 sequence ( D 5 1 N ,  N 5 9 D ,  V 24 7 I, TsisI, M 3 3 3 L ,  
K34 8E and K614R) as can be seen in figure 4.1. These seven amino acids were also 
present in the FA27p amino acid sequence, suggesting that these amino acids are 
representative of FA27 and that this env clone is the true A component of FA27. The 
C components (FA27-C5, FA27-C7 and FA27-C12) displayed a high degree of 
similarity to each other and to the FA27p env sequence. The three env clones were 
slightly different from one another, but there were four amino acid changes present in 
all three env clones that were different from both FeLV-A/Giasgow-1 and the FA27p 
amino acid sequence. The first difference can be found in the VRA region, namely a 
HgyL substitution when compared to FeLV-A/Giasgow-1 amino acid or a FgyL 
substitution when compared to the FA27p amino acid sequence. The HeyL substitution 
could result in the loss of a positive polar side chain, as leucine has a non-poiar 
hydrophobic side chain whereas histidine contains a positively charged polar side 
chain. When compared to FA27, there Is no difference in the nature of the side chain 
as both amino acids contain non-polar hydrophobic side chains. At position 301, there 
is an I to V substitution, a mutation that is also present in the FeLV-C/Sarma amino 
acid sequence. I to V does not result in a change in polarity. Further along the 
sequence, there is a TsisD mutation relative to FeLV-A/Glasgow-1 or an laieD 
substitution relative to FA27. Both threonine (T) and isoleucine (I) contain two centres 
of asymmetry and both amino acids do not contain a polar side chain, however 
threonine is hydrophilic whereas isoleucine is hydrophobic. As aspartate (D) has a 
negatively charged side chain, the overall polarity is altered. Lastly, a six amino acid 
stretch (^®^KGHKGT^^®) was found in alt three env clones that was not present in the 
FA27p amino acid sequence. In the FA27p amino acid sequence, this stretch was 
identical to the stretch found in FeLV-A/Glasgow-1, namely ^^^QGHTGA^®®, however 
in the FA27 clones and indeed in FeLV-G/Sarma this stretch reads ^^^KGHKGT^^®. 
Both glutamine (Q) and threonine (T) contain a negatively charged side chain, 
whereas lysine (K) contains a positively charged side chain, resulting in an altered 
polarity. In addition, the AaseT substitution results in the substitution from a 
hydrophobic residue to a hydrophilic residue.
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The hydrophobic side chain in aianine is a side chain that will avoid contact with water 
and thus this residue will be on the inside of a protein structure, whereas the 
hydrophilic side chain in threonine is a side chain that encourages contact with water 
and thus this residue will favour a location on the outside of a protein structure, or will 
co-localise with other hydrophilic residues within a structure. Therefore, the 
substitution of a hydrophobic residue with a hydrophilic residue may alter the protein 
structure. When compared with the FA27p amino acid sequence and the other C 
components identified, clone FA27-C5 is the sole env clone that has maintained a 
lysine on position 614, which have substituted this lysine to arginine, although this 
substitution does not alter the overall polarity. With the exception of two amino acid 
differences (RzeoG and ReuK), clone FA27-C7 was Identical to clone FA27-C5. Clone 
FA27-C12 had several substitutions that were not present in the other 0  components 
of FA27; these were N 5 3 S ,  H 5 2 3 R ,  W 5 6 1 G  and Q 6 1 2 H  when compared to FA27-G5 and 
FA27-G7. Only one of these changes resulted in a change in the polarity of the side 
chain, this being Q 61 2H, changing the side chain from an uncharged, polar residue to a 
positively charged, hydrophilic residue. Interestingly, the K&wE substitution that is 
present in both clone FA27-G6 (the A-component of this primary isolate) and the 
FA27p clone, is not present in the other three clones identified as G components 
(FA27-G5, FA27-G7 and FA27-G12). This substitution alters the polarity of the side 
chain of these amino acids from positively charged for lysine to negatively charged for 
glutamic acid.
FY981
Env clone FY981-G11 was identical to clone FY981p. The substitution present 
in env clone FY981-14 (characterised in chapter three), T 2 3N relative to FY981p 
amino acid sequence, is not present in the FY981-G11 clone described in this part of 
the thesis.
FX343
The env clone isolated after biological selection of primary isolate FX343, 
FX343-G8, appeared to be the G component of this primary isolate. However, as this 
was the only clone identified for this isolate, the changes found in the amino acid 
sequence relative to FeLV-A Glasgow-1 cannot be confirmed as representative of the 
parent sequence.
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As discussed previously in chapter three, an isolate was classified as subgroup C 
when the VRA region of the isolate contained length polymorphisms relative to the 
VRA region of FeLV-A/Glasgow-1 or displayed substantial divergence from FeLV- 
A/Glasgow-1. With fifty-one amino acids, the VRA region of clone FX343-C8 was 
shorter than the VRA region of FeLV-A/Glasgow-1, which contains fifty-six amino 
acids. Furthermore, there were six additional amino acid differences in the envelope 
glycoprotein sequence when compared with FeLV-A/Glasgow-1. The first substitution 
is situated at the end of the VRA region, TggA, substituting a hydrophilic residue for a 
hydrophobic residue. As discussed previously, the substitution of a residue with a 
hydrophobic side chain with a residue with a hydrophilic side chain may affect the 
protein structure. Similarly, the converse substitution of a hydrophilic residue with a 
hydrophobic residue may also affect the protein structure. An identical substitution 
was found after the VRB region (TiseA), again affecting the charge. As a Tsiel 
substitution was also present in FX343-26 and FX343-28, the T 31BI mutation would 
appear to be representative of FX343. Tsial results in a change of polarity of the side 
chain (threonine has a hydrophilic side chain while isoleucine has a hydrophobic side 
chain): therefore the structure may be altered in this region of the envelope 
glycoprotein. M 3 3 3 P  may affect the structure, as proline is a residue that contributes to 
bends in a polypeptide sequence and can be considered hydrophilic, whereas 
methionine (M) has a hydrophobic side chain. G 260R results in a change of polarity of 
the side chain, as glycine has a neutral side chain and arginine contains a basic side 
chain. The remaining two amino acid differences between FX343-C8 and FeLV- 
A/Glasgow-1 may not alter the overall polarity of the side chains ( M 3 3 3 P  and V 5 9 4 I ) .
FA621
Biological selection of primary isolate FA621 on the selective cell line 10401 
yielded three unique env clones, one of which (FA621-C4) was the A-component and 
two clones (FA621-C1 and FA621-G3) that were G components. As with primary 
isolate FX343, no representative amino acid sequence was known, therefore it was 
not possible to distinguish between determinants of the subgroup G phenotype and 
changes in the sequence that were unrelated to structure and function. There are five 
amino acid differences between the FA621 clones and the published FeLV- 
A/Glasgow-1 sequence that are present in all three env clones, therefore suggesting 
that these differences are unique to the primary isolate.
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There is one subsequent change that is present in FA621-C4 (the A-component) and 
FA621-C3 (a C component), but not present in the other C component (FA621-C1), 
this is a T 3 5 A  substitution prior to the VRA region, which is a change from a 
hydrophilic residue to a hydrophobic residue. With the exception of the substitutions 
listed, there is one additional change in the FA621-C4 sequence when compared to 
FeLV-A/Giasgow-1 ; S 147R two amino acids upstream of the VRB region. The change 
from an uncharged hydrophilic residue to a positively charged hydrophilic residue 
could be significant, taking its location into consideration. Both C components of 
FA621 were very similar, however there were some differences between the amino 
acid sequences. Clone FA621-C3 has a valine residue rather than an isoleucine at 
the start of the mature protein (a similar residue is found in the published sequence of 
FeLV-C/Sarma). There is one additional change that can only be found In clone 
FA621-C3, this is T 241A, as discussed previously resulting in a change from a 
hydrophilic residue to a hydrophobic residue.
FZ215
Biological selection of primary isolate FZ215 yielded two unique env clones, 
FZ215-G6 and FZ215-G7, with clone FZ215-G6 resembling FeLV-A/Glasgow-1 and 
clone FZ216-G7 resembling FeLV-B/Gardner Arnstein. The A-component of the 
primary isolate, clone FZ215-G6, contained seven amino acid differences relative to 
FeLV-A/Giasgow-1, these were also present in clone FZ215p and thus these changes 
were thought to be representative of the parent isolate. There were two additional 
changes that were found neither in the published FeLV-A/Glasgow-1 amino acid 
sequence nor in the FZ215p amino acid sequence. These substitutions were a N2 4H 
substitution (which results in a change from an uncharged side chain to a positively 
charged polar side chain) and a S392A substitution. Serine is the hydroxylated version 
of aianine, with this difference that alanine is hydrophobic and serine is hydrophilic, 
therefore this could alter the structure of the protein.
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A separate amino acid alignment was performed on the two isolates that closely 
resemble FeLV-B Gardner-Arnstein (FZ215-G7 and FZ215-12, described in chapter 
three, see figure 3.7; the isolates were compared to the published sequences of 
FeLV-B/Gardner Arnstein (Accession number P03391), FeLV-B/Snijder-Theilen 
(Accession number K01208) and the parent isolate FZ215. The two env genes 
isolated are very similar to one another, indeed there is only one amino acid 
difference between the two isolates, namely FZ215-G7 has a histidine on position 590 
rather than the predicted glutamine in both FeLV-B/Gardner Arnstein and FZ215-12. 
To sum up, there are two changes in these Env amino acid sequences that cannot be 
found in either the FeLV-B/Gardner Arnstein amino acid sequence or the parent 
FZ215 amino acid sequence. These changes are L^ l^ just prior to the VRA region and 
T 165I (compared to the FeLV-B/Gardner Arnstein sequence) in the VRB region. As 
discussed previously in chapter three, the latter substitution results in a change of 
polarity of the side residues from uncharged polar to hydrophobic, possibly resulting in 
a change of structure of the envelope glycoprotein.
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Env clone # Nucleotide Amino acid Nucleotide Amino acid Subgroup
similarity similarity to similarity to similarity to determined
to FeLV-A FeLV-A FeLV- FeLV- by
Glasgow 1 Glasgow 1 C/Sarma C/Sarma sequencing
FA27-C5 95.8% 97.7% 89.5% 95.1% C
FA27-C6 98.5% 99.3% 90.7% 94.6% A
FA27-C7 94.9% 97.5% 90.2% 94.9% 0
FA27-C12 95.8% 97.0% 89.5% 97.0% C
FA621-C1 96.9% 98.0% 90.8% 94.2% 0
FA621-C3 95.1% 98.0% 89.2% 94.4% 0
FA621-C4 97.9% 98.5% 90.9% 94.0% A
FY981-C11 96.4% 97.7% 89.6% 93.9% C
FZ215-C6 98.0% 98.7% 89.8% 93.9% A
FZ215-C7 76.6% 89.7% 77.6% 88.4% B
FX343-C8 97.5% 98.3% 91.0% 94.1% 0
Table 4.2: Nucleotide and amino acid sequence homology of the env genes isolated 
following selection in 104C1 cells. Sequences were compared with FeLV-A/Glasgow- 
1 and FeLV-C/Sarma.
1 6 3
Env clone # Amino acid 
similarity to 
FeLV-A  
Glasgow 1
Amino acid 
similarity to 
FeLV-C/Sarma
Predicted 
subgroup 
determined by 
sequencing
FA27-C5 95.9% 93.9% C
FA27-C6 98.6% 93.8% A
FA27-C7 95.2% 93.2% C
FA27-C12 94.6% 92.6% C
FA621-C1 95.6% 92.6% C
FA621-C3 95.9% 92.6% C
FA621-C4 98.7% 91.8% C
FY981-C11 93.9% 89.9% C
FZ215-C6 97.2% 93.2% A
FZ215-C7 98.0% 93.1% B
FX343-C8 75.4% 75.0% C
Table 4.3: Amino acid sequence homology of the VRA region of the novel env genes 
relative to FeLV-A/Glasgow-1 and FeLV-C/Sarma. The VRA region is a stretch of fifty- 
six amino acids starting from amino acid fifty, relative to the published sequence of 
FeLV-/VGIasgow-1 (D 5 3  to Huo).
1 6 4
I
ü)e
cô&I
CO
"n<DISI
'oI
0)Ii
S
g
§?Ig
0  
cots1 IIt
o
CD
01 <
c ô
i
(D
i S
I I
"OI,c
8  e  
8II
cCD
i
gI
■S
01Q.
O
S
0  •Q CD
1 3
21.C
Ïd  S2
LL S
1CDI
CD
I
■§
2I
Z )co
CD-C
I
CD
: SIIC
iQ.
8
01
CD
2I
■Di
.52I
CD
■I
a
"88I
CD
§
I
j D
CO
gCD.Q
.c
I
CD
0 0I
8iIti
t■iI"OIg
CD.Q8c
cx>Igi
CDi
CDC
g  i
8  -8 — o
CL
^  .E
01
<c
I
CL
CDf :
R
§1
§I
CDiS
oos
-J
I
"cD
"%
c:I
t•i
£CL
■OCDI
II
"cD
%g1
è -t•iI
"O<DI
CI
COCD•c
I
CD-C
CMIi;Q ,  CDI  ^
I
CDg
N.
C3)O)
CD
"%
>:
CDCDPQ
N /
00O)
! ë
■ o
§S'<y>
CD
q)
i
SgI
ICLII
g g g g g g g g g g g g g g g g g g
k k k k k C U k k k k k k & f t f t k k kO O U U U U U U U U U U U U U U U Usgsggesgggegesssssk k k k k k k k k k k k k k k k k k
k k k & k k k k k k k C L k k k f t k k
o  o  o a  06 o  oo  o o  oo  o o  o
X  X X  X
Oi  06 Oi X  06 06 06
>H >H r«  >H
" ^ 3 3 8
iiiii06 06 06 06 06
X X XU U U u u u u u u u u u uÜ  Ü  Ü O U CD O q q q q q q
X  Xw  cn CO CO CO CO cn CO CO CO CO CO COCO CO CO CO CO CO CO CO CO CO CO CO0 »  CO CO COOr  O r  Or CO CO CO CO CO CO
CD CD
O  O O  OO  OO  OX  X
X  XX  X
X  Xu u u u
CO CO CO COCO CO CO COCO CO CO CO
X  X  X  X  
OK OS 09 o r
. » • ' * • • • « - • • ' • ' • ^
s s s i s s a t a c s s  q q q q CO CO qX q X X X. . . . i J  k  • • •
O  D  Q  Q  Q  *  • f •
X X X X X X X X X X X X X 0 5 X X X
U U U U U U U U U U U U k U k l U U
Q  Q  Q  Q  0 9  »  Q  Q  Q  Q  Q  k  Q
X  X  X  X
X X XU U UIII
q q q q q q q q q q q q q q q q q qIiiiiiiii
H  Eh H  H  X  X  X  X
IIH
S 3 S S
H  H  H  H  X  X  X  X>H >H >4
H  H  Eh  Eh 
X  X  X  X
>H >< >4 pM
X  X
>4 >4
X  X
q q q q
g § g g g g g | g g
o
q q q q
CO COCO CO
a  o o  o
O t O f O O ' O O O ' O i O i O ' O O O ' O O O p o o
ÎHÎMÎM>4 >4 >4 >4 >4 >4 t >4 >4 >4>4 >4 >4H H H H H H H > H H > H H H H H Ho o o o o o o o o o o o o o o o oK X X X X X X X X X X X X X X X XX X X X X X X X X X X X X X X X XCO CO CO CO CO CO CO CO CO CO CO CO CO CO CO CO COX X X X X X X X X X X X X X X X X
CD < n  ( N  U  ft “•SD 04
rH iH I—I VD U 00 I
rH >4 04 Ol
00 k  <  <  CN
CTi k  k  <
f t  f t  CO 00
r ~  u  u  UU  CN I I II <  f t  f t  mk  CN CN ^
vo vo m N
CN I!«  CNgg(CJCO
M  0) Ü  <•H q X  k
U  v o
CN v o
k  k
165
m
û :
>
o > > > > > > > > > > > > > > > > > >
o  o t o o i o i o o i o o o o o o a o o o o o  
( N K o i a p i P i c t î o s c t î c ï i c c i a o i o i P i c t j p i o i c e :  c n w w ü i c n ü i c / j c n c n c / i c o c n c n c n w c n w c o
e e g g g s e g g g e e g s g e g e
[ t i p L i l j L i k P i i D ü k i D ü l i i r L i C i i C i i k C i ^ k k k k i
> > M M M M M M M M M M M ^ M M M M
Al P4 Û4eee
333
04 04ggggg g
K  ^hO J
04  04gg gg g ghJ J33
0 4  04gg g goi ci3333
0 4  04gg g gPi Oi3333
gg
3333
Ci l  eu CXig g gü ü o M  to HPi Pi Oi333333
0 4  04ggggPi Pi3333
O Ü Ü Ü O O Ü O O Ü O O Ü O O Ü Ü O
0404040404040404040404040404040 I 0404gggggggggggggggggg
gggggg04 [14o  o
M W
II
EEo  o
m M
o  oil
gg
gg
ilgg
gg
iio  o
gg
o  oIIgg
gg
o  oII?ÿ04 04
0 0 0
g g g
ggg
O4 O4 O4 O4 O4 O4 O4 O4 O4 O4 O4 O4 O4 O4 O4 O4 O4 O4l l l l l l l l i i i i i l l l l lÜOOOOÜÜOCDÜOOOCKOOOO
U U U U U U U U U U U U U U M U U Uu u u u u u u u u u u u u u u u u u
B K S B c o c o c o c n c o c n c o c o t o t o t o t o t o t o
S z z S f t B M S s a z z z z z z z z a î s
O O O O O O O O O o S s 0 0 0 0 0 0
C O C O C Q C O C O C O C O C O C O C Q C O C Q C O C O S t O t O C O
C O C O C O C O a a i t O t O C O t O t O t O t Q C Q C O C O t O C OCDOÜOÜOÜOOOOOÜOOCDOOgggggggggggggggggg
MMMMMMMMMMMMMMMMMM
iiiiicn üi co co w co co co co co co to CD to E-> 04 04 04 04 04 M m X
>4 >4 >4 >4 >4 >4 >4i  i  i  i  3 § ico co co co co co coco co co co co et coH H H H H H HO4 Û4 O4 O4 04 Û4 CI4^ u:
iiiico co co co co co co co H H H H 04 04 04 04 ^ iico co“gt>i X
 ^â ^ü ü o 
U^UUUUUi ^  ^
IIIm
 ^^  ^  UUU
UUUUUU ^ ^
 ^w â
UUUUUU
§  <  <
 ^^  ^  UUUI: ^  ^sssUUU 
< ^ <
 ^^  ^
UUUUUU
< < <
 ^^  ^
UUUUUU< § ^
k k k P L i k k i k k i l & k D L i l j L i l j L i k k i
i i g l i l m i i i i i g
u u u u u u u u u u u u u u u
g g g g g g g g g g g g § g g g gu u u u u U u U U U U U U U U U Ub X b b b Ui ùi m Ui Ui b b X X « X
04 04 04 04 04 04 04 04 O404 O4O4b b b b bu u u u u u u u U u U U U u U U UH: ij ►J ►4 Jtas rQrHco co cococo co co co COco co COCOcoco co CO0 04 0 4 04 04 04 04 04 04 04 Oi b b b b b b brH < < < < < < < < < < < < < < < < <
nvo (Ti CN u rH A in CN 04r4 n Cu > vo iH0 0 0 rH rH tHU u rH u Uu in a U rcJrH rH rH 10 u 00 u CN rH (U MH H H (T\ r~ r- < rH rH r o CN u [" UrH rH rH rH ?H CN CN r- b CN CN N (0 CN •H00 CO 00 00 ÏI4< < CN VO VO r o b B< Pi<T> b b < < < X iH b>H b b b b nJ <CI4 co
u
>  >  >  0 0 0ggg
ËÊë[14 C14 b
04 04 04eeeg g g
333333
UUU ^ ^
04 04 04maaa
o oIIo o £
a  o
w  >
•-a l-q . J  
04 04 04
u « u
UUU
g i i
0 0 0
co co co co co « 
U U U
iiico co co co co co 
M  H  H  
04 04 04 kd
6  6  6  
U U Uggg
UUUUUU
^ I  <
6 6 6k, b k
i§i
UUU
gggggg
04 04 04 UUU Jco co co
04 04 04 
<  <  <
u  vo M u10
r4  CN 
CN voes
1 6 6
o  M  H  
r o o  O O U U U
g g gb  b  b  b  b  b  
O i P i P i
cn co co
C5 o  o  CD 
u  u  u  ug g g gb  b  b  b  b  b  b  b  
P i P i P i P i
co co co co
CD CD U Uggb  b  b  b  
b  P i
CO co
CD CD U U
b  b  b  b  
P i P i CO CO
CD CD u  Uggb  b  b  b  
P i P i CO CO
CD CD U  U
b  b  b  b  
P i P i CO CO
CD CD U Uggb  b  b  b  
P i P i CO CO
u  u  u  u  
6 6 6 6
u  u  u  u  
u  u  u  u66
u  u  u  u  u  
u  u  u  u  u
g ;  6
g g g
b b b b b b b b b b b b b b b b b
>H >H >4
Eh Eh H
CD CD CDp P P
> > >u u Uz Z ZM
U u U
b b b
Q 0 Q
CD 0 pEh Eh Eh
CD CD CD
M
b
M
oi
M
bbb bb bb
CD CD CD
H H  Eh H II H  H Ehgggz  z  z H  H  Hgggz  z  z
Q Q Q Q Q Q P Q Q Q Q
8 8 5 8 8 8 8 8 8 8stf-rg 
e  è: g  ë:
co co co co
P i P i P i P i 
<  <  <  <
g g
CD
g g g g g g
6:
CO CO co co CO coPi Pi Pi Pi Pi Pi
b  b  b  b  b  b
^  ^  ^  ^  ^  ^co co co co co co
u  u  u  u  u  u
B  K  Ë  g g gCO co CO b  b  b
< < <
>  u
g g&g
co co co co
P i P i P i P i b  b  b  b  
<  *  <  <  CO CO CO CO
u  t s  u  u
O O O O 0 < < D I O O 0 I O O O 0 I C D < O O Q Pb b b b b b b b b b b b b b b b a bb b b b b b b b b b b b b b b b b b
o o o o o o o o o o o o o o o o o o
■■■IIII
b  b b  b b  b b  b
co co co co co co co co co co co co co co coCD ü  CD CD CD CD CD CD o r CD CD CD CD
O  O  O O  O O  O O  O O  O  O O  o o  o o  oco co co co co co co co co co co co co co co co co coex  CD< o ex  ex ex  ex o  o o  o o  exex  e x  ex ex exb  b b  b b  b b  b b  b b  b b  bco co co co co co co co co co co co co co co co co cob  bb  b  b b  b b  b b  b  b b  b b  b b  b
b b b b b b b b b b
b  b  
04 04
CU C U C I 1 O4 Û4 C U C U O 4 O4 CU
b b b b b b b b b bi i i i i l l i i lc x e x p p p e x c x p e x pb b b b b b b b b bb b b b b b b b b b
Eh H E h Eh Eh Eh H E h Eh Eh
i H H M M M M M M M M M
O E h Eh Eh Eh Eh Eh Eh Eh Eh Eh
( N c o c o c o c o c o c o c o c o c o c o
b  b  b b  bX  X X  X
b  b  b b  b
b  b  b b  b
illb  b  b  b  b  b  Eh Eh Eh
n  CD
p  exb  bb  b
CO CO co co co co
IIb  b  b  b  Eh Eh
VO m  (N CD rH ( b  m  C" (N 
O O O r H r H r H C J C J  rH rH rH VO ü  CO I I En EH En I OV [H-rH rH rH rH ^ H C N C N C H
00 00 00 o o U < i < ( N
en u  u  <
û i  rH r o  00  ( b  >  vo 
r H C H U O C D i n C U
u  CN I I I rH Q) I
I <  rH rH r o CN u  r-
u  (N CN N* N rO CN
vo vo r o u  6  rt!
< < X iH uU U U  n]
co
< < <
CD CD u  uggb  b  b  b  b  b  co co
U U Um
>H >H >H
8 8 8  b  b  b
fil
g g
co co b  b
< <
u
p  p  p  b  b  bb  b  b
Iii
b  b  b
p  ex p  
co co co ex p  pb  b  b  
co co cob  b  b  
b  b  b  
Û4 eu euIffïiib  b  b  b  b  b  Eh H  Eh M M M
Eh Eh Eh CO CO CO
u  vo 
M  u
CN VO N <  U  U
(M
167
O U U U U U U U U U U P P P P P P P P P Po M U U U U U U U U U U U U U U U U U U U UTf M M M M M M M M M M M M M M M M M M M
d d d g d d d d d d d d d d d dub ub ub g g b g g g g g g g ub g b ub ub g g gQ Q Q Q Q Q Q Q Q Q p p p P p p P P p p pCO CO CO CO co CO CO CO CO CO co co co M co co CO CO co < coH H H H H H E- Eh Eh Eh H H H Eh Eh H H H Eh Eh Eh
cncotocococncocncocococococococococo
M M M M M M M H M M M M M M H M M Hu u u u u u u u u u u u u u u u u ub b b b b b b b b b b b b b b b b b
I I I i O C D O O U O O O O O o  o
< < < < < < < < < < < < < < < <Z Z Z z Z z Z z z Z z Z Z
p >H $H >H ? >H >H >H >H >H pEh H Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh H Eh Eh
U CD CD U CD O u CD ü CD CD CD U CD CD UZ Z Z z z Z co CO CQ z z z Z Z Z zb b b b b b b b b b b b b b b b
U  CD
>1>H>I>-I>-I>H>H>H>I>-I>-I>H>1>4>4
“ - E C a C K K K K a C K a C W K K K W
P O O
c D 6 6 c D o o 6 6 6 6 6 a 6 6 6  
g  a  g  æ  ac ac w
U U Ub  b  b
CD CD CD
CD CD CD 
Z  Z  ZCU CU Û4
m
X X X  
b  b  b
s e eCD CD CD 
U
minil
b  b  b  b  
b  b  b  b
CD CD CD CD
p  p  p  pliltU U
g g g g
b  b  b  b  b  b  b  beeeeCD CD CD CD
P
P  P  P  PIII
b  b  b  b  b  b
e s eCD CD CD
nil
b  b  b  b  b  b  b  beeeeCD CD CD CD
C J U U U U U U U U U U U U U U U Usiii'isgf'iimsssii
CDCDgCDCDCDCDCDCDCDCDCDCDCDCDCDCDCD
WÜ1COWWMCOWWC/3COCOC/ÎC/3WCOWCO> > > > > > > > > > > > > > > > > >
U U U U U U U U U U U U U U U I z l U U
c o c o c n c o c o w w w c Q c o c n c o w c n c o w w w
M M M M M M M M M H H M M M M
Eh Eh H H H E h E - ' H E h Eh Eh H E - ' E - ' E h
*  «b  b  M Mw CO
d d
b  b  b  b
at Orb  b  M M
CO CO
d 5
CO CO •a b  b  b  
b  b
P  P  P  b  b  b  
V *  w  B
CO CO CO b  b  b  
b  b  b  
b  b  b
P  P  b  b  
Q  QCO CO
d d
CO CO b  b  
b  b  
b  b
g g
s g
d d
CO CO 
b  b  
b  b  
b  b
P  P  Pb  b  b  H  M  m
CO CO CO
d d d
CO CO CO b  b  b  
b  b  b  
b  b  b
ggH  M
CO CO
d d
CO CO b  b  
b  b  
b  b
CO CO COCO W CO
g
M CD CD CD CD Ü CD
O P P > P Pro M M M M
VO ov (N U rH (bo o O r4 rH tHrH M M VO U 00
Eh En Eh mrH M M rH >400 00 00 GO k
P P P P P P P P P P P P P
Z Z Z Z Z Z Z Z Z Z Z Z Z
i n i ^ c N  t t r H f o o )  O j > vo 
U U r H r H O U U t n c U
I I U  CN I I I i-t 0) I
C" r -  I r f J i - t i H r o c N U r ^  C N C N r ' b C N C N ^ N  10 CN <  <  CN vo vo m b  E <U b  <  <  <  X  G bb  b  b  b  (0CO
gg
g  g  
d d
CO CO b  b  
b  b  
b  b
P  P
z  z
CO COii
. 1 1  
b  b
6  6  6
g  g
II
X X X  b  b  b
e e eCD CD CD 
M M H U U U
888
CD CD CD 
CO CO co >  >  >  U U U
co co coM M Miii
p  p  p  b  b  b  
«  M  H  
CO CO CO
d d d
co co cob  b  b  b  b  b  
b  b  bIii
co co co
U  CD J  u
u  vo ^  
M  u  u
CN vo 
N  <  
b  b
CO
1 6 8
O Q P Q Q Q Q Q Q Q Q Q Q P Q Q D Q QO P P P P P P P P P P P P P P P P P P
i n O C D O O O O O O O O C D Ü O Ü O O Ü OO i P i O i O i O i O i O i O i P i P i Q i P i O i O i O i P i O i O iIISIIIIIIIIIISIISI 
î î î î i i î i î î i î î i î ' ^ ' ' ' ^
M  U  M  M  
CO CO CO CO p  p  p  p  
CO CO CO CO
3 5 3 3
«  «  X  X
u  u  u  u
p  p  p  p
< < < < < < < < < < < < < < < < < <
c o c o c o c o c o c o c o c o c o c o c o c o c o c o c o c o c o c o
U  M u  u M  U  
CO COdd33
M  M U  U U  U U  M
CO COCO CO CO CO CO CO CO CO CO CO
CO COCO CO CO CO CO CO CO CO CO CO
CO CO CO CO CO CO CO CO CO COCO COX  X X  X
u  u u  u U  M u  u
M M M M M
c o c o c o c o c o c o c o c o c o c o c o c o c o c o c o c o c o c o
u u u u u u u u u u u u u u u u u uu u u u u u u u u u u u u u u u u uiiiiiiiiiiiiiiiiii
p p p p p p p p p p p  
H  H  H  Eh  H
ac a  SC
o O « O O O  O o o O a o o o  a o O O o o op P P P P P P p p p p p p p P p P P p p p
o o o o a O  O a o a a O o o  o O o a o o oX X X X X X X X X X X X X X X X X X X X X
u u u u u u u u u u u U u u u u u u u u u
o o o o o o  o o o o  o o o o  o o o o o o o
< < < < < < < < < < < < < < < < <
Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh EhU U U U U U U U u u u U U U u u U u U U UP P P P P P P P p p p P P P p p P p P P P
Eh Eh H E h Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh
C D O U O O O O U U O U O U O O O U UEh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh Eh EhO C D U O U O C D O U O O U O C D O O O O> > > > > > > > > > > > > > > > > >C 5 0 0 0 0 0 0 0 0 C D 0 0 0 0 Ü 0 C D C 5aâââââââsasaaaaaaa
M M M M M M M M M M M M M M M M M M
g Q C D Q Q U C D Q Q C D O U O O O Q U O  O O O O O O O O O C D O O O O O o O
C D U n Q Q Q Q Q C p Q Q C p Q C D Q C D Q C ?O S O O O O O O O O Q O O O O O U Oiiiiiiiiiiiiiiiiii
3 3 3 3 3 3
CO CO CO CO CO CO
M M M M M M
b  b  b  b  b  XU  U  U  U  U  Z
X  X  X  X  X  2X  X  X  X  X  Xu  u  u  u  u  u
X  X  X  X  X  X
3 3 3 3
CO CO CO CO 
M M M M 
b  b  b  bu  u  u  u
X  X  X  X  X  X  X  X  u  u  u  u  
X  X  X  X
3 3
CO CO 
b  bss
X  X  u  u
X  X
3 3
M >
b  bu  u
u  u  
X  X
3 3
CO CO 
M M 
b  bIiu  u  
X  X
3 3
CO CO 
M M 
b  bu  u
X  X  
X  X  u  u  
X  X
u u u u u u u u u u u u u u u u u u
U U u u u u u U u U u u u U U u u u u u ub b b b b b b b b b b b b b b b b b b b bo a O o a O  O o o a  o o o O  O o o o o o oK X K X a w X w K X K a X z X a ag g g g g C g g g c g g g g c g g g
M X g X E X E E X X X E E X E
O b b b b b b b b b b b b b b b b b b b b b
Hj* Z z z z z z z Z z z Z z z z z z z z z z z
vo m (N u M (b lO CN (b M n 00 Ib > vo '2 > u vo N*o o O M M rH u u M [ H u u U m c u (0 d M u u
M M M vo u 00 u CN M <u <u vo
Eh H Eh m r - CH < M M ro (N u I H u < in MM M M M >4 (N CM [ H U CN (N Tf N (0 CN u M CN00 CO00 CO U < < CN VO VD ro U < X u CN vo<JV U U < < < X u N <>4 U U u U (0 u uu co
333U U U
X X X
iff
Eh Eh H 
U U UIII
aaaM M M888
iiiIII
1 6 9
o > > > > > > > > > > > > > > > > > >
o c o c o c o c n c o w w c o w c o c o w w c o c o c o c o c oV D M M M M M H M M M M M M M M M M M M
x x x x x x x x x x x x x x x x x xssgssssgssssssasss
e Ê Ê Ê g £ £ È : £ Ê Ê g E Ê Ê Ê Ê gO'OCXOOOOO'OIOIOO'OOIO'OOO'> > > > > > > > > > > > > > > > > >
p  p  p  p
“ I I I
p p  p  p
X  X  X  a
p p  p  p  p  pX X  X  pJ o< o<3 3M MU  U  U  U  U  u  
b  b  X  b  X  b  
O  Ü  Q  O  O  O  b  U  w  U  U  b  p  p  p  p  p  p
p p p p p p p p p p p p p p p p p p
X  X33 33
u u u  u u u u  uU U U U
b b  b  b b b  b  b b  b  b  b
CD O Ü  O CD CD CD CD CD CD CD CDb b  b  b b fa b  b b  f a  f a  f a
M M M M
b b  b  b  
CD CD CD CD
3b b  b  b  
CD CD CD CD b  b  b  b  CD CD CD CD
b b  b  b  
CD CD CD CD
b b  
CD CD
Z Z Z E E Z Z Z Z Z Z S Z Z Z Z Z S :M M M M M M M M M M M M M M M M M M
c o w c o c o c o c o w c n c o c n c o c n c n c o w c o c o c o
c o c o c o w c o c n c o c o c n c n c o c o t o w c o c o w c oM M M M M M M M M M M M M M M M M MP P P P P P P P P P P P P P P P P PËÈËËËËËËËËËËËËËEËÈb b b b b b b b b b b b b b b b b b
Z Z Z Z Z Z Z Z O Z Z Z Z C Ü Z Z Z Z
b  b  b  b  
CO CO CO CO X  ■
b b  b  b  
X  X  X  X
b  b  b  b  
X  X  X  X
b  b  b  b  
CO CO CO CO
b  b
CO COX  X
CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CD CDU  M  M  M U  U  U  U U  U  U  U U U U U Ub b b  b b b  b b b  b  b b b
0  3:
BCDCDCDCPCDCDCDCDCDCDCPCDCDCDCDCD8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
COCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCÔQ Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Qb b b b b b b b b b b b b b b b b bP P P P P P P P P P P P P P P P P POOQOOOO'QQ'OOQiOOQ'QiOQio o o o o o o o o c x o i o o o o o o Sx x x x x x x x x x x x x x x x x x
g g g g g g g g g g g g g g g g g g
X X X X X X X X X X X X X X X X P Xu u u u u u u u u u u u u u u u u ux x x x x x x x x x x x x x x x x xaaaalalalaaaaaaaal
S S S ë S S Smill.CD CD CD CD CD CD CD
g g Ë Ë Ë ë  S9§99§âS
CD CD CD CD CD CD CD CD CD CD CD
X  w
Q Q Q Q Q
<  <  <
b  b
8 8  u u U M
b b b b b b b b b b b b b b b b
O U U U C J U U U C J U U U U U U UU C J U U U U U U U U U U U U U Uu u u u u u u u u u u u u u u u
U U U U U U U U U U U U U U U U U Up p p p p p p p p p p p p p p p p p
CDCDCDCDCDCDCDCDCDCDCDCDCDCDCDCDCDCDC D C D C D O C D O C D C D C D C D C D C D O C D U C D O OU U U U U U U U U U U U U U U U U UO O O O O O O O O O O O O O O O O O Ip p p p p p p p p p p p p p p p p p
M b b b b b b b b b b b b b b b b b bO P P P P P P P P P P P P P P P P P P
l O M M M M M M M M M M M M M M M M M M
T)VDOVOJUM ftlOtHCN A M ro 00 A  > VO VH >
.............................................. ............................................  "  g
X  b
O O O M M M U U M
M M M VD
H H E- U  00 m
>4
[H C" 
CN CN
U  CN <
00 00 00 o o b < < C N
b b
U O U  in C U
I M (U
ro CN U  [H
b  CN CN N to (Nvo vo ro b  Ê <
<  <  X  C  Ub  b  b  10
CO
>  >  >  CO CO CO M M Mill
p p
CO CO CO
p o pb b  b
888X X X
g g g
S 8 8
U U U
3 3 3
b  b b  
P  P  P
U vo Tf M U CJ VO I I
in M 
M (N 
CN VO 
U  <  
b b
1 7 0
Q ; ! »eu 04 X X X X X X X X X X X X X X X X X X X
z X X X X X X X X X X X X X X X X X X X XQ p P p p P P P P P P P P P P p P p p P PX 04 X X X X X X X X X X X X M X X X X X XP p p p p p P P P p P P P P P p P p p P P>4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4Q O o o  o O O a 9 o O O O O 9 o O o o O OX X X X X X X M & o t X X X X O « X X X X X
H H H M M M M M M M M M M H H M M M M M M2 9 a o 9 o o O SBo 9 o o o O o 9 o o o Oa o a o o o o o O o a a o o o o 5 o a o o
>4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >4 >H
O 9 9 o 9 a o 9 9 o a 9 o o 9 Q 9 9 9 9 oo o a o 5 a a o o o o a o Q a a a o o o o
H H H H H H H e-4 E- E-4 E-4 e-4 E-4 H e-4 e-4 H e-4 e-4 e-4 e-4P P p P P p p p P P p p P P p p p p p p p
P
M
P
M
P
M M
P  P
M
p
M
p
H
P
H
P
M
P
M
P p P P p
M
p p
M
p
M
P p
M
p
1 Î O s s o o O a § S S S S S î g g g g î> > > > > > > > > > > > > > > > > > > > >
VD (Ts CN u rH a in [H CN a rH 00 a > vo T)VH > M voO O O rH rH M U u rH r - U o u i n c U (0 c rH u ui H rH rH VO u 00 u CN rH 0) X 0) VDH H E-* en [H f H < rH rH r o CN U CH O < i n rH
tH rH rH rH >4 CN CN [H b (N (N T)4 tS3 (0 CN 3 rH (Nco 00 00 œ b < < CN VO VO r o b E < X b CN VO(Tt b b < < < X Vh b N <>4 b b b b (0 < b b
b CO
171
4.3.2 Assaying the production of mature enveiope glycoproteins by 
immunofluorescence
To assess whether the novel env gene products were folded correctly, 293T  
cells were transfected with VR1012 env constructs, fixed with ice-cold methanol and 
stained using 6-15, a monoclonai antibody recognising the FeLV envelope 
glycoprotein. FeLV-A/Glasgow-1, FeLV-B/Gardner Arnstein, FeLV-C/Sarma and 
FY981 were included as controls. The results of the antibody staining are shown in 
figure 4.4. From the eleven novel env gene products assessed, nine were capable of 
producing a protein that was recognised by the monoclonal antibody 6-15 (FA27-C5, 
FA27-C6, FA27-C7, FA27-C12, FA621-C1, FA621-C3, FA621-C4, FY981-C11 and 
FZ215-C6). The remaining two constructs (FX343-G8 and FZ215-G7), were incapable 
of forming protein that was recognised by the antibody.
As described previously in section 3.3.2, cells that were transfected efficiently 
and were able to produce protein recognised by 6-15 were evident from the localised 
fluorescence on the surface membrane of the cells, indicating the production and 
export of the envelope glycoprotein from the cells. The two env gene constructs 
(FZ215-G7 and FX343-G8) that did not produce a protein that was recognised by the 
antibody were indistinguishable from the background cells, as can be seen in figure 
4.4. To ensure the presence of cells in the field examined, a second image was 
recorded using bright field microscopy, the results of which can be seen in figure 4.4. 
As there are cells present in the field photographed, the negative antibody staining 
was due to the env constructs producing a protein that was no longer recognised by 
the antibody. As discussed in chapter three, a likely explanation for this is the 
disruption of the conformational structure through changes in the amino acid 
sequence and subsequently, loss of recognition by the antibody.
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FA27-C5 FA27-C5 FA27-C6
FA27-C7 FA27-C12
FA621-C1 FA621-C3 FA621-C4
FX343-C8 FX343-C8
1 7 4
FY981-C11
FZ215-C6 FZ215-C7 FZ215-C7
FeLV-A/Glasgow-1 control
FY981 control FeLV-C/Sarma control
FeLV-B/Gardner Arnstein control
Figure 4.4: Evaluation o f the expression of the mature envelope glycoprotein.
The 2 9 3 7  cells that were transiently transfected with the FeLV env constructs, a
plasmid containing MuLV gag-pol and a marker gene were stained with the anti-
M Sgp70 monoclonal antibody 6-15 and examined by immunofluorescence.
4.3.3 Cell tropism of the FeLV enWMuLV gag pol pseudotypes
FeLV enWMuLV gag pol pseudotypes were prepared and plated onto a range 
of cell lines to determine the tropism. The results of which are shown in table 4.4. As 
discussed in chapter three, pseudotypes bearing the FeLV-A, FeLV-B and FeLV-C  
env proteins were capable of infecting the cell lines predicted by previous studies, 
with FeLV-A having the most restrictive in vitro tropism and FeLV-C the broadest in 
vitro tropism (Jarrett O. et al., 1973; Sanaa P.S. et al., 1975; Hardy W.G.Jr., 1993). 
The titres in this section of the study were generally lower than the titres found In 
chapter three; this was most likely due to differences in the transfection efficiency of 
the 293T cells.
FeLV-A infected the feline cell line H06T1 and the cell line Mink to titres of 10  ^
CFU/m l, no other cell lines were susceptible. FeLV-B Infected the feline cell line 
H06T1 (to a titre of 1.3x10^ CFU/m l) and as expected the human cell line HeLa (to a 
titre of 6.5x10® CFU/m l), the canine cell line MDCK (to a titre of I.OxlO'^ CFU/m l) and 
the porcine cell line ST Iowa to a titre of 1.3x10^ CFU/m i (porcine cells were shown 
previously to be permissive to FeLV-B infection but resistant to FeLV-A and FeLV-C  
infection (Hardy W.G.Jr., 1993)). FeLV-B also infected the cell line Mink, however with 
a lower titre compared to both FeLV-A and FeLV-C (to a titre of 22 CFU/m l compared 
to 3.6x10® CFU/m l and 1.7x10® CFU/m l respectively). Similarly, FeLV-C infected the 
feline cell line H06T1 (to a titre of 4.0x10^ CFU/m i) and as expected the human cell 
line HeLa (to a titre of 5.4x10^ CFU/m l) and the guinea pig cell line 104C1 (to a titre of 
1.3x10® CFU/m l), the latter of which is known to be permissive to FeLV-C infection 
only (Hardy W.G.Jr., 1993). The titres of the FeLV-C control were lower than the titres 
for the other controls included in the studies, on average the titres were five to ten fold 
lower than the titres found for other constructs. As expected, none of the constructs 
produced viruses that were capable of infecting the murine cell line 3T3 (murine cells 
were shown previously to be resistant to FeLV infection (Jarrett O. et al., 1973)).
The constructs, which were not recognised by the monoclonal antibody 6-15, 
namely FZ215-C7 and FX343-C8, did not produce pseudotypes capable of infecting 
the panel of cell lines, suggesting that the proteins formed were non-functional.
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H06T1 104C1 Mink Hela CB MDCK ST Iowa 3T3
FA27-C5 3.6X10^ 6.7X10^ 3.1X1 O'* 2.6X10' 0 0 0
FA27-C6 3.6X10^ 0 3.2X10' 0 0 0 0
FA27-C7 4.6X10^ 1.2X10'* 3.4X10' 6.2X10' 0 0 0
FA27-C12 43 0 1.6X10' 26 0 0 0
FA621-C1 91 60 6.2X10' 17 97 0 0
FA621-C3 3.6X10^ 26 1.2X10' 0 0 0 0
FA621-C4 60 0 1.0X10' 0 0 0 0
FY981-
C11
1.5X10^ 3.6X10^ 1.9X10' 1.0X10' 0 0 0
FZ215-C6 1.1X10^ 0 9 0 0 17 0
FZ215-C7 0 0 0 0 0 0 0
FX343-C8 0 0 0 0 0 0 0
CL29A 6.8x10'* 0 3.6x10' 0 0 0 0
FeLV-
B/GA
1.3x10'* 0 22 6.5x10' 1.0x10* 1.3x10' 0
Sarma C 4.0x10' 1.3x10'* 1.7x10® 5.4x10' 0 0 0
FY981 8.9x10' 2.1x10* 1.8x10* 6.8x10' 0 3.8x10' 0
Table 4.4: Titres (CFU/ml) o f the novel unique env clones established by infection of 
a panel of cell lines. The cell lines tested are: the feline kidney cell line HOST 1, the 
guinea pig cell line 10401, the mink lung cell line MvlLu (Mink), the human cervical 
carcinoma cell line Mela CB, the canine kidney cell line MDCK, the porcine testes cell 
line ST IOWA and the murine cell line NIH 3T3.
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The env constructs most closely resembling FeLV-A and capable of producing viable 
protein, FA27-C6, FA621-C4 and FZ215-C6, infected the same panei of cell lines as 
the FeLV-A control, albeit to lower titres than the control (to titres of 3.6x10^ CFU/ml, 
60 CFU/ml and 1.1 xIO^ CFU/ml respectively for H06T1 infection and to titres of 
3.2x10^ CFU/ml, 1.0x10^ CFU/ml and 9 CFU/ml respectively for mink infection). 
Construct FZ215-C6 also infected the porcine cell line ST with a low titre (17 CFU/ml), 
suggesting that the tropism of subgroup A viruses may not be as restricted as 
suggested by earlier studies on viral growth in vitro (Jarrett O. et al., 1973; Sarma 
P.S. et al., 1975; Hardy W.G.Jr., 1993). The e/?v constructs that were classified as C 
components through sequencing analysis and that were capable of producing viable 
protein (FA27-C5, FA27-C7, FA27-C12, FA621-C1, FA621-C3 and FY981-C11) 
infected the same ceil lines as the control construct FeLV-C/Sarma (to titres of 
3.6x10^ CFU/ml, 4.6x10^ CFU/ml, 43 CFU/ml, 91 CFU/ml, 3.6x10^ CFU/ml and 
1.5x10^ CFU/ml respectively for H06T1 infection and to titres of 3.1x10® CFU/ml, 
3.4x10® CFU/ml, 26 CFU/ml, 17 CFU/ml, 0 CFU/ml and 1.0x10^ CFU/ml respectively 
for mink infection). With the exception of construct FA27-C12, titres were comparable 
to the titres obtained with the control construct FeLV-C/Sarma. Construct FA27-C12 
had an unusual tropism as it was capable of infecting both H06T1 and mink cells (to a 
titre of 43 CFU/ml and 26 CFU/ml respectively), however it was not capable of 
infecting the guinea pig cell line 104C1, a determining factor for the C-phenotype. This 
could indicate the presence of an alternative receptor on the cell surface, which is 
used by FeLV-C/Sarma. Alternatively, the receptor present on 104C1 cells is slightly 
altered and thus prevents infection by FA27-C12. Interestingly, construct FY981-C11 
was incapable of infecting the pig cell line ST Iowa in contrast to the parent control 
construct FY981 and the previously characterised construct FY981-14. This could be 
due to the fact that the overall titres of this construct are iower than the titres found for 
the previously identified construct FY981-14 and therefore infection of ST Iowa cells 
could not be detected. Construct FA621-C1 had an extended in vitro tropism; as it 
was also capable of infecting the canine cell line MDCK (to a titre of 97 CFU/ml), in 
contrast to the subgroup C control FeLV-C/Sarma.
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As was noted in chapter three, few constructs yielded viruses that were 
capable of Infecting the human cell line HeLa, although as discussed in section 3.4, 
this could be due to the choice of human cell line tested rather than an Inability of the 
env constructs tested in this study (previous studies used 293T cells).
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Virus isolate Original 
mixture of 
subgroups
Env 
clone #
Subgroup 
predicted by 
sequencing
Antibody 
staining 
using 6-15 
monoclonal 
antibody
Subgroup 
established 
by virus 
infection
FA27 A/C C5 C + C
C6 A + A
C l C + C
C12 C + C?
FA621 A/C Cl C + C
C3 C + C
C4 A + A
FY981 A/B/C C11 C + C
FX343 A/C C8 C - -
FZ215 A/B/C C6 A + B
C7 B - -
Table 4.5: Subgroups of the novel envelope glycoproteins as determined by 
sequencing and pseudotype infection on a panel of cell lines from a range of species.
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4.4 Discussion
To date no single amino acid or stretch of amino acids has been identified that 
can change the subgroup of an isolate of FeLV. Therefore, we aimed to isolate and 
characterise the C-components of a panel of natural Isolates in order to identify the 
regions involved in defining the phenotype of these isolates. When the primary 
isolates described previously in chapter three (see table 3.1), were plated onto FEA 
cells, a non-restrictive cell line, a number of C components could not be isolated, most 
likely due to the relative scarcity of the C phenotype In the viral pool of a specific 
primary isolate. Therefore, the panel of primary isolates was plated onto the guinea 
pig cell line 104C1, which is restrictive to FeLV-C infection alone. Thus, It was 
anticipated that the remaining C-components of the natural Isolates would be 
enriched, enabling their isolation and characterisation. After biological selection on 
104C1 cells, twenty-two novel FeLV env clones were identified. Using the criteria 
described in section 3.3.1 (the presence of length polymorphisms and a high degree 
of divergence in the VRA region relative to the published FeLV-A/Glasgow-1 envelope 
glycoprotein sequence), the env clones were classified into either the A component or 
the C component of an isolate. Thus, four clones appeared to be the A component of 
the primary isolate and sixteen clones appeared to be the C component. As discussed 
in chapter three, as the envelope glycoprotein of FeLV-B/Gardner Arnstein was highly 
divergent from both FeLV-A and FeLV-C, it was relatively easy to establish that the 
remaining two ciones were the B-component of that specific primary isolate.
4.4.1. The sequence of the novel FeLV-C envelope glycoproteins
4.4.1.1. Envelope glycoproteins described in this study are divergent from 
published envelope glycoprotein sequences
Although previous studies by Brojatsch et al (Brojatsch J. et al., 1992) and 
Rigby et al (Rigby M.A. et al., 1992) into the amino acids determinants of In vitro cell 
tropism utiiised the same isolates of FeLV, the sequences described in the two 
studies contained significant discrepancies.
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Thus, a representative clone of each primary isolate was characterised and an amino 
acid alignment was prepared (see figure 3.2). When the novel envelope glycoproteins 
characterised in this thesis were compared with the published FeLV envelope 
glycoproteins, the data confirmed that the C component of a primary isolate was 
represented by more than one sequence, and that the sequences described 
previously may have represented single variants and may not have been 
representative of the dominant phenotype within the pool.
4.4.1.2. Each primary isolate is represented by muitiple envelope glycoprotein 
sequences
As discussed previously, when the FeLV env A and C sequences identified in 
this study were compared, the majority of the envelope glycoprotein sequence was 
conserved and each independent isolate appeared to contain characteristic 
differences throughout the sequence that were unique to that specific primary isolate. 
The majority of the differences were present in the variable regions of the envelope 
glycoprotein, but further differences were scattered throughout the entire envelope 
glycoprotein. The differences discussed in more detail in chapter three were also 
present in the env clones described in this section of the thesis. For example, the A 
component of primary isolate FA27, FA27-C6, was identical to the A component 
described in chapter three, FA27-53, thus again strengthening the conciusion that the 
env sequences of both clone FA27-C6 and clone FA27-53 were indeed representative 
of the A component of primary isolate FA27. Similarly, the C component of primary 
isolate FY981, FY981-C11, was identical to env clone FY981-14, with the exception of 
one amino acid (Ngi found in FY981-C11 compared to T21 found in FY981-14), which 
may not a iter the overali structure. When comparing the C components identified for 
primary Isolate FA621 (FA621-C1 and FA621-C3), they were very similar, indeed 
there were only three amino acid differences present ( I 9 V ,  T 3 3 A  and A 2 5 1 T  in clone 
FA621-C3 relative to clone FA621-C1), Of these differences, the arginine residue on 
position 251 was present only in clone FA621-C1, compared to a threonine residue in 
both FA621-C3 and FA621-C4 (the A component of primary isolate FA621).
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4.4.1.3. The abundance of the C-component within each primary isolate pool
When the panel of primary isolates was plated onto FEA cells (a non- 
restrictive cell line), it became apparent that the abundance of the C component in the 
viral pool varied for each primary isolate. For example, the C component of primary 
isolate FY981 (previously classified as an A/B/C mixture) was relativeiy abundant, as 
all seven env clones identified appeared to be the C component, whereas the 0  
component of primary isolate FZ215 (previously classified as an A/B/C mixture) was 
not detected. After plating the panel of primary isolates onto 104C1 cells (a cell line 
restrictive to FeLV-C infection alone) a number of the C components that had not yet 
been identified, were isolated. For example, after plating primary isolate FA621 onto 
104C1 cells, six env clones were isolated and five appeared to be the C component. 
As discussed in chapter three, after plating this primary isolate onto FEA cells, the C 
component was not identified. After selection onto 104C1 cells of a number of primary 
isolates, the number of clones that appeared to be the C component was more 
abundant than after plating onto FEA cells. For example, primary isolate FA27 yielded 
ten novel env clones, nine of which appeared to be the C component, thus these 
results were in contrast with the results discussed in chapter three, where only two out 
of four clones appeared to be the C component. In conclusion, the C component was 
isolated from the majority of the primary isolates after plating onto the restricted cell 
line 104C1. However, to date the C component of two of the panel of primary isolates 
(FZ215 and L3728F) remains to be isolated, this may be due to the relative scarcity of 
the C phenotype in the viral pool of the specific primary isolate.
4.4.2. Characteristics of the C phenotype of FeLV
The main features and the clustering of mutations within the envelope 
glycoprotein described in Chapter 3 were also found In the env clones described in 
this Chapter. Indeed, the findings in Chapter 4 further strengthen the findings 
described in Chapter 3. The main features that ascertain a C-phenotype (mutations in 
a series of amino acids consisting of ^TNVKHG^ resulting in the loss of a N-linked 
glycosylation site and the substitution VeaW) were present in all isolates that were able 
to produce pseudotypes capable of infecting 104C1 cells.
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These findings strengthen the hypothesis that the while the mechanism by which 
mutations arise in the viral envelope glycoprotein may be random; the mutations are 
retained in areas of significance to protein structure (for example the receptor binding 
site) or biological function (evasion of the host immune response).
4.4.3. The envelope glycoprotein sequences of the A components
Of the twenty-two clones identified, four novel env clones were classified as 
the A component of the primary isolate, using the criteria described previously (lack of 
both variation and length polymorphisms in the VRA region of the envelope 
glycoprotein). When the A components identified in this study were compared, the 
envelope glycoprotein amino acid sequences were not identical, indeed there were 
differences present throughout the envelope glycoprotein sequence. For example, 
when comparing both the A components and the C components identified for primary 
isolate FA27, a D^N substitution and a N5 9 D substitution (relative to the FeLV- 
A/Glasgow-1 sequence) in the VRA region were present in all the clones identified to 
date. Thus, these results strengthen the findings discussed in Chapter 3 that, 
although FeLV-A amino acid sequences were very similar, there were amino acids 
present that were specific for a particular primary isolate, rendering these changes 
unique to that particular primary isolate. Given that these subtle differences in amino 
acid sequence fall within the predicted receptor binding domain, these observations 
raise the possibility that variants of FeLV-A may exist that have distinct cell tropisms.
4.4.4. Effects of the env sequence on antibody staining and 
biologicai function
In order to establish the function and the host range of eleven of the unique 
envelope glycoproteins isolated, FeLV/MuLV pseudotypes were generated and their 
cell tropism investigated in vitro (see figure 4.4 and table 4.4). Further, recognition of 
the viral env protein by the anti-gp70 antibody 6-15 was examined by 
immunofluorescence (see figure 4.3).
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4.4.4.1. The production of mature envelope glycoprotein in vitro
Of the eleven env constructs characterised further, two constructs (FZ215-07 
and FX343-C8) failed to react with the anti-gp70 monoclonal antibody 6-15, 
monoclonal antibody 6-15, suggesting that the proteins produced by these env clones 
were no longer recognised by the antibody. As discussed in chapter three, the binding 
site of the monoclonal antibody 6-15 has not yet been characterised, however as the 
antibody recognises all three subgroups, it is likely that the antibody binding site is 
located in a highly conserved region of the envelope glycoprotein. As described in 
chapter three in more detail, there were two possible explanations for the production 
of a protein that was no longer recognised by this antibody (firstly, the conformational 
structure of the protein was disrupted and thus the antibody epitope was no longer 
available to the protein and secondly, the mutations were present In the antibody 
epitope and thus antibody binding was disrupted). As was found for the four env 
constructs described in Chapter 3 that failed to bind the anti-gp70 antibody 6-15 
(FS246-4, FX343-26, FY981-10 and FZ215-12), there were a number of changes in 
the amino acid sequence that were not present in the env clones identified from the 
same primary isolate that were recognised by the monoclonal antibody. The 
mutations for each clone were as follows:
a) FX343-G8: TiogA and G2 6 0 R
b) FZ215-C7: T2 3A and Ties!
As was discussed previously (see Chapter three), the mutations appeared to fall in 
distinct regions of the envelope glycoprotein, thus strengthening the findings 
discussed in chapter three that the mutations In the envelope glycoprotein altered the 
conformational structure of the protein and therefore disrupted the antibody epitope 
which lead to the protein failing to react with the anti-gp70 monoclonal antibody 6-15.
185
4.4.4.2. Altered cell tropism of novel FeLV env clones
In order to establish whether the novel env clones were functional, 
FeLV/MuLV pseudotypes were generated and the in vitro cell tropism was examined. 
Previous studies have examined the in vitro cell tropism of FeLV-A, FeLV-B and 
FeLV-C and have shown that FeLV-A has the most restricted in vitro cell tropism and 
is capable of infecting feline cells alone (Jarrett O. et al., 1973; Sarma P.S. et al., 
1975; Hardy W.G.Jr., 1993). In contrast, FeLV-B and FeLV-C have a broader in vitro 
cell tropism and are capable of infecting both feline and non-feline ceils. Guinea pig 
cells alone support infection of FeLV-C, whereas porcine cells alone support FeLV-B 
infection (Jarrett O. et al., 1973; Sarma P.S. et al., 1975; Hardy W.G.Jr., 1993).
Similar to the four env clones that failed to react with the anti gp70 monoclonal 
antibody 6-15 described in chapter three (FS246-4, FX343-26, FY981-10 and FZ215- 
1 2 ), the two constructs described in this part of the study that failed to produce protein 
recognised by the 6-15 antibody (FX343-C8 and FZ215-C7) did not produce 
pseudotypes capable of infecting the cell lines tested, thus suggesting that the 
proteins produced were indeed non-functional. Pseudotypes derived from the 
remaining nine viable env constructs (FA27-C5, FA27-C6, FA27-C7, FA27-C12, 
FA621-C1, FA621-C3, FA621-C4, FY981-C11 and FZ215-C6) were capable of 
infecting the panel of cell lines tested.
Pseudotypes derived from the three env constructs that appeared to be the A 
components (FA27-C6, FA621-C4 and FZ215-G6) infected the same range of cells as 
the control FeLV-A/Glasgow-1, namely the feline cell line H06T1 and mink cells, 
although the titres found for the novel env constructs were lower than the titres found 
for the control FeLV-A/Glasgow-1 construct (9.8x10^ CFU/ml for FeLV-A, compared to 
3.6x10^ CFU/ml for FA27-C6, 60 CFU/ml for FA621-C4 and 1.1x10^ CFU/ml for 
FZ215-C6). Interestingly, FZ215-C6 derived pseudotypes were capable also of 
infecting the porcine cell line ST Iowa, in contrast to pseudotypes derived from env 
clone FZ215-9 (the A component of primary Isolate FZ215 described in chapter 
three), which were incapable of infecting ST Iowa cells. When the amino acid 
sequences of FZ215-C6 and FZ215-9 were compared, there were two amino acid 
changes present In FZ215-C6, but not in FZ215-9 ( N 3 S  and N 2 2 H ) .
186
NsS is present also in the amino acid sequence of FZ215p, however pseudotypes 
derived from this isolate were not plated onto the porcine cell line ST Iowa. The 
second substitution, N2 2 H, is unique and can be found only in FZ215-C6. The amino 
acid residue (aspartic acid on position 51) associated with the extended host range of 
the pseudotypes derived from env constructs FA27-53, FY981-14, FeLV-B/Gardner 
Arnstein and FY981p (i.e. capable of infecting porcine cells, see 4.4.3) was not 
present in FZ215-C6. Thus, this aspartic acid residue on position 51 cannot be the 
soie residue important in the extended in vitro cell tropism of the three novel env 
constructs (FA27-53, FY981-14 and FZ215-C6) to include porcine ST Iowa cells.
With the exception of env construct FA27-C12, pseudotypes derived from the 
env constructs that appeared to be the C components (FA27-C5, FA27-C7, FA27- 
C12, FA621-C1, FA621-C3 and FY981-C11) were capable of infecting the feline cell 
line H06T1, the guinea pig cell line 104C1 and mink cells to comparable titres as 
those derived from the control FeLV-C/Sarma (4.6x10^ CFU/ml for the control FeLV-C 
compared to 3.6x10^ CFU/ml for FA27-C5, 4.6x10^ CFU/ml for FA27-C7, 91 CFU/ml 
for FA621-C1, 3.6x10^ CFU/ml for FA621-C3 and 1.5x10^ CFU/ml for FY981-C11 
when infecting H06T1 cells). The inability of FA27-C12 to infect 104C1 cells was 
possibly due to the diminished titres of this construct. In comparison, the control 
FeLV-C/Sarma pseudotypes were able to infect H06T1 cells to a titre of 463 CFU/ml, 
whereas FA27-C12 pseudotypes had a titre of 43 CFU/ml when Infecting H06T1 
cells, resulting in a ten-fold reduction of infectivlty. With the exception of FA621-C3, all 
pseudotypes were capable also of infecting HeLa cells, similar to the control FeLV- 
C/Sarma derived pseudotypes. FA621-C3 derived pseudotypes were incapable of 
infecting HeLa cells, even though FA621-C3 derived pseudotypes were able to infect 
H06T1 cells to comparable titres as those derived from the control FeLV-C (360 
CFU/ml in comparison to 463 CFU/ml for the control FeLV-C/Sarma construct). 
Interestingly, although the titres of FA621-C3 pseudotypes were four fold higher than 
the titres found for FA621-C1 pseudotypes (which also appeared to be the C 
component of primary isolate FA621), FA621-C1 derived pseudotypes were capable 
of infecting HeLa cells. When the amino acid sequences of the two C components 
were compared, there were 3 amino acid differences between clones C l and C3, V9 I, 
T 3 3 A  and T 2 5 1 A .
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Two amino acid differences (V9 I and T2 5 1A) were present in regions of the envelope 
glycoprotein thought to be associated with cell tropism (determined amongst others by 
Bae et al (Bae Y. et al., 1997)). As the first substitution (V9 I) was also present in the 
published FeLV-C/Sarma amino acid sequence and FeLV-C/Sarma derived 
pseudotypes are incapable of infecting ST Iowa cells, it was unlikely that this residue 
was involved in altering the in vitro cell tropism of FA621-C3. T 3 3 A  lies in the region 
immediately upstream of the VRA and was also found in FA621-C4, an env clone that 
behaved as subgroup A. The third substitution ( T 2 5 1 A )  is unique to clone C l. The 
switch from a hydrophilic side chain (threonine) to a hydrophobic side chain (alanine), 
may be sufficient to alter the conformation of the FA621-C1 env such that it has a 
broader tropism than FA621-C3, or conversely, may be responsible for the narrower 
cell tropism of FA621-C1.
The env construct most closely resembling FeLV-B/Gardner Arnstein (FZ215- 
C7) did not produce protein recognised by the monoclonal antibody 6-15, nor was it 
capable of producing functional protein as was shown by the lack of infection by 
FZ215-C7 Env-bearing pseudotypes, these findings were in accordance with the 
novel FZ215 env clone resembling FeLV-B/Gardner Arnstein described in chapter 
three (FZ215-12). Thus both FZ215-C7 and C l 2 produced non-functional Env 
proteins.
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CHAPTER FIVE
EXPRESSION OF THE FeLV-C 
RECEPTOR feFLVCR IN VIVO
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5.1 Introduction
In 1999, Tailor et al (Tailor C.S. et al., 1999c) described the cloning 
and characterisation of a cellular receptor for FeLV-C from a cDNA library prepared 
from a human cell line. Subsequently, the feline homologue of this molecule was 
cloned and characterised (Quigley J.G. et al., 2000). Both molecules are members of 
the major facilitator superfamily (MFS) (discussed in detail by Pao (Pao S.S. et al., 
1998)) and are multi-transmembrane domain molecules that are thought to function 
as transporters (see also section 1.5.2). By screening a polyA (+) mRNA northern blot 
consisting of RNAs from both haematopoietic and non-haematopoietic tissues. Tailor 
et al (Tailor C.S. et al., 1999c) demonstrated that the huFLVCR transcript was 
preferentially expressed in haematopoietic tissues, although low levels of the mRNA 
transcript were also present in non-haematopoietic ceils. These findings led to the 
conclusion that FeLV-C preferentially infected haematopoietic cells in vivo, in 
agreement with previous studies by Dean et al (Dean G.A. et al., 1992) into the 
preferential haematopoietic target cells of FeLV-C infection. Dean et al (Dean G.A. et 
al., 1992) described three potential mechanisms by which the FeLV-C Env protein 
could cause an erythroid cell-specific cytopathic effect and thus pure red cell aplasia 
PRCA:
1 ) The FeLV-C receptor is expressed solely on erythroid progenitor cells and 
thus these cells are targeted selectively by the virus.
2) The binding of FeLV-C to its receptor on the cell surface Impairs the 
normal function of its receptor and cells of the erythroid lineage have an 
absolute dependence on the function of this molecule for survival.
3) The binding of the virus to its receptor has an effect through a mechanism 
that, to date has not been characterised.
Dean et al showed that viral Env protein gp70 and capsid protein p27 could be 
detected in bone marrow populations containing erythroid, but also lymphoid and 
myeloid cells at similar levels when samples taken from cats infected either with 
FeLV-A or FeLV-C were compared, suggesting that the FeLV-C receptor was not 
expressed solely on erythroid progenitor cells.
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Further, these findings were strengthened by Tailor et al (Tailor C.S. et al., 1999c) 
when the preferential expression of huFLVCR on haematopoietic cells was detected, 
however the huFLVCR expression was not restricted exclusively to erythroid 
progenitor cells. To date, the impairment of the normal function of the receptor due to 
the virus binding, has not been investigated. Dean et al concluded that the most 
plausible explanation for the devastating effect that FeLV-C infection has on 
erythropoeisis, is inhibition of the normal function of the receptor in the production of 
erythrocytes. This conclusion is in agreement with the results described by Abkowitz 
et al (Abkowitz J.L., 1991). Abkowitz et al hypothesised that the FeLV-C/Sarma 
envelope glycoprotein interfered with the interaction of transferrin and Its receptor, 
suggesting that either the transferrin receptor is also the FeLV-C/Sarma receptor or 
that gp70 produced intracellularly interfered with the recycling of the transferrin 
receptor and this subsequently led to a defect in the uptake of transferrin by Its 
receptor.
The main aims of the studies described in this chapter were:
1) To examine the expression of the feline FeLV-C receptor in both 
haematopoietic and non-haematopoietic tissues.
2) To study the expression of the receptor in bone marrow popuiations that 
were either enriched with or depleted of cells involved in the erythroid 
maturation.
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5.2 Methods
The main haematological symptoms of PRCA are a reduced number of late 
erythroid precursor cells (CFU-E) in spite of a normal number of early erythroid 
precursor cells (BFU-E), suggesting a defect in the maturation of BFU-E into CFU-E 
(see figure 1.6 and (Abkowitz J.L et al., 1985)). In order to investigate the role of the 
FeLV-C receptor in the development of the PRCA associated with FeLV-C infection, a 
range of both lymphoid (bone marrow, thymus, spleen, mesenteric lymph node MLN, 
peripheral lymph node PLN) and non-lymphoid (skeletal muscle, saliva gland, heart, 
brain, liver, kidney) tissues were collected from a number of cats at post mortem and 
used for RNA preparation and subsequent northern blotting and RT-PCR analysis. In 
addition, bone marrow cells were fractionated into erythroid and non-erythroid 
lineages using the monoclonal antibody K1, an antibody thought to recognise 
erythroid progenitors (Gengozian N., 1998). RNA was prepared from each of the bone 
marrow fractions and the abundance of the FLVCR RNA transcript quantified by RT 
PCR.
The tissues were collected from a range of cats at the time of post mortem. 
The cats were involved in projects underway in the Department of Veterinary 
Pathology. In total, bone marrow was collected from six cats, four of which were 
FeLV-negative as assessed by p27 ELISA at the time of post mortem, while two cats 
were positive for FeLV as assessed by p27 ELISA at the time of post mortem. In 
addition, a full range of tissues was collected from six cats, three of which were FeLV 
positive at the time of post mortem while the remaining three were FeLV negative. 
The tissues that were collected from each cat are summarised in table 5.1.
Cats F4 and F8  were cats from a FIV vaccination trial. These cats were FIV- 
negative as assessed by p27 ELISA at the time of post mortem and had never been 
in contact with FeLV. Both bone marrow and a panel of tissues were collected from 
cat F4, whereas only bone marrow was obtained from cat F8 . The tissues were snap 
frozen in liquid nitrogen and stored at -70°C until required.
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F4 F8 E2 ES E6 L22 L23 L32 L36
Bone marrow ✓ ✓ X X X y y y ✓
Kidney y X ✓ V ✓ X X y y
Heart V X V V ✓ X X ✓ y
Saliva gland y X V V ✓ X X y y
Liver ✓ X ✓ V y X X ✓ y
Thymus ✓ X ✓ y y X X y v'
Brain ✓ X X X X X X X X
Spleen ✓ X ✓ y >/ X X y y
Skeletal muscle ✓ X y V y X X V y
MLN ✓ X V V y X X y y
PLN X X V V y X X y y
Table 5.1:Tissues collected during post mortem examinations from each of the cats. The 
cat numbers shown in red were positive for FeLV p27 at the time of post mortem, 
whereas the cats shown in green were negative for FeLV.
Cats E2, E5 and E6 were cats from an immunopathogenesis study. All three cats 
were FeLV positive at the time of post mortem, with varying amounts of provirus 
detected using real time PCR and FeLV p27 ELISA (data not shown). Tissues from this 
group of cats were collected, snap frozen in liquid nitrogen and stored at -70°C until 
required.
Cats L22, L23, L32 and L36 were cats from a FeLV vaccination trial. Tissues and bone 
marrow were collected from two groups of cats; cats L22 and L23 were FeLV-positive 
after FeLV infection, whereas cats L32 and L36 remained FeLV-negative after FeLV 
infection (data not shown). As described previously, the tissues were snap frozen in 
liquid nitrogen and stored at -70°C until required.
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5.2.1 Preparation of RNA from tissues
Care was taken to prevent RNA degradation whilst working with tissues and 
RNA samples. In order to do this, all work surfaces were cleaned with RNase ZAP® 
(Invitrogen NV, Leek, The Netherlands) to destroy RNAse, all pipettes, filtered tips 
and reagents were used for RNA work only and Isolated from common use equipment 
to minimise the risk of RNAse contamination. The samples were maintained on ice at 
all times and long delays were avoided to keep the risk of degradation to a minimum. 
All centrifugations were carried out in a refrigerated bench top centrifuge at 4°C.
5.2.1.1 Preparation of RNA from tissues using RNAzol™ B
A range of tissues was collected from cats during post mortem. The following 
tissues were snap-frozen in liquid nitrogen and stored at -70°C until required: thymus, 
spleen, mesenteric lymph node (MLN), peripheral lymph node (PLN), brain, heart, 
saliva gland, skeletal muscle, liver and kidney. To prevent RNA degradation, tissues 
were stored at -70°C until required and maintained on dry ice when removed from 
storage. The tissues were pulverised using a mortar and pestle filled with liquid 
nitrogen. The pulverised tissues were then resuspended in 2ml RNAzol™ B 
(Biogenesis, Dorset, United Kingdom). RNAzol™ B contains phenol and guanidine 
thiocyanate and is used for the single step method of RNA isolation described in 1987 
by Chomczynski and Sacchi (Chomczynski P. and Sacchi N., 1987). In order to 
separate the phases, 0.2ml chloroform was added per 2ml RNAzol™ B. This was 
shaken vigorously for a few seconds, incubated on ice for 15 minutes and spun at 
3,000rpm for 15 minutes. The upper aqueous layer containing the RNA was 
transferred to a fresh tube and precipitated with an equal volume isopropanol, 
incubated on ice for 15 minutes and spun at 3,000rpm for 15 minutes. The RNA pellet 
was transferred to a 1.5ml tube and washed once with 70% ethanol by centrifugation 
for 8 minutes at 13,000rpm in a microcentrifuge. The pellet was then dried in a 
vacuum drier and resuspended in 50pl dH20. The RNA concentration was determined 
using spectrophotometry as described previously (see section 2.2.3.3).
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The A2 6 0 /2 8 0  ratio was typically 1.9, confirming the purity of the RNA and that there was 
no protein contamination. The RNA was stored in 20p.g aliquots at -70°C until 
required.
5.2.1.2 Preparation of RNA from tissues using RNA-Bee™
During the course of these studies, the RNAzol™ B reagent was discontinued 
and thus an alternative product was used. “RNA-Bee™” (Biogenesis, Dorset, United 
Kingdom) was used to isolate RNA from tissues collected from cat L22 onwards. 
RNA-Bee™ is similar to RNAzol™ B and therefore follows a similar method for the 
isolation of RNA and is derived from the single step method described previously by 
Chomczynski and Sacchi (Chomczynski P. and Sacchi N., 1987). Similar precautions 
were undertaken when using RNA-Bee™ for the preparation of RNA in order to 
prevent RNA degradation. Following pulverisation of the tissue, 1ml RNA-Bee™ was 
added per 50mg pulverised tissue to disrupt the cells and then 0.2ml of chloroform 
was added per 1ml RNA-Bee™. The mixture was shaken vigorously for approximately 
15 seconds and incubated on ice for 5 minutes. The phases were then separated by 
centrifugation at 3,000rpm for 15 minutes and the upper aqueous layer was 
transferred to a new centrifuge tube. RNA was precipitated by adding 0.5ml 
isopropanol and incubating at room temperature for 10 minutes followed by 
centrifugation at 3,000rpm for 5 minutes. The RNA pellet was washed once with 1ml 
70% ethanol per 1ml RNA-Bee™ by centrifugation at 13,000rpm for 5 minutes. The 
pellet was then air-dried briefly and resuspended in 50pl dH20 and incubated at 56°C 
for 10 minutes to aid the solubiiisation of the RNA. The final RNA concentration was 
determined and samples were stored as described in section 2.2.3.3.
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5.2.2 Selection of enriched and depleted bone marrow populations 
using miniMACS columns
In order to investigate whether the FLVCR RNA transcript was differentially 
expressed in erythroid progenitors, bone marrow was extracted from the femurs of 
cats at post-mortem and fractionated using the monoclonal antibody K1 (an antibody 
raised against erythroid progenitors (Gengozian N., 1998)). Gengozian demonstrated 
that following depletion of bone marrow cells using the K1 antibody, the remaining 
population showed an 80% reduction in BFU-E progenitor cells. As previous studies 
have suggested that a defect in the development of CFU-E from BFU-E is thought to 
underlie the development of PRCA, differential expression of the FLVCR receptor 
may explain the specific targeting of BFU-E by FeLV-C (Abkowitz J.L et al., 1985). 
Accordingly, if the expression of the FeLV-C receptor was restricted to ce I is involved 
in erythroid maturation, then feFLVCR RNA would be reduced in the K1 depleted 
population. Conversely, if the expression of feFLVCR was not restricted to cells 
involved in the erythroid maturation then the feFLVCR RNA would be expressed in 
both depleted and enriched populations of bone marrow.
5.2.2.1 Extraction of bone marrow from the feline femurs
Femurs were obtained from cats at post-mortem. The ends were removed 
from the femurs using bone cutters and the bone marrow collected by flushing RPMI 
medium through the bone with a 20ml syringe and an 18 gauge needle. Once all bone 
marrow was removed, a single cell solution was obtained by repeatedly pipetting the 
solution with a 10ml pipette and pelleted by centrifugation at SOOOrpm for 10 minutes. 
Cell pellets were washed twice with RPMI and pelleted by centrifugation at SOOOrpm 
for 10 minutes. The cell pellet was resuspended in 500|il MACS buffer and the cell 
concentration was determined by counting the cells using a haemocytometer as 
described previously (section 2.2.1.2.2). 2x10® cells were used per antibody for 
selection. The cells were pelleted, labelled with 1ml unconjugated primary antibody 
(as culture supernatant).
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The cells were washed once In MACS buffer by centrifugation and labelled with 40^1 
goat anti-mouse IgG microbeads (Miltenyi Biotec Ltd., Surrey, United Kingdom) to a 
final 1:5 dilution and incubated at 4°C for 15 minutes. During this incubation period, 
miniMACS MS columns (Miltenyi Biotec Ltd., Surrey, United Kingdom) were placed in 
a miniMACS magnetic holder and rehydrated with 500pl MACS buffer. The column 
matrix consists of ferromagnetic spheres, allowing separation of cells less than 30pM 
in size. After a subsequent wash step, the cells were resuspended in SOOpI MACS 
buffer and applied to the MS columns. The columns were washed twice with 500|il 
MACS buffer and all eluates were collected as the "antibody-depleted" population. A 
further 500p,l MACS buffer was added to the columns, after which the columns were 
removed from the magnetic holder. The K1-positive population was eluted by 
expelling the MACS buffer from the columns using the plungers supplied. Both 
populations were counted as previously (section 2.2.1.2.2) to determine the 
concentration of these populations after which the cells were pelleted, snap frozen 
and stored at -70°C until required. An unselected bone marrow sample that had been 
neither enriched nor depleted using the antibody K1 was included in the assay.
5 2.2.2 Preparation of RNA from cells using either RNAzol™ B or RNA-Bee™
As described previously, great care was taken to prevent RNA degradation. To 
lyse tissue culture cells, 0.2ml RNAzol™ B or RNA-Bee™ was added per 10® cells. 
The RNA was separated and precipitated as described previously (section 5.2.1.1 and 
section 5.2.1.2 respectively).
5.2.3 RNA gel electrophoresis and transfer onto a nitrocellulose 
membrane (northern blotting)
The RNA aliquots (containing 20pg RNA) were thawed rapidly in a 60°C water 
bath and vacuum dried. The samples were then resuspended in 20pl loading buffer 
and incubated at 65°C for 15 minutes. A 1% agarose gel containing 1x MOPS and
2.1 M formaldehyde was prepared and poured in a laminar flow hood.
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After incubation, 5pi RNA dye was added and the samples were loaded onto the gel. 
A 0.24-9.50 Kb RNA ladder was included to determine the size of the RNA bands 
(Invitrogen ™ Life technologies (Paisley, United Kingdom)). The samples were run for 
approximately 10 minutes at 100 volts before a circulation pump was attached and the 
samples were run for a further 3 hours at 100 volts and then stained in dHgO 
containing ethidium bromide (1.1 mg/l (w/v) ethidium bromide) for 10 minutes. The gel 
was destained for 30 minutes in dH^D twice and then visualised on a UV 
transilluminator and photographed (section 2.2.3.5). The lanes containing the RNA 
ladder remained in fresh dHgO for destaining overnight and were photographed the 
following morning. The lanes containing the RNA samples were rinsed for 30 minutes 
in lOx SSC and a northern transfer was set up as described previously (Current 
Protocols in Molecular Biology, (Ausubel F.A. et al., 1992). The following day, RNA 
was immobilised using a spectrolinker XL-1500 UV-crosslinker (Spectronics 
Corporation, New York, USA) using the “optimal crosslink” setting (1200 Watt). The 
blot was then stored at room temperature until required.
5.2.4 Hybridisation of northern blots
6.2.4.1 Hybridisation of northern blots using “RapidHyb™” hybridisation buffer
The northern blot was hybridised using "RapidHyb™” buffer (Amersham 
Biosciences Europe GmbH, Freiburg, Germany). The buffer was pre-warmed to 65°C 
before adding to the blot. The blot was prehybridised at 65°C for a minimum of 15 
minutes, during which the [a-®^P]-dCTP probe (the preparation of which is described 
in section 2.2.S.9) and the salmon sperm DNA (ssDNA, to a final concentration of 100 
jj.g/ml) were denatured at 100°C for 10 minutes and subsequently chilled on ice. The 
ssDNA was added to reduce the background and was added at a 1/1000^ volume of 
the RapidHyb™ buffer. The [a-®^P]-dCTP probe was added to a final concentration of 
1x10^ cpm/ml RapidHyb™ buffer. The blot was allowed to hybridise with shaking for 2 
hours after which it was washed with the following stringency washes: 2x SSC rinse, 
0.5%SDS/0.5xSSC rinse, 0.5%SDS/0.5xSSC 20 minutes, 0.5%SDS/0.5xSSC 20 
minutes.
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The final wash for the blot was adjusted, depending on the strength of the probe and 
the abundance of the gene of interest. The blot probed with the feFLVCR probe was 
washed using 0.5%SDS/0.5xSSC 20 minutes, whereas the blot probed with the 
GAPDH probe was washed with 0.5%SDS/0,1xSSC for 20 minutes. The washed blot 
was sealed in a bag and was then exposed to film (Hyperfilm MP, supplied by 
Amersham Biosciences UK Limited, United Kingdom) at -70°C using two 
intensifying screens. The film was developed In an automated processor (Automated 
Processor: Compact X4 supplied by Xograph, Wiltshire, UK.) following the 
manufacturer’s Instructions.
S.2.4.2 Hybridisation of northern blot using ULTRAhyb™ hybridisation buffer
As the feFLVCR gene appeared to be expressed at low levels, a second 
northern blot was hybridised using ULTRAhyb™ hybridisation buffer (Amblon Europe 
Ltd, Cambridgeshire, United Kingdom). The buffer was pre-warmed to 6 8 °C before 
the blot was immersed in sufficient buffer to uniformly wet the blot. The blot was 
subsequently prehybridised at 42°C for 45 minutes during which time the [a-^^P]- 
dCTP probe (the preparation of which is described In section 2.2.3.9) was denatured 
at 100°C for 10 minutes and subsequently chilled on ice. The [a-^^P]-dCTP probe was 
added at a final concentration of 1x10® cpm per ml of ULTRAhyb ™ and was allowed 
to hybridise overnight with shaking at 42'^C. The following morning, the blot was 
washed as follows: 0.5%SDS/2xSSC 2x5 minutes, 0.5%SDS/0.5xSSC 15 minutes, 
after which the blot was sealed In a polythene bag and was exposed to film at -70°C 
using two intensifying screens. The film was developed In an automated processor 
(Automated Processor: Compact X4 supplied by Xograph, Wiltshire, UK.) as 
described by the manufacturer.
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5.2.5 Reverse transcription PCR
5.2.5.1 First strand cDNA synthesis from total RNA
First strand cDNA synthesis consisted of two steps. The first step involved 
denaturing of the total RNA and an oligo(dT)i5 primer. The second step was the 
transcription of cDNA in the presence of the enzyme “reverse transcriptase" 
("Expand™ Reverse Transcriptase”, Roche Applied Science, East Sussex, United 
Kingdom). All incubations were performed using a Perkin Elmer 9700 thermal cycler. 
For the cDNA synthesis, 1pg of total RNA and 0.5pg of an oHgo(dT)i5 primer (Roche 
Applied Science, East Sussex, United Kingdom) were denatured at 65°C for 10 
minutes and cooled Immediately to 4°C. To this, a bulk mix containing the following 
reagents was added: 1x Expand™ Reverse Transcriptase buffer (first strand), lOmM 
DTT, ImM each of dATP, dCTP, dGTP and dTTP, 20 units of RNase inhibitor (Roche 
Applied Science, East Sussex, United Kingdom), 50 units of the enzyme Expand™ 
Reverse Transcriptase to a total volume of 20pl. This mixture was incubated at 42°C 
for 1 hour and cooled immediately to 4°C. The cDNA was used immediately for PCR 
amplification as described below and the remainder was stored at -20°C until 
required.
S.2.5.2 PCR amplification of cDNA
5pl of the cDNA synthesis product was used In each PCR reaction. 
Oligonucleotide primers were synthesised corresponding to the 5' start codon and 3’ 
stop codon of the FeLV-C receptor feFLVCR (5’-TCA AAT TGC TGA TTC TGA CTG- 
3' and 5 -CTC AAC TGC CTG GGT GCC TGG-3’) and of the housekeeping gene p- 
actln (5-ATC TGG CAC CAC ACC TTC TAC AAT GAG CTG CG-3’ and 5’- CGT CAT 
ACT CCT GCT TGC TGA TCC ACA TCT-3'). In each PCR reaction, the final 
concentrations of the components were the following: 1x buffer 2 (Roche applied 
science, East Sussex, United Kingdom), lOmM dNTP (Promega, Southampton, 
United Kingdom), 37.5pmol of each primer (MWG, United Kingdom) and 2.5 units 
enzyme 1 (Roche applied science. East Sussex, United Kingdom).
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The amplification was performed under the following conditions: dénaturation at 94°C 
for 3 minutes, followed by 30 cycles of dénaturation at 94°C for 30 seconds, annealing 
at 50°C for 1 minute and extension at 72°C for 3 minutes after which there was an 
additional 10 minutes extension step at 72°C. The amplification reaction yielded a 
1.6 kb product as predicted for the FeLV-C receptor (feFLVCR) and a 1.3kb product as 
predicted for the housekeeping gene (p-actin). The samples were separated by 
electrophoresis and visualised by ethidium bromide staining as described previously 
(section 2.2.3.5).
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5.3 Results
5.3.1. feFLVCR expression in a panei of tissues using northern blot 
analysis
5.3.1.1 Northern blot hybridisation using RapidHyb™ buffer
RNA samples from cats F4 and F8  were separated by electrophoresis and 
northern blotted (section 5.2.3.) in order to analyse the distribution of the FeLV-C 
receptor mRNA in both haematopoietic and non-haematopoietic tissues. The blot was 
probed using an a-32p labelled feFLVCR probe containing the entire FLVCR gene 
and subsequently exposed to the film at -70°C for 3 days before the film was 
developed. As figure 5.1a shows, no FLVCR bands were detected in the blot probed 
with the FLVCR probe. However, subsequent screening of the same blot with the 
control housekeeping gene GAPDH, revealed transcripts of a similar intensity in all 
lanes, confirming that the lack of message on the blot with the feFLVCR probe was 
not due to differences in loading of the RNA samples but more likely due to the 
FLVCR gene being rare in these tissues. The presence of bands rather than smears 
when probed with the GAPDH probe confirmed that the RNA was intact and had not 
been degraded. To overcome the problems in analysing the distribution of the FLVCR 
due to the scarcity of the FLVCR transcript, an aiternative hybridisation buffer, 
ULTRAHYB™, was used to hybridise an additional northern blot. As the 
manufacturers of ULTRAHYB™ (Ambion Europe Ltd, Cambridgeshire, United 
Kingdom), described their product as being sensitive enough to pick up rare 
transcripts, ULTRAHYB™ was used for subsequent hybridisations.
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5.3.1.2 FLVCR expression In feline tissues by northern analysis using 
ULTRAHYB™ hybridisation buffer
RNA samples from cat F4 were separated by electrophoresis and a northern 
blot was prepared and hybridised as described previously (section 5.2.3.). The blot 
was exposed to the film at -70°C for 3 days prior to developing the film. As can be 
seen in figure 5.1b, when the northern blot was probed using the feFLVCR probe, 
expression of the feFLVCR transcript could not be detected in the majority of the 
tissues studied. A faint band corresponding to the feFLVCR transcript was visible in 
the sample lanes bearing mRNA from thymus and salivary gland suggesting that the 
transcript was present at levels close to the sensitivity of northern blotting. When the 
same northern blot was probed with the GAPDH probe, transcripts of similar intensity 
were detected in all RNA samples. This demonstrated that similar amounts of RNA 
were loaded onto the gel, the RNA was intact and subsequently confirmed that the 
failure to detect FLVCR transcripts was due to the low level of gene expression. As 
was shown in the northern blot hybridised using RapidHyb™ buffer, the RNA was not 
degraded as there were bands rather than smears present in each iane.
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FLVCR GAPDH
1 2 3 4 5 6 7 8 9  1 2 3 4 5 6 7 8 9
4
A: Northern blot using RapidHyb™ hybridisation buffer.
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9
B: Northern blot using ULTRAhyb^" hybridisation buffer.
Figure 5.1: Northern blot analysis of total RNA prepared from a panel of tissues 
collected from cat F4. The northern blots were hybridised using either RapidHyb or 
ULTRAhyb™with either, ^^P-labelled feFLVCR ora housekeeping gene, GAPDH. The 
order of the lanes is as follows: 1 - MLN, 2 - thymus, 3 - heart, 4 - brain, 5 - spleen, 6 - 
salivary gland, 7 - liver, 8 - skeletal muscle and 9 - kidney.
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5.3.2 feFLVCR expression in a panel of tissues using RT PCR 
analysis
5.3.2.1 Expression of the FeLV-C receptor in a panel of tissues collected from 
cat F4
cDNA was synthesised from RNA collected from cat F4 (a cat from an FiV 
vaccination trial and thus FeLV negative). The cDNA was subsequently used for PCR 
amplification with primers encoding either feFLVCR or p-actin. The PCR products 
were separated by electrophoresis and visualised by ethidium bromide staining (figure 
5.2). PCR using the p-actin primers yielded products of a similar intensity, confirming 
that the cDNA synthesis reactions contained amplifiable cDNA in broadly similar 
amounts. Therefore, when comparing the intensity of the PCR products following 
amplification using the feFLVCR primers, the intensity of the PCR products could be 
correlated broadly with the level of expression of the feFLVCR gene in that particular 
tissue. FLVCR was relatively abundant in both the liver and the MLN, but expressed 
at lower levels in kidney, heart and thymus. The saliva gland, spleen and brain 
showed intermediate levels of FLVCR expression. Thus, in cat F4, there was no 
evidence for the preferential expression of the FLVCR mRNA in haematopoietic 
tissues.
5.3.2 2 RT PCR on RNA prepared from tissues collected from cat E2
cDNA was synthesised from RNA collected from cat E2 (a cat from a FeLV 
immunopathogenesis trial and at the time of post mortem positive for FeLV p27). The 
cDNA was subsequently used for PCR amplification with primers encoding either 
feFLVCR or p-actin (figure 5.2). In contrast to cat F4, PCR using the p-actin primers 
yielded products with varying Intensity, in particular the kidney and the skeletal muscle 
show diminished intensities, suggesting that the cDNA synthesis reactions contained 
amplifiable cDNA in varying amounts. Thus, the results of feFLVCR RT-PCR from 
both the kidney and skeletal muscle cDNA should be interpreted with caution.
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When amplifying cDNA synthesised from RNA collected from the remaining tissues, 
PCR using the p-actin primers yielded products of similar intensity, confirming that the 
cDNA synthesis reactions contained amplifiable cDNA in broadly similar amounts. 
Thus, variations in the Intensity of the feFLVCR PCR products were likely due to 
differences in the level of feFLVCR mRNA in each tissue. feFLVCR mRNA was not 
detected in the kidney, heart or thymus, in contrast, the mRNA was relatively 
abundant in salivary gland, liver and spleen. Lower levels of mRNA were detected in 
skeletal muscle, mesenteric lymph node and peripheral lymph node. Thus, in cat F4, 
expression of feFLVCR mRNA did not appear to be restricted to haematopoietic 
tissues.
5.3.2 3 Expression of the FeLV-C receptor in a panei of tissues collected from 
cat E5
cDNA was synthesised from RNA prepared from the tissues from cat E5 (a cat 
from a FeLV immunopathogenesis trial and at the time of post mortem positive for 
FeLV p27) and subsequently used for PCR amplification using primers specific for 
either feFLVCR or p-actin. The PCR products were separated by electrophoresis and 
visualised by ethidium bromide staining (figure 5.2). As was found for cat E2, the 
levels of p-actin expression varied between the tissues screened, suggesting that the 
amounts of amplifiable cDNA present varied between the cDNA synthesis reactions, 
in particular for the heart, liver and skeletal muscle. Thus the results obtained with 
these tissues following PCR amplification using the feFLVCR primers should be 
interpreted with caution. The remaining PCR using primers encoding for p-actin 
yielded products of comparable intensity and thus amplifiable cDNA was present in 
the cDNA synthesis reactions in broadly comparable amounts. FeFLVCR mRNA was 
relatively abundant in the kidney, spleen and peripheral lymph node. There were 
lower levels of mRNA detected in the remaining tissues (salivary gland, thymus, 
spleen and MLN). Despite the poor quality of the liver cDNA template, a product was 
detected following feFLVCR PCR, suggesting that the feFLVCR transcript was 
abundant in this tissue. Thus, in cat E5, feFLVCR was expressed in both 
haematopoietic and non-haematopoietic tissues.
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S.3.2.4 Expression of the FeLV-C receptor in a panel of tissues collected from 
cat E6
Tissues collected from cat E6  (a cat that was FeLV p27 positive at the time of 
post mortem) were used for RNA preparation. After cDNA synthesis and PCR  
amplification, the PCR products were visualised on an agarose gel (figure 5.2). The 
levels of p-actin expression were broadly similar between the tissues screened, with 
the exception of the skeletal muscle and mesenteric lymph node samples which 
showed low intensity products, suggesting that less amplifiable cDNA was present in 
the cDNA synthesis reactions from these tissues and thus the results for the feFLVCR  
PCR from the cDNAs derived from these tissues should be interpreted with caution. 
Interestingly, both the skeletal muscle and MLN show high levels of expression of 
feFLVCR, suggesting that the FeLV-C receptor was relatively abundant in both 
tissues. When comparing the remaining tissues, the heart showed relatively abundant 
expression of feFLVCR, whereas there was very low or no expression of the gene in 
the salivary gland, thymus and peripheral lymph node. The remaining tissues (kidney, 
liver and spleen) showed intermediate levels of expression, thus strengthening the 
findings of the previous studies that the FeLV-C receptor feFLVCR is not preferentially 
expressed in haematopoietic tissues.
5.3.2 5 Expression of the FeLV-C receptor in a panei of tissues collected from 
cat L32
The tissues in this part of the experiment were collected from a cat that was 
part of a FeLV vaccination trial and which remained FeLV p27 negative at the time of 
post mortem. After cDNA synthesis and PCR amplification, the PCR products were 
visualised on agarose gels (figure 5.2). Comparable levels of RNA were used for the 
initial cDNA synthesis, as the intensity of the PCR products in the lanes containing the 
p-actin products were of equal intensity. Therefore, variations in the intensity of the 
feFLVCR PCR products were due to differences in the level of expression of feFLVCR  
mRNA.
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Comparing the levels of expression in the lanes containing the feFLVCR PCR  
products, no feFLVCR mRNA was detected in the spleen while high levels of 
feFLVCR expression were detected in the heart, salivary gland, skeletal muscle and 
thymus.
S.3.2.6 Expression of the FeLV-C receptor in a panei of tissues collected from 
cat L36
The tissues in this RT PCR assay were collected from a cat was part of a 
FeLV vaccination trial and was FeLV p27 negative at the time of post mortem. The 
PCR products were visualised on agarose gels and are shown in figure 5.2. The p- 
actin PCR products from the spleen and kidney were poor in comparison with the 
remaining tissues, indicating that the results found for feFLVCR expression in both the 
kidney and the spleen should be interpreted with caution. With the exception of both 
the MLN and the PLN, feFLVCR was expressed to high levels in all tissues tested 
from this particular cat. Interestingly, the feFLVCR expression in both the spleen and 
the kidney was comparable to the expression in the remaining tissues, indicating that, 
despite the poor quality of the template cDNA, high levels of feFLVCR mRNA could 
still be detected in these tissues. The distribution of the feFLVCR mRNA in tissue 
from cat L36 was consistent with expression being widespread in the cat and not 
restricted to a single lineage of cells.
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Figure 5.2: R T  PCR on a panel o f tissues collected from a range of cats. Oligonucleotide primers 
were synthesised according to the published sequences feFLVCR or the housekeeping gene p- 
actin. Amplified products were visualized on agarose gels with ethidium bromide staining.
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5.3.3 feFLVCR expression in bone marrow enriched for or depieted 
of erythroid progenitors
Bone marrow was extracted from the femur of four cats (F4, F8 , L22 and L36) 
and subsequently used to either enrich or deplete cells reactive with the monoclonal 
antibody K1, an antibody directed against erythroid progenitor cells (Gengozian N., 
1998). in a population that has been depleted of cells reacting with this antibody, 
BFU-E progenitors will have been reduced by approximately 80%. A control bone 
marrow population that had not undergone this treatment was also included.
5.3.3.1 Selection of bone marrow populations using an antibody directed 
against erythroid progenitors
After selection of bone marrow populations from cats F4, F8 , L22 and L36, the 
populations were counted, aiiquoted and stored at -70°G until required. RNA was 
prepared as described previously (section S.2.2.2) and subsequently used for cDNA  
synthesis and PCR amplification using primers encoding either feFLVCR or p-actin. 
The PCR products were separated by electrophoresis and visualised by ethidium 
bromide staining (figure 5.3).
S.3.3.2 RT PCR analysis on mRNA from erythroid progenitors
As can be seen in figure 5.3, the PCR products amplified using primers 
encoding for p-actin were of equivalent intensity in the samples from F8 , L22 and L36, 
indicating that equivalent amounts of amplifiable cDNA were present in the initial 
cDNA synthesis. The samples from F4 yielded variable intensity products and thus 
the results of feFLVCR PCR for this sample should be interpreted with caution. 
Following RT-PCR for feFLVCR mRNA, a product was detected in control bone 
marrow samples from the four cats. In samples F4, F8  and L22, depletion of the 
sample with K1- antibody reduced the levels of feFLVCR mRNA.
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Conversely, in samples F4 and L22 there was a strong product for the feFLVCR  
mRNA in the K1- enriched fraction. Interestingly, F4 had a relatively weak intensity 
product for p-actin in the K1-enriched sample suggesting that the feFLVCR product 
must be relatively abundant in the K1- enriched population from this cat. Enrichment 
for K1+ cells in the L36 bone marrow sample also markedly increased the intensity of 
the feFLVCR product, although in this sample the K1- depleted sample did not differ 
in intensity from the control sample, it is notable that the p-actin product was 
considerably stronger in the K1- depleted sample from this cat and weaker in the K1- 
enriched sample, suggesting that relative to the p-actin product there had been a 
marked enrichment for feFLVCR mRNA with K1- selection. No feFLVCR product was 
detected in bone marrow sample F 8  following either enrichment or depletion of the 
K1+ population. Thus, in three out of four samples, there was evidence for 
segregation of the feFLVCR transcript with the K1+ erythroid progenitor population.
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Figure 5.3: Effect of enrichment o f erythroid lineage cells on abundance of feFLVCR  
mRNA. Bone marrow populations were either enriched for or depleted of cells 
reactive with the anti-erythroid lineage antibody K1. RNA was isolated from the three 
cell populations and cDNA prepared. The cDNAs were then assayed for the presence 
of p-actin or feFLVCR cDNAs by PCR. Amplified products were visualized on 
agarose gels with ethidium bromide staining.
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5.4 Discussion
Both the human (huFLVCR) and the feline (feFLVCR) receptor for FeLV-C 
have been identified and characterised (Tailor C.S. et al., 1999c, Quigley J.G. et al., 
2000). As described previously (see section 1.5.1), both the human and feline 
receptors are multiple transmembrane domain proteins that are transporters and are 
members of the major facilitator superfamily (MFS, (Pao S.S. et al., 1998)). Studies 
on the human FeLV-C receptor, huFLVCR, suggested that the receptor was 
expressed preferentially on haematopoietic cells, but not solely on erythroid 
progenitors (Tailor C.S. et al., 1999c). To date, the feline receptor, feFLVCR, has not 
been characterised in such detail. Dean et al (Dean G .A. et al., 1992) found that FeLV 
antigens (gp70 and p27) were present in both populations that contained erythroid 
cells and populations containing myeloid or lymphoid cells and that the proteins were 
present to comparable percentages in the samples tested. However, Tailor et al 
(Tailor C.S. et al., 1999c) showed that huFLVCR (the human FeLV-C receptor) was 
expressed preferentially on haematopoietic cells, but it was not ascertained whether 
receptor expression was restricted to erythroid progenitor cells. Thus, in an attempt to 
clarify the possible role of the FeLV-C receptor in the onset of PRCA, a panel of both 
haematopoietic and non-haematopoietic tissues were screened for expression of 
feFLVCR. At the same time, bone marrow samples were collected and either depleted 
or enriched using an antibody reactive with erythroid progenitors and RNA was 
prepared from these bone marrow populations. The RNA samples were subsequently 
analysed using either northern blot analysis or RT PCR techniques for expression of 
the feFLVCR mRNA.
5.4.1 feFLVCR expression in a panel of tissues using northern blot 
analysis
When the level of expression of the FeLV-C receptor feFLVCR was analysed 
using northern blotting, it was evident that the feFLVCR mRNA was not expressed at 
high levels in any of the tissues studied.
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The inability to detect the feFLVCR mRNA transcript by using northern blotting is in 
contrast with the findings of Tailor et al (Tailor C.S. et al., 1999c) where a panel of 
human tissues was screened using a huFLVCR probe. Tailor et ai concluded that the 
human FeLV-C receptor, huFLVCR, was preferentially expressed in haematopoietic 
tissues. However, expression of the 2.0kb transcript was also detected in pancreas 
and kidney, and a faint transcript may have been present in other non-haematopoietic 
tissues. The northern biot used in the study described by Taiior et al was a custom 
made biot that contained polyA (+) mRNA, whereas in the study described In this 
thesis the northern blots contained total RNA. Thus it is conceivable that the lack of 
feFLVCR expression in the northern blot analysis described here may be due to the 
type of RNA used initially to prepare the northern blots, as polyA (+) mRNA is more 
pure that total RNA and thus more of the transcript will be present in polyA (+) mRNA 
than in total RNA. The amount of transcript present in the type of RNA is also 
reflected in the amount of RNA loaded onto the Initial gel; Tailor et al describe loading 
2 pg of polyA (+) mRNA onto the gel, whereas in this study, 20 pg of total RNA was 
loaded onto the gel.
5.4.2 feFLVCR expression in a panel of tissues using RT PCR 
analysis
Due to the relative scarcity of the feFLVCR transcript, it was concluded that 
northern blot analysis was not sensitive enough to detect tissue expression of 
feFLVCR. Therefore, the RNA prepared from both haematopoietic and non- 
haematopoietic tissues was screened using RT PCR, a more sensitive technique than 
northern blotting. RT-PCR revealed that the FeLV-C receptor feFLVCR was 
expressed widely in both haematopoietic and non-haematopoietic tissues and 
indicated that no single tissue expressed consistently low or high levels of the 
feFLVCR transcript when comparing between cats. In agreement with Tailor et al., the 
majority of lymphoid tissues tested (spleen, thymus, mesenteric and peripheral lymph 
node) expressed the feFLVCR transcript. However, in contrast with the observations 
of Tailor et al,, the feFLVCR transcript was also detected at similar levels in non­
lymphoid tissues such as the salivary gland or the liver.
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5.4.3 feFLVCR expression in bone marrow populations following 
enrichment for cells of the erythroid lineage
The main haematologlcal symptoms of PRCA are decreased levels of CFU-E, 
but normal levels of BFU-E, suggesting a defect in the maturation from BFU-E to 
CFU-E (see also figure 1.6 ). Thus, if the FeLV-C receptor was expressed exclusively 
on cells involved in erythroid maturation, the screening of an enriched bone marrow 
population using primers encoding for feFLVCR would result in higher amounts of 
PCR product, whereas screening depleted bone marrow populations would result in 
low amounts of PCR product. Following depletion of erythroid progenitors from the 
bone marrow cell suspensions, levels of the feFLVCR transcript detected by RT-PCR  
were markedly reduced. Further, in the majority of cases, the feFLVCR transcript 
appeared to be enriched in the K1+ population (erythroid). These data indicate 
segregation of feFLVCR transcript expression with cells of the erythroid lineage and 
do raise the possibility that the selective targeting of erythroid progenitors by FeLV-C  
is the result of high level expression of the feFLVCR transcript in this lineage of cells 
and accordingly, an important role for the feFLVCR protein in the development of cells 
of this lineage. Further samples should be analysed to confirm the validity of these 
data.
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CHAPTER SIX
IDENTIFICATION AND CHARACTERISATION 
OF A PUTATIVE FeLV-A RECEPTOR
2 1 8
6.1 Introduction
Both the FeLV-B receptor Pit-1 and the FeLV-C receptor FLVCR have been 
identified and characterised previously (Takeuchi Y. et al., 1992; Tailor C.S. et al., 
1999c; Quigley J.G. et a!., 2000). FeLV-B shares its receptor P iti with the gibbon ape 
leukaemia virus GALV (Takeuchi Y. et al., 1992). The FeLV-B receptor P iti is a Na^- 
dependent inorganic phosphate transporter that has 1 0  transmembrane domains and 
5 extracellular loops (see figure 1.8 a). Both the human and feline receptors for FeLV- 
C have been identified (by Tailor et al (the human homologue huFLVCR (Tailor C.S. 
et al., 1999c)) and Quigley et al (the feline molecule feFLVCR (Quigley J.G. et al., 
2000) respectively). Both molecules show a high degree of similarity (83% nucleic 
acid similarity and 89% amino acid similarity) and both molecules have 12 
transmembrane spanning domains and six extracellular loops (see figure 1.8b). To 
date, the FeLV-A receptor remains to be Identified and characterised. Ghosh et al 
(Ghosh S.K. et al., 1992) attempted to identify a FeLV-A receptor by using purified 
envelope glycoprotein gp70 of a representative FeLV-A virus 61E (accession number 
M l8247, (Donahue P R. et al., 1988)) to bind the viral receptor. ^^®i-labelled gp70 
protein bound to FeT cells (3201 cells) was employed to detect membrane proteins 
that interact with the gp70 following affinity cross-linking. These methods identified a 
complex of 130 to 140 kDa, leading to the conclusion that the FeLV-A receptor is a 
cell surface molecule of approximately 70 kDa. To date, this molecule remains to be 
identified and characterised. This method has been used previously to characterise, 
amongst others, the interaction of human immunodeficiency virus (HiV) and CD4+ 
(McDougall J.S. et al., 1986).
As discussed previously (section 1 .5.2), a number of receptors of the y-type 
retroviruses are members of the major facilitator superfamily, MFS, and It is 
conceivable that the FeLV-A receptor is also a member of this extensive family of 
molecules. Furthermore, due to the high degree of homology between FeLV-A and 
FeLV-C, it is likely that both viruses utilise related molecules.
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6.2 Methods
6.2.1 Cloning of a receptor using a retroviral library
Two libraries (a feline T-cell library and a human T-cell library in the pBabe X  
retroviral vector (Kitamura T. et al., 1995)) were screened to identify the putative 
FeLV-A receptor (see also figure 6.1). Ceils were transfected using the CaP0 4  
method as described previously by Gorman (Gorman C.M. et ai., 1985). On day 1, 
8x10® 293T cells were plated in 150mm dishes in 20mls 10% DMEM. On day 2, 
chloroquine was added to the cells to a final concentration of 25pM (the pH of the 
medium is increased by this endosomal agent, which in turn inhibits lysosomal 
hydrolytic enzymes and thus decreases the risk of degradation of endocytosed 
material (Luthman H. and Magnusson G., 1983)), 24|o.g of either the feline T-ceii 
library or the human T-cell library, 24pg Hlt60 (which contains MuLV gag-po/to enable 
formation of FeLV env/MuLV gag-pol pseudotypes (Soneoka Y. et al., 1995)) and 
24pg mfg LacZ, (carrying the p-galactosidase marker gene (Dranoff G. et ai., 1993)) 
were combined and the total volume made up to 1752pl with distilled water. To this 
mixture, 248pl of 2M CaCl2 was then added without mixing. 2000pl 2xHBS was added 
slowly and the DNA mixture was added to the cells. After a 10 hour incubation, the 
transfection mixture was replaced with fresh 10% DMEM and the cells were then 
incubated overnight at 37°C. On day 3, the cells were washed twice with PBS and 
fresh growth medium was added. Target cells 104C1 and 3T3 (both 3T3 and 104C1 
are not susceptible to FeLV-A infection, as can be seen in table 3.5) were plated onto 
six 100mm dishes at a concentration of 5x10® cells per dish and incubated overnight 
at 37°G. 293T cells were plated in 150mm dishes at a concentration of 8x10® cells 
per dish and incubated overnight at 37°C. The following day, the supernatant of the 
transfected 293T cells was removed, filtered using a 0.45pM filter and fresh 10% 
DMEM was added to a total volume of 100ml.
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The transfection efficiency was estimated by staining the cells for LacZ activity. The 
cells were fixed for 10 minutes in PBS containing 0.5% glutaraldehyde, washed three 
times with PBS and p-galactosidase activity was determined by incubation with x-gal 
buffer (5mM potassiumferrocyanide, 5mM potassiumferricyanide, 2mM MgCL) 
containing 1 mg/ml x-gal (5-bromo-4-chloro-3-indolyl p-D galactopyranoside). Five of 
the 100mm dishes containing either 3T3 or 104C1 cells were transduced using 10ml 
of the 293T supernatant in the presence of 4|ig/ml (w/v) polybrene (hexadimethrine), 
to enhance the uptake of retrovirus into the cells (Coelen R J . et al., 1983)) and 
incubated overnight at 37°C. The remaining two dishes were a negative control; 10% 
DMEM containing 4|xg/ml (w/v) polybrene was added to the remaining two dishes and 
these dishes were incubated overnight at 37°C. On day 5 , the 100mm dishes 
containing the transduced 3T3 or 104C1 cells and both control dishes were 
subcultured into 150mm dishes as described previously in section 2.2.1.2.3. The 150 
mm dishes containing 293T cells were transfected using 24pig FeLV-A env, 24|ig 
HIT60 and 24pg pBabe Puro (this vector permits the selection of cells that have been 
transduced successfully by adding growth medium containing puromycin, 
(Morgenstern J.P. and Land H., 1990)) in the presence of 25pM chloroquine and 
incubated for 9 hours after which the medium was replaced with fresh growth 
medium. On day 6 , the 293T cells that were transfected were washed twice with PBS, 
after which 2 0 ml growth medium was added to the cells and cells were incubated for 
24 hours at 37°C. After 24 hours incubation the supernatants of the transfected 293T  
dishes were filtered at 0.45|iM and fresh 10% DMEM was added to a total volume of 
100ml. Again, 150mm 293T dishes were stained for transfection efficiency by fixing 
the cells for 10 minutes in PBS containing 0.5% glutaraldehyde, washed three times 
with PBS and p-galactosidase activity was determined by incubation with x-gal buffer 
(5mM potassiumferrocyanide, 5mM potassiumferricyanide, 2mM MgClg) containing 
Img/m! x-gal (5-bromo-4-chloro-3-indolyl p-D galactopyranoside). The 150mm dishes 
containing the transduced 3T3 and 104C1 cells were infected with the 293T  
supernatant and were incubated at 37°C for 3 days. At this point, each dish containing 
104C1 cells was subcultured into 2 dishes and each dish containing 3T3 cells was 
subcultured into 3 dishes. After 4 hours incubation to allow the cells to adhere to the 
dishes, puromycin was added to the dishes at a concentration of 2j^g/ml for the 3T3 
cells and 0.5pg/ml for the 104C1 cells.
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The puromycin-containing medium was refreshed every 2 days and after 
approximately one and a half weeks, puromycin resistant colonies appeared in the 
dishes. The puromycin resistant colonies were picked using autoclaved 3MM paper 
disks soaked in trypsin/versene, placed in a well of a 24 well plate containing 10%  
DMEM and incubated overnight at 37°C. The following day, the 3MM paper disks 
were removed, the cells were washed twice with PBS and puromycin was added to 
the medium as previously. When the cells were confluent, each well was subcultured 
into 2 wells of a 24 well plate. Once confluent, the cells of one well were infected with 
FeLV-A env/mfg LacZ to determine whether the picked colonies were positive when 
infected with supernatant containing FeLV-A mfg LacZ particles as described 
previously (section 3.2.7). The wells corresponding to the cells that were positive 
when stained for p-galactosidase were used to prepare HMW  DNA.
6.2.2 Isolation of receptor cDNA
Cell pellets of colonies that tested positive for FeLV-A env/mfg LacZ infection 
as determine by the p-galactosidase assay described previously (section 3.2.7) were 
used to prepare HMW DNA (section 3.2.2). The prepared DNA was subjected to PCR  
amplification using primers flanking the insert in the pBabe X  vector (5’- 
GATCCCAGTGTGCTGGAAAG-3’ and 5-GGTGGGGTCTTTCATTCC-3'). The 
amplification was performed under the following conditions: dénaturation at 94°C for 3 
minutes, followed by 30 cycles of dénaturation at 94°C for 30secs, annealing at 54°C  
for 1.5 minutes and extension at 6 8 °C for 7 minutes. The PCR products were 
expected to be approximately 2 .0 kb in size.
6.2.3 Molecular cloning of PCR products
The PCR products were cloned into the pCDNA3.1V5HisTOPO vector 
(Invitrogen NV, Leek, The Netherlands) using the TA cloning system as described 
previously (section 2.2.3.7) and transformed into E.coli INVaF' competent cells 
(section 2.2.3.8) as described previously.
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Colonies were picked, inoculated in 2.5m l L-broth containing 50p.g/ml ampicillin and 
grown overnight at 37°C. DNA was prepared using the “small-scale plasmid 
preparation” method (section 2.2.3.2,1) and the plasmid DNA was digested using 10 
units of the restriction enzyme BstXI to establish the presence of an insert (section 
2.2.3.5).
6.2.4 Nucleic acid sequencing of a putative FeLV-A receptor
The putative FeLV-A receptor clones were sequenced using an ABI PRISM  
3100 genetic analyser (section 2.2.3.11) using either the universal M13 forward 
primer (5’-GTA AAA CGA CGG CCA GT-3 ) or the universal M13 reverse primer (5’- 
CAG GAA ACA GCT AT G A C -3), these primers can be used with any vector 
containing the N-terminus of p-galactosidase. The sequences obtained were analysed 
using the NCBI blast nucleotide search on the website 
(http://www.ncbi.nlm.nih.aov/BLAST/1 to establish possible homology to proteins that 
function as receptors.
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6.3 Results
6.3.1 Screening of the feline T-cell library on murine 3T3 cells or 
guinea pig 104C1 ceils
After puromycin selection of both the cells transduced with the feline T cell 
library and the negative control cells, colonies were picked and each colony plated 
into a single well of a 24 well plate. Interestingly, no puromycin resistant colonies were 
present on the 104C1 control plates, whereas twenty-three puromycin resistant 
colonies were present on the 3T3 control plates. The plates that contained either 3T3 
transduced or 104C1 transduced cells contained one hundred and twenty four and six 
puromycin resistant coionies respectively. Thus, when comparing the number of 
puromycin resistant colonies on the 3T3 transduced cells with the number of coionies 
on the 3T3 control plates, there is a significant increase in the number of coionies 
appearing after puromycin selection. Once confluent, these colonies were screened 
for their ability to support FeLV-A env/mfg LacZ infection. However, none of the 
coionies were capable of supporting FeLV-A env/mfg LacZ infection. This led to the 
conclusion that, despite these colonies being puromycin resistant, none of them 
displayed the putative FeLV-A/Glasgow-1 receptor on the cell surface.
6.3.2 Screening of the human T-cell library on murine 3T3 cells or 
guinea pig 104C1 cells
Similarly, after puromycin selection of either 10401 or 3T3 cells that were 
transduced with the human T-ceil library, none of the sixteen or eighty five colonies 
isolated respectively were able to support FeLV-A env/mfg LacZ infection. As was 
found for the feline T cell library, there were no puromycin resistant colonies present 
on the 10401 control plates and twelve puromycin resistant colonies on the 3T3 
control plates (these control plates had not been transduced with the supernatant of 
transfected 293T cells, but otherwise had undergone the same protocol as the 
transduced cells).
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Library screened Cell line used to 
obtain puromycin 
resistant colonies
Number of 
puromycin resistant 
colonies isolated
Number of colonies 
able to support 
FeLV-A infection
Feline 3T3 124 (23) 0
Human 3T3 85 (12) 0
Feline 104C1 6 (0 ) 0
Human 10401 16 (0 ) 0
Table 6.1: Summary o f the screening of either the feline or the human T ceii library, in 
order to identify the FeLV-A receptor. In brackets is the number of puromycin resistant 
coionies present on the control plates.
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6.4 Discussion
To date, the FeLV-A/Glasgow-1 receptor is the sole FeLV receptor that has 
not been identified and characterised. Ghosh et al (Ghosh S.K. et al., 1992) identified 
a putative FeLV-A/Glasgow-1 receptor, however, this molecule was not characterised 
in depth. In order to Identify the cellular FeLV-A receptor, the same method, which 
has been used successfully by Tailor et ai (Tailor C.S. et al., 1999c) in the 
identification of the FeLV-C receptor, was employed. However, when this approach 
was applied to the identification of the FeLV-A/Glasgow - 1  receptor, we found that It 
was not possible to identify the viral receptor. There are a number of possible 
explanations for the difficulties encountered when screening either the human or the 
feline T-ceil library, they are:
1. The receptor is being expressed only transiently on the surface of the cell and 
is removed from the surface due to the molecule being toxic to the cells.
2. mRNA for the FeLV-A receptor was not expressed at sufficiently high levels in 
the library and thus the probability of isolating the receptor was low.
3. When the cells are taking up the viral particles, this occurs through a non­
specific pathway rather than through the receptor being expressed on the cell 
surface.
While it is unlikely that the uptake of the viral particles is though a non-specific 
pathway, the more likely the occurrence of false positive puromycin resistant colonies 
is due to either the libraries being not specific enough or due to the receptor being 
toxic to the ceils.
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The occurrence of puromycin resistant colonies on the plates containing control cells 
that have not been transduced (and thus should not contain the FeLV-A receptor) 
does indicate that there is “leaking" of the virus into the cells through a non-specific 
pathway. However, if this were the preferred method of uptake of the viral particles, 
this would have led to a positive infection when using FeLV-A/mfg LacZ containing 
supernatants. With respect to the cellular molecule encoding the putative receptor 
being toxic to the ceils, Zhang et al (Zhang C.C. et al., 1999) have described similar 
problems encountered when attempting to stably express the Estrogen receptor (ER) 
in the human cell line HeLa. It was found that the molecule encoding for this receptor 
was highly toxic to these cells and thus was removed from the cell surface 
immediately, comparable to problems encountered when screening the cDNA library. 
Furthermore, both Dr C. Tailor and Dr T. M iyazawa attempted to identify the FeLV- 
A/Glasgow-1 receptor In a similar fashion as described in this thesis and were unable 
to identify a putative receptor (personal communications), in agreement with the 
studies described in this thesis. However, it is also possible that the library screened 
to identify the cellular receptor is not specific enough. A potential resolution to this 
would be the preparation of a library from a cell line or a tissue that is highly 
susceptible to FeLV-A infection, for exampie a feline cell line such as FEA or H06T1. 
Both these cell lines are readily infected by FeLV-A/Glasgow-1 and thus it is probable 
that the receptor will be present at high levels in these cell lines.
Another possible way to successfully identify the FeLV-A receptor will be to 
link the library to a system that is driven by an inducibie promoter such as an antibiotic 
resistance gene. An exampie of such a system is the tetracycline-regulated system 
described originally by Gossen et al (Gossen M. and Bujard H., 1992). In brief, this 
tetracycline-regulated system Is based on regulatory elements of the Tn10  specified 
tetracycline resistance operon of Escherichia coii. The tetracycline repressor TetR  
negatively mediates transcription of the resistance-mediated genes, meaning that in 
the presence of tetracycline, TetR does not bind to its operators within the promoter 
region and thus allows transcription. Similarly, in the absence of tetracycline, TetR is 
able to bind to its operators, which are located in the promoter region, and thus 
transcription does not occur.
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CHAPTER SEVEN
DISCUSSION
2 2 9
7.1 Introduction
Feline leukaemia virus is a common disease of the domestic cat and 
infection with the virus invariably leads to death three to five years after infection. 
Infection causes a number of diseases ranging from lymphoma to erythroid 
hypoplasia (pure red ceil aplasia, PRCA). There are three known subgroups 
(FeLV-A, FeLV-B and FeLV-C), as determ ined by interference assays. FeLV-A is 
the subgroup that is most frequently isolated, it is present in 1 0 0 % of natural 
isolates, whereas FeLV-C is most seldom isolated; It is present in only 1% of all 
natural isolates. FeLV-B is the result of recombination between the FeLV-A  
envelope glycoprotein and endogenous FeLV-related proviruses that are present 
in the feline genome. FeLV-A and FeLV-B share approximately 74% amino acid 
homology when the predicted am ino acid sequences of the envelope 
glycoproteins are compared. FeLV-C arises as the result of point mutations in the 
FeLV-A envelope glycoprotein and thus these subgroups share approximately 
93% homology when comparing the envelope glycoproteins. The three subgroups 
show distinct in vitro tropisms; FeLV-A is capable of infecting feline ceils only 
(ecotropic), whereas both FeLV-B and FeLV-C display a broader tropism and are 
capable of infecting both feline and non-feline cells (amphotropic). Infection with 
FeLV-C leads to PRCA, an anaemia that is characterised by the defective BFU-E  
to CFU-E maturation (see figure 1.6 for a diagram of erythroid maturation). It is 
hypothesised that the onset of PRCA is due to the loss of the normal function of 
the protein encoded by the FeLV-C receptor gene, FLVCR (Dean G.A. et al., 
1992). The-aim of the studies described in this thesis was to exam ine the role of 
the virus-receptor interaction in the development of PRCA.
7.2 Elucidation of the envelope glycoprotein region involved in 
altered in vitro cell tropism of FeLV-C
When the am ino acid sequences of the A and C subgroups of FeLV are 
compared, most of the differences between the two sequences are located in the 
N-term inal region of the protein, an area referred to as the first variable region, the 
“VRA” region, (Riedel N. et al., 1988; Rigby M.A., 1989; Brojatsch J. et al., 1992; 
Bae Y. et al., 1997).
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The predicted structure of the FeLV Env protein (based on the Friend MuLV env 
structure (Fass D. et a!., 1997)) suggested that the VRA region Is located on the 
surface of the envelope glycoprotein, consistent with this region being a 
component of the receptor binding domain. W hen the clones that were 
characterised during this study were compared, the majority of the mutations 
observed were located in the VRA region of the envelope glycoprotein, however 
there were additional clusters of mutations in distinct areas of the entire envelope 
glycoprotein. To date, no single amino acid or amino acid motif has been identified 
that confers an altered in vitro tropism. Brojatsch et al (Brojatsch J. et al., 1992) 
proposed that a single lysine to arginine substitution at position 64 in the published 
FeLV-A sequence would result in an altered in vitro host range. W ith the exception 
of the clones characterised from primary isolate FS246, this K6 4R substitution was 
absent from all clones identified in this thesis. These findings lead to the 
conclusion that it is not likely that this single lysine to arginine substitution is the 
sole determ inant of an altered in vitro tropism and that there are either more am ino 
acids or an entire region of amino acids involved in determining the in vitro 
tropism. Rigby et al (Rigby M.A. et al., 1992) have shown previously that the first 
variable region of the envelope glycoprotein, the VRA region, is a determ inant of in 
vitro tropism. When the am ino acid alignments were analysed (see figure 3 . 6  and 
4.3), there were two motifs in the VRA region that were present only in the clones 
that displayed an in vitro tropism consistent with FeLV-C. Firstly, clones that had a 
tropism consistent with FeLV-A contained a stretch of six amino acids consisting of 
^^TNVKHG®®, whereas clones that lacked this motif showed an in vitro tropism 
similar to FeLV-C, as shown by infection of the guinea pig cell line 104C1. 
Secondly, all subgroup C components contained a valine to tryptophan 
substitution at position 63 (VeaW). The presence of a tryptophan residue (a residue 
with a hydrophobic side chain) may create a hydrophobic pocket on the surface of 
the envelope glycoprotein. It has been shown previously by Zavorotlnskaya et al 
(Zavorotinskaya T. and Albritton L.M., 1999) that the presence of a tryptophan 
residue at position 142 of the ecotropic MuLV envelope glycoprotein is critical for 
binding of the envelope glycoprotein to the receptor. Similarly, Wang et al (Wang 
Q-Y. et al., 2002) illustrated the necessity of a conserved tryptophan residue in the 
viral envelope glycoprotein of the Rous Sarcoma Virus-subgroup A in ensuring 
correct protein folding and subsequent binding of the receptor.
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Consequently, the substitution of a valine to a tryptophan residue on position 63 in 
the clones, that displayed an in vitro tropism similar to FeLV-C, may be an 
important factor in the altered receptor recognition and in vitro tropism of these 
clones. The hypothesis that mutations outwith the VRA region are necessary for 
correct folding of the protein and in turn an altered in vitro tropism of the virus, is 
comparable to results described previously for human immunodeficiency virus 
(H IV) (Stamatatos L. and Cheng-Mayer C., 1993; Milich L. et al., 1993; Labrosse
B. et al., 2001). The envelope glycoprotein gp120 of H IV contains five variable 
regions, V I  to V5. The third variable region of gp120 (the V3 loop) contains thirty- 
five amino acids and displays a high degree of sequence variability between 
isolates. An altered H IV tropism is linked to changes in the V3 loop, in particular 
amino acid changes flanking the GPGR-motif in this loop. This motif is predicted to 
be located on the periphery of the envelope glycoprotein, thus the location of this 
motif is comparable to the predicted location of the VRA region of the FeLV  
envelope glycoprotein. The am ino acid composition within the V3 loop determines 
the overall structure and presentation of the loop. In turn, several regions including 
the V3 loop determ ine the overall structural conformation of the envelope 
glycoprotein gp120. The Env conformation defines the extent and type of post 
binding structural changes that lead to viral entry. Hence, changes in one region of 
the envelope glycoprotein can affect the function of other regions of the Env and 
the biological phenotype of an isolate is determined by the overall structure of the 
envelope glycoprotein and not by a single region (Stamatatos L. and Cheng-Mayer
C., 1993; Milich L. et al., 1993; Labrosse B. et al., 2001). Similar findings have 
been described for the envelope glycoprotein gp1 2 0  of feline immunodeficiency 
virus (FIV). The Env of FIV contains 5 variable regions and the third variable 
region (V3), which is believed to be a determ inant of in vitro tropism and receptor 
recognition, contains 62 amino acids. Verschoor et al (Verschoor E.J. et al., 1995) 
have shown that a single mutation in the V3 loop of the FIV Env resulted in an 
altered cell tropism of the virus. Furthermore, mutations outwith the V3 loop, in 
particular mutations located in the TM  of the envelope glycoprotein, alter the in 
vitro tropism by facilitating changes in the conformational structure of the envelope 
glycoprotein (Vahlenkamp T.W . et ai., 1997) Thus, although a region of the protein 
may be necessary for the function of the protein, other regions of the molecule are 
involved in maintaining the proper folding of the protein. This may explain the 
presence of clusters of mutations throughout the FeLV envelope glycoprotein; 
these mutations are essential to counteract mutations in other regions of the Env 
and thus result in maintaining the proper folding of the protein.
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The importance of amino acid residues in distinct regions of the Env to maintaining 
structurai integrity is underlined by the Envs that were not recognised by the 
monoclonal antibody (mAb) 6-15. This monoclonal antibody 6-15 is directed 
against the FeLV envelope glycoprotein and all three subgroups are recognised by 
this antibody. Two possible explanations for the env clones no longer being 
recognised by mAb 6-15 are 1) the mutations were located within the antibody 
binding site, resulting in the binding site being destroyed and 2 ) the mutations 
were located outwith the putative antibody recognition site and resulted in an 
altered conformational structure of the envelope glycoprotein and thus disrupted or 
masked the antibody binding site. As the mAb 6-15 and its antibody binding site 
remain to be characterised in full, the underlying mechanism behind the inability of 
the antibody to recognise the env clones cannot be confirmed. However, as the 
mAb 6-15 recognises ail three FeLV subgroups, it is likely that the antibody 
binding site is located in a highly conserved region of the envelope glycoprotein. 
When the amino acid sequences of the Envs that were no longer recognised by 
the antibody were compared, it was evident that the mutations that were present in 
these clones were scattered throughout the envelope glycoprotein and were not 
restricted to a single region. It is therefore likely that the mutations in the envelope 
glycoprotein induced an altered conformational structure and thus disrupted the 
mAb 6-15 binding site.
In order to comprehend more fully the impact that mutations in the VRA  
region of the envelope glycoprotein could have on the overall structure of the 
protein, FeLV env structures were generated as described in section 2.2.13. As 
can be seen in figure 7.1, a structure for FeLV gp70 can be modelled successfully 
based on the MuLV structure. Figure 7.2 illustrates a comparison of the predicted 
structures of the variable regions of a selection of FeLV-A and FeLV-C Envs. The  
natural isolates that showed an in vitro tropism comparable to FeLV-C/Sarma 
indeed also showed a similar structure, whereas FeLV-A/Glasgow-1 and isolate 
FS246 showed structures comparable to one another, but distinct from the 
structures displayed by FeLV-C/Sarma. As was expected, the structure of FeLV- 
B/Gardner-Arnstein was highly divergent from both the FeLV-A/Glasgow-1 and the 
FeLV-C/Sarma envelope glycoprotein structures. Thus, the structural predictions 
suggest that while several of the FeLV-C may have a similar structure, FS246 
provides an exception and thus no single structural element can be identified that 
confers the subgroup C phenotype.
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When a spacefilling structure was prepared of FeLV A and C envelope 
glycoproteins (figure 7.3), it was evident that the variable regions were in close 
proximity. Thus mutations in the VRA region may need to be counteracted by 
mutations elsewhere in the envelope glycoprotein in order to maintain the correct 
three-dimensional structure and ultimately the function of the protein. Recently, the 
structure of the Receptor Binding Domain of FeLV-B (FeLV-B RBD) was solved by 
Barnett et al ((Barnett A.L. et al., 2003), PDB accession code: 1LCS). When the 
FeLV env structure predictions generated in this study were compared with the 
structure of FeLV-B RBD, it was evident that the structures were very similar, 
strengthening the validity of the structure predictions based on MuLV and the 
conclusions that were drawn from these structures and the locations of the 
variable regions in the envelope glycoprotein.
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7.3 Expression of the feline FeLV-C receptor. feFLVCR
In order to characterise in more detail the role of the feline FeLV-C receptor 
(feFLVCR) in the development of PRCA, the expression of this gene was studied 
in a panel of both haematopoietic and non-haematopoietic tissues. Due to 
relatively low levels of mRNA expression in the tissues screened, it was not 
possible to detect the feline FeLV-C receptor by conventional northern blot 
analysis. However, the RT-PCR results indicated that the receptor was expressed 
widely, albeit at low levels. Furthermore, there appeared to be no single tissue 
where the gene was either consistently expressed to high levels or consistently not 
expressed. These findings are in contrast with the findings described by Taiior et 
al (Tailor C.S. et al., 1999) when screening a pre-made poiy A(+) northern blot 
with the human FeLV-C receptor huFLVCR. Tailor et al concluded that huFLVCR 
was expressed preferentially in haematopoietic tissues, consistent with the 
hypothesis that the development of PRCA is due to the FeLV-C receptor being 
expressed at a high ievel on cells that are involved in erythroid maturation and that 
this lineage of cells may be particularly sensitive to the cytopathic effect of FeLV-C 
infection (see also Dean et al, 1992).
It is likely that the anaemia that develops after infection with FeLV is the 
result of the loss of the normal function of the gene encoding for FLVCR. Perkins 
et al (Perkins C.P. et al., 1997) have reported similar findings with the ecotropic 
MuLV receptor mCAT-1. The mCAT-1 gene encodes a basic amino acid 
transporter and also acts as the receptor for ecotropic MuLV (Albritton L.M. et al., 
1989). When a mutation occurs in the mCAT-1 gene, the normal transporter 
function of the gene is abolished, resulting in mice that develop anaemia and are 
approximately 25% smaller than their iittermates. Yamaguchi et al (Yamaguchi S. 
et al., 2003) studied the expression of the mCAT-1 gene in a panel of both 
haematopoietic and non-haematopoietic tissues and found that the gene is 
expressed widely, with the exception of the heart, liver and muscle tissues. Thus, 
impairment of FLVCR function may manifest as a lineage-specific defect, despite 
the receptor being expressed widely in the cat. Similarly, Wang et al (Wang H. et 
al., 1992) described the effect infection with ecotropic MuLV has on the amino acid 
transport in the infected cell through the viral receptor.
239
It was found that when cells were chronically infected with ecotropic MuLV, the 
uptake and outflow of L-arginlne was reduced significantly, whereas when 
extracellular gp70 was added to cells, the transport of amino acids was not 
altered. These results indicate that binding of the virus to the cellular receptor does 
indeed affect the normal function of the molecule.
The main characteristic of PRCA in the cat is the disrupted maturation of 
BFU-E to CFU-E cells, possibly by Impairing the ceii surface expression or 
function of the receptor (Young N.S. et al., 2000). When feline bone marrow 
populations were either enriched for or depleted of cells that are part of the 
erythroid lineage and subsequently subjected to RT-PCR analysis, the results 
indicated that FLVCR receptor expression may be higher in cells of the erythroid 
lineage In comparison to populations of cells that were depleted of cells of the 
erythroid lineage. Thus, it is possible that although FLVCR expression is 
widespread, erythroid cells may be extremely sensitive to perturbations in its the 
normal cellular function of the molecule. In contrast, in cells of other lineages, the 
function of FLVCR may be dispensable.
7.4 Identification of the FeLV-A receptor
To date, the FeLV-A receptor remains to be identified and characterised, 
although a putative binding protein has been identified previously (Ghosh S.K. et 
al., 1992). However, the 70 kDa molecule? identified by Ghosh et al, remains to be 
characterised fully. The method utilised in this thesis, has been used successfully 
previously in the identification of CCR5 as an HIV receptor (Deng H. et al., 1997) 
and the FeLV-C receptor (Tailor C.S. et al., 1999). Thus, the problems 
encountered whilst attempting to isolate the FeLV-A receptor are unlikely to be 
due to a flawed experimental approach, but more likely due to other factors, such 
as the molecule being toxic to the cells or the libraries screened not being 
abundant in the receptor cDNA. Comparable problems were encountered when 
Zhang et al (Zhang C.C. et al., 1999) attempted to stably express the Estrogen 
Receptor (ER) in the human cell line HeLa. It was found that the receptor was 
highly toxic to cells and thus the transfected HeLa cells attempted to remove the 
toxic molecules as soon as possible.
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7.5 Future work
7.5.1 Envelope glycoprotein studies
Two features of the FeLV-C envelope glycoprotein, that appeared to be 
involved in altering the in vitro tropism of FeLV, were identified. They were 1) the 
lack of a ®^TNVKHG®® motif and 2 ) a VeaW substitution. Furthermore, a D5 1 N 
mutation appeared to be involved in allowing the infection of porcine cells in 
clones that were designated the A component of the primary isolate, in order to 
confirm the role of these features in infection, primers for each motif will be 
designed and subsequently used to generate clones displaying each feature. 
Thus, the ®^TNVKHG®® motif will be introduced into the envelope glycoprotein of 
FeLV-C/Sarma by PCR-based mutagenesis. The clones obtained will then be 
used to produce FeLV env/MuLV gag-pol pseudotypes and their in vitro tropism 
compared with the prototypic A and C strains by plating onto a panel of both feline 
and non-feline cells lines. Similarly, the VesW substitution will be introduced into 
the envelope glycoprotein of FeLV-A/Glasgow-1 , in order to assess whether it can 
alter the subgroup of the virus from A to C. Finally, the D5 1 N mutation will be 
introduced into the envelope glycoprotein of FeLV-A/Glasgow-1 , to assess 
whether the tropism of the virus can be extended to the porcine cell line ST Iowa.
In order to test receptor usage of the novel clones described in this thesis, 
pseudotypes derived from the novel env clones, can be plated onto cells stably 
expressing the FeLV-C receptor feFLVCR to determine if these novel clones are 
capable of using feFLVCR efficiently. Similarly, the env clones that contained the 
D5 1 N mutation and were capable of infecting the porcine cell line ST Iowa can be 
plated onto cells stably expressing either Piti or Pit2 to establish the receptor 
usage of these clones.
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7.5.2 Expression of the feline FeLV-C receptor
Preliminary results from the RT-PCR studies on the bone marrow samples 
collected from a number of cats indicated that the FeLV C-receptor is expressed 
preferentially in bone marrow populations that have been enriched for ceils that 
are involved in the erythroid maturation. In order to confirm these findings, more 
bone marrow populations will be collected and subsequently screened using 
primers encoding feFLVCR, as described in chapter five of this thesis. If similar 
results are obtained from the additional bone marrow samples, these results will 
strengthen the hypothesis that PRCA is the result of disruption of the normal 
function of the receptor gene in cells in which FLVCR is essential for growth.
In addition, the expression of feFLVCR can also be examined using 
quantitative real time PCR. The main advantage of this technique is that it is a 
more quantitative method than the RT PCR described in this thesis. Therefore, the 
amount of feFLVCR present in each tissue can be established and thus give a 
clearer understanding of the distribution of the receptor in each tissue.
7.5.3 Identification and characterisation of the FeLV-A receptor
Thus far, the FeLV-A receptor remains to be identified. In order to increase 
the probability of identifying this receptor, there are four possible future directions;
o Firstly, additional cell lines should be screened for suitability for use in 
library screening. It was found that when attempts were made to prepare 
murine 3T3 cells that stably expressed the human FeLV-C receptor, these 
cells were not able to express the gene for any length of time, despite a 
G418 selection step. In contrast, when the same construct was used to 
prepare stably expressing CHO cells (a Chinese hamster ovary cell line), it 
was found that the cells were indeed able to express the gene in the 
presence of the antibiotic. This would suggest that ectopic expression of 
the FLVCR molecule might be toxic to some cell lines, 
o Secondly, a cDNA library will be constructed from a cell line that is highly 
susceptible to FeLV-A infection (e.g. the feline cell line FEA), As FEA cells 
are highly susceptible to FeLV-A infection, the mRNA encoding the FeLV-A 
receptor is anticipated to be present at high levels in these cells.
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Thus increasing the probability of identifying the receptor gene wiil be 
increased. The new library will subsequently be screened as described in 
chapter six.
Thirdly, it is likely that, although the puromycin resistant cells no longer 
express the putative FeLV-A receptor, the gene encoding the molecule 
may still be present in the cellular genomic DNA, Thus, DNA prepared from 
puromycin resistant ceiis will be subjected to PCR using primers flanking 
the insertion sites of the library in order to amplify a putative FeLV-A 
receptor.
Finaiiy, the cDNA library wiil be constructed in a vector in which expression 
of the cDNA is inducible, for example the "Tet-on” system (BD Biosciences, 
Oxford, United Kingdom). In such an antibiotic regulated system, the 
expression of the gene can be either switched on or off in the presence or 
absence of the antibiotic. Thus, the period during which the gene is being 
expressed can be limited, enhancing the probability that the receptor is still 
being expressed on the ceil surface and not having been removed due to 
its toxicity.
When considering the possible directions in which future research may 
proceed, it is important that the results obtained from the screening of the bone 
marrow samples are repeated, in order to confirm the cautious conclusions 
described in chapter five. Similarly, the role of the motifs described in chapters 
three and four in altering the in vitro tropism should be elucidated. If these motifs 
are indeed crucial in the altered in vitro tropism of the novel clones, it may be 
possible to identify the receptor binding domain on the viral Env protein and thus 
understand more fully the mechanism by which the virus exerts its devastating 
effect on erythroid maturation.
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APPENDIX A
MATERIALS
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Materials in regular use, such as equipment, general reagents and solutions are 
described in this section. A full list of manufacturers is supplied in appendix B.
A.1 CELL CULTURE MATERIALS
A.1.1. Plasticware
Tissue culture flasks, 100mm cell culture dishes and 150mm cell culture dishes 
were supplied by Corning incorporated (Corning, NY).
Cryotubes were supplied by Nunc (DK 400, Roskilde, Denmark).
Falcon conical centrifuge tubes were supplied by Becton Dickson U.K. Ltd. 
(Oxford, United Kingdom).
A.1.2. Solutions, media and supplements
All solutions and media for cell culture were supplied by Invitrogen ™ Life 
technologies (Paisley, United Kingdom), unless otherwise stated.
A. 12.7. Media
Ail media were supplied as sterile solutions and stored at +4°G.
Dulbecco’s Modified Eagle's Medium (DMEM).
A. 1.2.2. Supplements
Foetal Calf Serum (PCS), (Perbio, Cheshire, United Kingdom): virus screened, 
mycoplasma screened. FCS was heat inactivated at 56°C for 30 minutes, then 
stored in 50ml aliquots at -20°C until use.
L-glutamine: supplied as a 100X stock solution containing 200mM L-giutamine. 
This was stored in 5mi aliquots at -20°C until use,
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Penicillin/streptomycin: supplied as a 100X stock solution containing lO.OOOunits 
penicillin and lO.OOOpg streptomycin per millilitre. This was stored in 5ml aliquots 
at -20^C until use.
Trypsin-EDTA: supplied as 10X liquid, stored at -20°C. This was diluted 1:10 in 
versene prior to use and stored at +4°C.
A.1.3. Cell lines
The cell lines used routinely are described in more detail in section 2.2.1.2.4.
FEA This cell line is a derivative of the Crandell feline kidney (CrFK) 
cell line. H06T1 cells were generated by transfecting CrFK cells 
with the plasmid pH06T1 carrying an activated Ha-ras 
oncogene. H06T1 cells are susceptible to infection with all three 
FeLV subgroups.
293T (originally 
referred to as 
293tsA1609neo)
This is a human embryonic kidney line transformed with 
adenovirus E1A and carrying a temperature sensitive T antigen. 
These ceiis are susceptible to infection with all three FeLV 
subgroups.
HeLa cell line This is a cell line that is derived from a human cervical 
carcinoma, its cells grow in an epithelial like monolayer. These 
cells are susceptible to FeLV-B and FeLV-C infection, but not to 
FeLV-A infection.
Mad in-Darby canine A cell line derived from the kidney of a normal, adult female 
kidney (MDCK) cell cocker spaniel. The cells grow in an epithelial like monolayer, 
line
Mv1 Lu ceil line This cell line was derived from the lungs of several near full term 
foetuses of the mink, Mustella vison, and grows in an epithelial 
like monolayer.
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ST Iowa cell line A cell line derived from the testes of an eighty to ninety days old 
porcine foetus, this cell line grows in an epithelial like
monolayer.
NIH/3T3 A cell line derived from Swiss albino mouse fibroblasts. These 
cells are, like all murine cell lines, not susceptible to FeLV 
infection.
104C1 104C1 are a guinea pig cell line and were a kind gift from Prof.
D.E. Onions (01 biotech, Glasgow, United Kingdom). These 
cells are susceptible to FeLV-C infection alone.
A.2 RADIOCHEMICALS
[a- P]-dCTP (specific activity of > 10 mCi/ml at reference date) was supplied by 
Amersham Life Science (Bucks, United Kingdom) and stored at -20°C until use.
A.3 GENERAL CHEMICALS
Chemicals used were of analytical or ultrapure quality and were supplied by 
Sigma-Aldrich Company Ltd. (Dorset, United Kingdom), BDH Ltd (Pooie, United 
Kingdom) unless otherwise stated.
Caesium Chioride: Roche applied science (East Sussex, United Kingdom). 
Agarose: Life technologies (Paisley, United Kingdom).
Bacterial agar and tryptone: Oxoid (Basingstoke, United Kingdom).
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A.4 COMPLETE KITS
QIAquickCs) Gel Extraction Kit supplied by QIAGEN ltd. (Crawley, United Kingdom). 
The QIAquick columns comprise o f a silica-gel membrane that binds the DNA in 
the presence o f high salt and a pH o f ^ .5 .  The columns are washed with an 
ethanol-containing wash buffer, which efficiently removes impurities. The DNA is 
then eluted with a low salt elution buffer, pH 8.5, or water.
QIAorep® Spin Miniorep Kit supplied by QIAGEN ltd. (Crawley, United Kingdom). 
The method used is a modification o f the alkaline lysis method first described by 
Birnboim and Doly in 1979 (Birnboim H.C. and Doly J., 1979). Bacteria are lysed, 
after which the lysate is neutralised. This lysate is applied to a column that 
contains a siiica-gel membrane. Similar to the QIAquick® Gel Extraction Kit, the 
siiica-gei membrane binds the DNA in the presence o f high salt and a pH of <7.5, 
after which the DNA is eluted with a tow salt elution buffer, pH 8.5, or water.
Endofree™ Plasmid Maxi Kit supplied by QIAGEN ltd. (Crawley, United Kingdom). 
The preparation and purification o f DNA using this method consists o f four steps, 
namely lysing o f the bacteria, removal o f endotoxins, binding o f the DNA to a 
column containing an Anion-Exchange resin, washing to remove impurities and 
subsequent elution o f the purified DNA. Similar to the QIAprep® Spin Miniprep Kit, 
this is a modification o f the alkaline lysis method described by Birnboim and Doly 
in 1979 (Birnboim H.C. and Doly J., 1979). As with the previously described kits, 
efficient binding of the DNA is dependent on the correct salt concentration and pH. 
As an additional step, endotoxins are removed by filtering the lysate through a 
QiAfilter cartridge and subsequent incubation with an endotoxin removal buffer, 
which prevents endotoxin molecules to bind to the resin in the columns.
QIAamp® DNA blood mini kit supplied by QIAGEN ltd. (Crawley, United 
Kingdom).
This kit is used to prepare DNA from a range of tissues, fluids and cultured ceiis. 
The sample is iysed using proteinase K and buffer AL. The iysed ceils are added 
to the silica gel membrane-containing column. Similar to QIAGEN’s other columns, 
the pH and salt concentration in the lysate ensure the binding o f DNA only to the 
columns.
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The bound DNA is washed twice with buffer AW1 and AW2 subsequently to 
remove residual contaminants. The DNA is subsequently eluted in buffer AE.
TOPO TA cloning kit supplied by Invitrogen NV (Leek, The Netherlands).
The vector used in this kit is linearized and contains single 3 ’ thymidine (T) 
overhangs to allow optimal ligation of the PCR products. The PCR products 
contain 3 ’ deoxyadenosine (A) overhangs due to the use o f Taq polymerase which 
has a non-template-dependent terminal transferase activity and thus adds these 
single 3' deoxyadenosine (A) overhangs to the PCR products. Due to the 
overhangs on both vector and PCR product, the iigation takes place at room 
temperature in 5 minutes. Subsequent transformation of chemically competent 
cells allow the analysis o f the obtained colonies,
ABI Prism® BiaPve^^ Terminator Cycle Sequencing Ready Reaction Kit, version 
2.0 was supplied by Applied Biosystems (Warrington, United Kingdom).
RadPrlme DNA labelling System was supplied by Invitrogen NV (Leek, The 
Netherlands).
This system is designed for rapid labelling and preparation o f high specific activity 
^^P-labelled probes. Random octamer primers are annealed to the DNA template 
after which it is extended in the presence of Klenow fragment and a a-^^P-dCTP. 
The prepared DNA probe is highly specific and can be used to detect both DNA 
and RNA.
FeLV d27 ELISA kit supplied by IDEXX Laboratories Limited (Buckinghamshire, 
United Kingdom).
This ELISA (Enzyme Linked ImmunoSorbent Assay) kit uses the indirect ELISA 
principle: a well of the plate is coated with the antigen o f interest (in this case FeLV 
p27) after which the coated plates are incubated with test solutions and the 
solutions to be tested. Unbound antibodies are washed away after which the 
coated plates are incubated with an antibody-enzyme conjugate and a substrate is 
added to the wells and colour change is observed.
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Expand reverse transcriptase kit was supplied by Roche applied science (East 
Sussex, U.K.).
Gene Amo PCR Core Reagents (Roche Molecular Systems Inc, New Jersey, 
USA) supplied in the U.K. by Applied Biosystems Ltd.
A.5 BACTERIAL STRAINS
E.coli INVaF' cells (Invitrogen NV, Leek, The Netherlands): F' endA^ recA1 
hsdR^7 (rL, m^ "^ ) sunE44 thi-l gyrA96 re/A1 (|)80/acZAM15 A(/acZYA-argF) U169 
deoR* XL
The above strain has the (|)80/acZAM15 marker, enabling blue-white screening by 
a-complementation of p-galactosidase encoded by vector DNA (e.g. pCR™ II). 
The genotypes endA1 and /?sdR17 give improved quality of miniprep DNA; recA1 
denotes recombination negative, recommended for stable replication of high copy 
number plasmids.
A.6 DNA
Plasmid, molecular weight marker and oligonucleotide DNAs were stored at -20°C 
until required.
A.6.1 Plasmids
* VR1012 (Hartikka J. et al., 1996)
This plasmid DNA expression vector has a modified pUC backbone and contains a 
kanamycin resistance gene to a//ow for bacterial growth selection. Furthermore, a 
CMV early promoter is present to regulate the expression o f the inserted gene.
* pHitBQ (Soneoka Y. et al., 1995)
The plasmid pHitGO is a CMV-driven MuLV gag-pol expression plasmid that 
contains the SV40 ori (SV40 origin o f replication). When plasmids containing the 
SV40 ori are introduce J into cells expressing the SV large T antigen (e.g. the 293T
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cell line), the copy number of these plasmids is increased and therefore a higher 
uptake o f plasmid is likely.
* MFG-lacZ (Dranoff G. et al., 1993)
This retroviral vector encodes the E. coli LacZ gene. The lacZ gene product li-  
galactosidase catalyses the hydrolysis of the substrate X-gal to produce a blue 
precipitate, and thus this vector can be used as a marker to ascertain the 
efficiency o f the transfection.
* pBabePuro (Morgenstern J.P. and Land H., 1990)
This retroviral vector contains a Moloney MuLV derived LTR promoter to drive the 
expression o f the genes inserted. A drug resistance marker (puromycin) is present 
to allow for selection in puromycin containing medium.
A.6.2 Molecular Size Standards
1 kb DNA Ladder (siae range 500-10.002 bp) was supplied by New England 
Biolabs (U.K.) Ltd. (Hilchin, United Kingdom).
0.24-9.5 Kb RNA ladder (size range 240-9.490 bp) was supplied by Invitrogen ™ 
Life technologies (Paisley, United Kingdom).
A.6.3 Oligonucleotide Primers
Oligonucleotides were supplied by MWG biotech (MWG biotech AG, Ebersberg, 
Germany).
IRD41 labelled primers for use with the LICOR model 4000 automated sequencer 
were supplied by Hybaid U.K. Ltd.
The primers used for the ABI PRISM 3100 genetic analyser were supplied by 
MWG biotech (MWG biotech AG, Ebersberg, Germany).
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A.7 ENZYMES
All enzymes and their reaction buffers were stored at -20°C, being removed 
immediately before use.
Restriction enzymes and their associated reaction buffers were supplied by Gibco 
BRL. (Invitrogen Lifetechnologies ™, Paisley, United Kingdom).
T4 DNA Ligase was provided by Gibco BRL or Invitrogen (as part of the TA 
Cloning Kit).
A.8 BUFFERS, SOLUTIONS AND GROWTH MEDIA
A.8.1 Water
Tissue culture grade distilled water was supplied by Gibco BRL Ultrapure water 
(for procedures involving recombinant DNA, PCR etc.) was provided by a Millipore 
Q50 water purification system (Millipore (U.K.) Ltd., Watford, United Kingdom). A 
Millipore RO10 system was used to supply water for preparation of general 
solutions and media.
A.8.2 Antibiotics
Ampicillin (Sigma Chemical Company, Dorset, United Kingdom): Solution of 
10Omg/ml prepared in dH20, filter sterilised and stored in aliquots at -20°C until 
use.
Kanamycin (Sigma Chemical Company, Dorset, United Kingdom) Solution of 
20mg/ml was prepared in dH2 0 , filter sterilised and stored in aliquots at -20°C until 
use.
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A.8.3 Buffers and solutions
A. 8.3.1 Molecular Biology Solutions
1xTE
1xTBE
2xHBS
10x MOPS
20x SSC 
100x Denhardts
Buffer P1 
Buffer P2 
Buffer P3 
Buffer QBT
Buffer QC 
Buffer QN 
Buffer TE
10 mM Tris.CI, ImM EDTA pH 7.5.
90 mM Tris-borate, 2 mM EDTA.
280 mM NaCI, 50 mM HEPES, 1.5 mMNa2 HP0 4 . pH to 7.05 
with 0.5 M NaOH. Filter sterilise with 0.4 micron filter.
0.2 M [3-(N-morpholino)propanesulfonic acid], 50 mM NaAc, 10 
mM EDTA, pH to 7.0 with 0.5 M NaOH and make up to 1 litre 
with milliQ water.
3 M NaCI, 0.3 M Tri-Na acetate.
2% Ficoll 400; 2% polyvinylpyrrolidine; 2% BSA, Filter sterilise 
with 0.4 micron filter.
50mM TRIS-Ci, pH8.0; lOmM EDTA.
200mM NaOH; 1% SDS. (Prepared immediately prior to use).
3.0M KOAc, pH5.5.
750mM NaCI; 50mM MOPS, pH7.0; 15% isopropanol; 0.15% 
Triton X-100.
1.0M NaCI; 50mM MOPS, pH7.0; 15% isopropanol.
1.6M NaCI; 50mM MOPS, pH7.0; 15% isopropanol. 
lOmM TRIS, pH8.0; ImM EDTA.
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RNA loading buffer SOOjllI formamide; 166yl formaldehyde; lOOjiil 10x MOPS; 234|il
dHgO.
RNA loading dye 5ml glycerol; 1 ml1 Ox MOPS; 4ml dHgO; few grains of
bromophenolblue. Store at -20°C.
Ethidium Bromide Made to a working solution of 10mg/ml in dHgO, stored at room
temperature away from light.
10X DNA Gel 
Loading .Buffer
0.25% Xylene Cyanol FF, 15% glycerol
Sequencing gel (for 27.7gr urea, 5.3ml Long Ranger Solution, 7.9ml 10X TBE buffer
use with LICOR made up to 65ml with dH^O to which 440pl 10% APS (made
4000) immediately prior to use) was added.
10x TBE, for use with 53.9g Tris base, 27.5g boric acid, 3.7g EDTA; to 500ml with
the LI-COR 4000 dH20, stored at 4°C for a maximum of 2 weeks
A. 8.3.2 Bacteriological Media
SOC Medium 2% Tryptone, 0.5% yeast extract, lOmM NaCI, 2.5mM KCI, 
lOmM MgCI2, 10mM MgS04, 20mM glucose.
L-Broth lOg bactotryptone, 5 g yeast extract, 10g NaCI, pH to 7.0 with 
0.5 M NaOH, make up to 1 litre. Autoclave.
L-agar lOg bactotryptone, 5 g yeast extract, lOg NaCI, pH to 7.0 with 
0.5 M NaOH, make up to 1 litre and add 1.5% Bacto™ Agar. 
Autoclave.
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A.8.3.3 Cell Culture Media
10%DMEIVl growth 
media
DMEM supplemented with 10%FCS, 2mM Glutamine, 100!U/ml 
penicillin and 100yg/ml streptomycin.
Freezing media Appropriate cell culture media supplemented with an additional
10% PCS and 10% DMSO.
PBS Phosphate buffered saline: Sodium chloride, 150 mM, and 
sodium phosphate, 150 mM, pH 7.2 at 25°C.
X-gal buffer 
X-gal
5mM potassiumferrocyanide, 5mM potassiumferricyanide, 2mM 
MgCh in PBS, store at room temperature away from light. 
5-bromo-4-chloro-3-indolyl U-D-galactopyranoside to a final 
concentration of 1 mg/ml (w/v) in dimethylformamide, store at -
20°C away from light.
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A.9 EQUIPMENT
A.9.1. Major equipment
* Benchtop centrifuge: Beckman GS-6 centrifuge (Beckman Coulter, United 
Kingdom).
* Centrifuge: Beckman J2-21 centrifuge (Beckman Coulter, United Kingdom).
* Ultracentrifuge: Beckman L8-M ultracentrifuge (Beckman Coulter, United 
Kingdom).
* Microcentrifuge: Biofuge 13 (Heraeus Sepatech, Germany).
* Incubators for tissue culture: Leec Ltd. (Nottingham, United Kingdom).
* Water baths: supplied by Grant Instruments (Cambridge) Ltd. (United Kingdom).
* Spectrophotometer: Model DU640, Beckman (Beckman Coulter, United 
Kingdom).
* Vacuum dessicator: Freeze drier modulo (Edwards Engineering Corp, NJ, USA)
* Automatic Sequencing Apparatus: Licor Model 4000 sequencer, sequencing 
plates etc. - Licor Inc., Lincoln, Nebraska.
* ABI PRISM 3100 genetic analyser (Applied biosystems, Warrington, United 
Kingdom.)
* Automated Processor: Compact X4 supplied by Xograph, Wiltshire, United 
Kingdom.
* Pipette man (P20, P200, and P1000): supplied by Gilson Medical Electronics 
(Villiers-le-Bel, France).
* Automatic Sarpette: supplied by Sarstedt.
* Ultraviolet Transilluminator: supplied by UV Products Inc. (San Gabriel, CA).
* Autoradiography (Film) cassettes: with intensifying screens (Cronex), supplied by 
Amersham Biosciences (Uppsala, Sweden).
* PCR machine: geneamp PCR system 9700 (PE applied biosystems, Warrington, 
United Kingdom).
* Orbital incubator: Basic orbital incubator supplied by Sanyo Gallenkamp pic, 
Loughborough, United Kingdom.
* Hybridisation oven: Hybaid mini 10 supplied by Thermo Hybaid -  UK, Ashford, 
United Kingdom
* Liquid scintillator counter: Beckman LSI 801 supplied by Beckman Coulter, 
United Kingdom
* Powerpack: Bio-rad powerpac 3000 supplied by Bio-Rad Laboratories Ltd, 
Hertfordshire, United Kingdom.
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* Gel electrophoresis tank: Bio-rad wide mini sub® cell GT supplied by Bio-Rad 
Laboratories Ltd, Hertfordshire, United Kingdom.
* Gel visualisation system: gel print 2000i supplied by MWG biotech AG, 
Ebersberg, Germany.
A.9,2 Consumables
* Screw top 1.5 ml eppendorf tubes, 0.5 ml and 1.5 ml eppendorf tubes were 
supplied by Treff AG (Degersheim, Switzerland).
* Pipette tips were supplied by Sarstedt.
* Syringes (two, five, 10, 20 and 50 ml) were supplied by Becton Dickinson.
* Round gel loading tips were supplied by Sorenson Bioscience Ltd.
* Filter tip pipette tips (30 pi and 200 pi) were supplied by Rainin Instrument Co. 
(Woburn, MA); for use in setting up PCR reactions and RNA preparation.
RNAse free 0.5ml tubes (Ambion (Europe) Ltd. Huntingdon, Cambridgeshire, 
United Kingdom) were used for all work involving RNA.
* Acrodisc syringe filters (0.22 and 0.4 pm) were supplied by Gelman Sciences 
(Ann Abor, Ml); these were used for sterilising of filtering small volumes of 
solutions.
* Petri dishes, bijoux and universais were supplied by Greiner, (Stonehouse, Glos. 
United Kingdom).
* Disposable, sterile scalpels were supplied by Swann-Morton (Sheffield, United 
Kingdom).
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1: List of manufacturers of chemicals
Ambion (Europe) Limited 
Spitfire Close,
Ermine Business Park, 
Huntingdon, PE29 6XY, 
United Kingdom. 
www.ambion.com
Applied Blosystems
Lingley House,
120 Birchwood Boulevard, 
Warrington, WA3 7QH, 
United Kingdom. 
www.appliedbiosvstems.com
Amersham Biosciences UK Limited
Amersham Place,
Little Chalfont, HP7 9NA,
United Kingdom.
www.amershambiosciences.com
BD Biosciences
21 Between Towns Road,
Cowley, 0X4 3LY,
Oxford,
United Kingdom. 
www.bd.com
BDH Ltd
Merck House,
Poole, BH15 1TD,
United Kingdom. 
www.bdh.com
Corning incorporated
Sullivan Park R&D Center, 
Science Center Drive,
Corning, New York 14831-0001, 
United States. 
www.cornina.com
invitrogen BV
De Schelp 26,
9351 NV Leek,
The Netherlands.
www.bioscience.ora
Becton Dickson U.K. Ltd.
Between Towns Road,
Oxford, 0X4 3LY,
United Kingdom. 
www.bd.com
IDEXX Laboratories Limited
Milton Court,
Churchfield Road,
Chalfont St. Peter, SL9 9EW, 
United Kingdom. 
www.idexx.com
Invitrogen ™ Life technologies
3 Fountain Drive, 
inchinnan Business Park,
Paisley,
United Kingdom, 
www.lifetechnoloaies.com
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MWG biotech
Anzinger Str. 7, 
D-85560 Ebersberg 
Germany.
www.mwa-biotech.com
New Engiand Bioiabs (U.K.) Ltd
73 Knowl Piece,
Wiibury Way,
Hitchin, SG4 OTY,
United Kingdom. 
www.NEB.com
Nunc
Postbox 280, 
DK-4000 Roskilde, 
Denmark.
Oxoid Limited
Wade Road,
Basingstoke, RG24 8PW, 
United Kingdom.
www.nalaenunc.com www.oxoid.com
Perbio Science UK Ltd. 
Century House,
High Street,
Tattenhall, CHS 9RJ, 
United Kingdom. 
www.perbio.com
QIAGEN Limited
Boundary Court, 
Gatwick Road, 
Crawley, RH10 9AX, 
United Kingdom. 
www.qiaaen.com
Roche applied science 
Bell Lane,
Lewes, BN7 1 LG,
United Kingdom. 
www.roche-applied-science.com
Sigma-Aldrich Company Ltd.
Dorset,
United Kingdom. 
www.siamaaldrich.com
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2: List of manufacturers of equipment
Beckman Coulter (U.K.) Limited
Oakley Court, Kingsmead Business Park, 
London Road,
High Wycombe, HP11 1JU,
United Kingdom. 
www.beckman. com
Bio-Rad Laboratories Limited
Bio-Rad House,
Mayiands Avenue,
Hemel Hempstead, HP2 7TD, 
United Kingdom. 
www.bio-rad.com
Edwards Engineering Corporation 
PO Box 487,
Pompton Plains, NJ 07444-0487 
United States. 
www.edwards-enq.cnm
Gelman Sciences inc.
600 South Wagner Road, 
Ann Arbor, Ml 48103-9019, 
United States, 
www.medtechi .com
Giison Medical Electronics 
19, avenue des Entrepreneurs,
B.P. 145,
F - 95400 VILLIERS LE BEL, 
France.
www.qilson.com
Grant Instruments (Cambridge) Limited
Shepreth, SG8 6GB 
United Kingdom.
www.qrant.co.uk
Greiner Bio-One Limited
Unit 5, Stroud water Business Park,
Brunei Way,
Stonehouse, GL10 3SX,
United Kingdom.
WWW.areiner-lab.com
M illipore (U.K.) Limited
Units 3&5, The Courtyards, 
Hatters Lane,
Watford, WD18 8YH, 
United Kingdom. 
www.miHipore.com
LEEC Limited
Private Road No. 7, 
Colwick Industrial Estate, 
Nottingham, NG4 2A.I, 
United Kingdom. 
www.leec.co.uk
Leica AG
Oskar-Barnack-StraBe 11, 
D-35606 Solms,
Germany.
www.leica.com
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LI-COR Biosciences UK Limited
St. John's Innovation Contre, 
Cowley Road,
Cambridge, CB4 OWS,
United Kingdom. 
www.licor.com
Rainin instrument Limited
Anachem House,
20 Charles Street,
Luton, LU2 DEB,
United Kingdom. 
www.rainin.com
Sanyo Gallenkamp pic
Monarch Way,
Belton Park,
Loughborough, LE11 5XG, 
United Kingdom. 
www.sanvoqallenkamD.com
Sarstedt Limited 
68, Boston Road, 
Beaumont Leys, 
Leicester LE4 1AW, 
United Kingdom. 
www.sarstedt.com
Sorenson Bioscioncr Limited 
6507 South 400 W ei \
Salt Lake City, Utah,
United States. 
www.sorbio.com
Swann-Morton Limited
Owlerton Green, 
Sheffield, S6 2BJ,
United Kingdom, 
www.swann-morton. com
Thermo Hybaid -  UK
Action Court,
Ashford Road, 
Ashford, TW15 1XE, 
United Kingdom. 
www.hvbaid.co.uk
Treff AG
Taastrasse 16, 
CH-9113 Degersheim, 
Switzerland.
www.treff-aq.ch
Uitra-Vioiet Prod Limted 
Unit 1,
Trinity Hall Farm E^; te, 
Nuffield Rd,
Cambridge, CB4 1TG,
United Kingdom. 
www.uvp.com
Xograph imaging Systems Limited
Xograph House,
Hampton Street,
Tetbury, GL8 8LD,
United Kingdom.
www.xoqraph.com
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A P S  a m m o n i u m  p e r s u l f a t e
B S A  B o v i n e  s e r u m  a l b u m i n
C s C I  C a e s i u m  c h l o r i d e
C i  C u r i e
d A T P  2 ’ d e o x y a d e n o s i n e  5 ’ - t r i p h o s p h a t e
d C T P  2 ’ d e o x y c y t i d i n e  5 ’ - t r i p h o s p h a t e
D E P C  d i e t h y l  p y r o c a r b o n a t e
D M E M  D u l b e c o ’ s  m o d i f i e d  E a g l e s  m e d i u m
D M S O  d i m e t h y l  s u l p h o x i d e
D N A  d e o x y r  b o n u c l e i c  a c i d
d N T P  d e o x u n u c i e o s i d e t r i p h o s p h a t e s
E.coli Eschericia coii
E D T A  E t h y l e n e D i a m i n e T e t r a A c e t i c a c i d  ( s o d i u m  s a l t )
env  E n v e k : p e  g l y c o p r o t e i n
E t B r  E t h i d i u m  b r o m i d e
P C S  F o o t  J  c a l f  s e r u m
F e L V  F e l i n e  l e u k a e m i a  v i r u s
F I V  F e l i n  i m m u n o d e f i c i e n c y  v i r u s
gag  G r o u p  s p e c i f i c  a n t i g e n
G A L V  G i b b r  i A p e  L e u k a e m i a  v i r u s
M B S  H E P r . S - b u f f e r e d  s a l i n e
H E P E S  N ~ [ 2 ~ i  : y d r o x y e t h y l ] p i p e r a z i n e - N ' - [ 2 - e t h a n e s u l f o n i c  a c i d ]
H I V  H u  : ; 1 i m m u n o d e f i c i e n c y  v i r u s
K A c  P C  1  i u m  a c e t a t e
M  m o l a
M B q  M e g a ,  e c q u e r e l
m g  m i l l i g m m
) i g  m i ' ^ r o p r a m
M g C b  m r q n  s l u m  c h l o r i d e
m l  m i  i i  3
p i  m i  r c  t r e
m M  m i ;  i n '  t a r
p M  m i c r o n  o l a r
M O P S  3 - ( N - m o r p h o l i n o ) p r o p a n e s u l f o n i c  a c i d
M u L V  M " n m "  l e u k a e m i a  v i r u s
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N a A c s o d i u m  a c e t a t e
N a C I s o d i u m  c h l o r i d e
N a O H s o d i u m  h y d r o x i d e
n g n a n o g r a m s
° C d e g r e e s  c e n t i g r a d e
O R F O p e n  r e a d i n g  f r a m e
P E R V P o r c i n e  e n d o g e n o u s  r e t r o v i r u s
P B S P h o s p h a t e  b u f f e r e d  s a l i n e
P C R P o l y m e r a s e  c h a i n  r e a c t i o n
pol p o l y m e r a s e
R N A r i b o n u c l e i c  a c i d
r R N A r i b o s o m a l  r i b o n u c l e i c  a c i d
m R N A m e s s e n g e r  r i b o n u c l e i c  a c i d
t R N A t o t a l  R N A
r p m r e v o l u t i o n s  p e r  m i n u t e
R T r e v e r s e  t r a n s c r i p t a s e
R T P C R R e v e r s e  t r a n s c r i p t i o n  p o l y m e r a s e  c h a i n  r e a c t i o n
T e m e d N , N , N ’ , N ’ - t e t r a m e t h y ! e t h y l e n e d i a m i n e
U u n i t s
U V u l t r a v i o l e t
v / v v o l u m e  p e r  v o l u m e
V v o l t s
v o l v o l u m e
W w a t t s
w / v w e i g h t  p e r  v o l u m e
% p e r c e n t a g e
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AMINO ACID CODE
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A l a n i n e A A l a
A r g i n i n e R A r g
A s p a r a g i n e N A s n
A s p a r t i c  a c i d D A s p
C y s t e i n e C C y s
G l u t a m i n e Q G i n
G l u t a m i c  a c i d E G l u
G l y c i n e G G l y
H i s t i d i n e H H i s
I s o l e u c i n e ! H e
L e u c i n e L L e u
L y s i n e K L y s
M e t h i o n i n e M M e t
P h e n y l a l a n i n e F P h e
P r o l i n e P P r o
S e r i n e 8 S e r
T h r e o n i n e T T h r
T r y p t o p h a n W T r p
T y r o s i n e Y T y r
V a l i n e V V a l
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